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This work is dedicated to my Mother.
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To T. Pruen Esqr
Let the usual Puncture be made in the arm with a Lancet- then
introduce the coated extremity of the ivory point, & suffer it to remain
near a minute, supporting it in its place btl the gentle pressure of the
finger, when the oozing fluids will dissolve the concreted vaccine Virus
and Patient be probably infected. I say probably, because the dried vaccine
matter tho' quite fresh, like that I consign to you, sometimes fails to infect
while that which is taken in its fluid state in some early stage of the
Pustule & inserted immediately from arm to arm, does not disappoint me
once in five thousand times.
El
Letter to Thomas Pruen from Edward Jenner (date unknown).
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ABSTRACT.
Introduction. The anti-idiotypic monoclonal antibody 10SAD7
mimics the tumour associated antigen 791T / gp72, present on
approximately 80% of colorectal cancer cells. A Phase I study using 10SAD7
in 13 patients with advanced colorectal cancer has shown that it is non-
toxic, and conferred a survival advantage on patients who received it
[Denton GWL 1994].
Aim. There were two aims of this work. The first was to assess
whether. the survival advantage seen in the Phase I study was
reproducible in a Phase II study. The second was to immunise patients
with primary colorectal cancer, in a non-randomised adjuvant study, and
explore further the immune responses generated.
Materials and Methods. Patients with advanced colorectal cancer
were recruited to a randomised, double-blind, placebo controlled survival
study. The first patient was recruited to this Phase II study in April 1994,
and the last in October 1996. Four trial centres were used- Nottingham,
Hull, Leeds, and Newcastle. Eligible patients had a life expectancy of 3
months, and none had received radiotherapy or chemotherapy in the
preceding 1 and 3 months, respectively. Patients attended on 3 occasions, 6
weeks apart, receiving 10",g of 10SAD7/ alum i.d. followed by 100",g i.m.
Venous blood was assayed for blood count and differential, liver function,
urea and electrolytes, and CEA. Chest X-rays and CT scans were performed
at trial entry and week 12 where possible. Dates of death were recorded
following consultation with General Practitioner or referring clinician.
In addition, patients with primary colorectal cancer were recruited
to a non-randomised adjuvant study, whereby they received 10SAD7
before surgery. Venous blood samples were taken between immunisation
and operation, and assayed for lymphocyte subsets. Samples taken from
resection specimens were analysed immunohistochemically. Fresh
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tumours were in addition disaggregated, and separated TIL labelled with a
panel of monoclonal antibodies, and analysed by flow cytometry. Control
tumours were similarly labelled. All analysis was performed blind.
Results. 162 patients were randomised to the Phase II study,
between April 1994 and October 1996. 85 received 105AD7 and 77 placebo.
The mean ages and sex-ratios of the two groups were comparable, as was
the time from diagnosis of advanced disease to trial entry (172v179 days).
Median survival from date on study was 124 and 184 days, in 105AD7 and
placebo arms, respectively (p=O.38). Survival from date of diagnosis of
advanced disease was 456 and 486 days (p=O.82). Chemotherapy and
radiotherapy all prolonged survival in a multivariate analysis. Only one
serious adverse event was seen in the 105AD7 arm, and this was felt
unlikely to be attributable to the vaccine.
Twenty-four patients were recruited to the adjuvant study.
Immunohistochemical analysis of tumour sections from 16 patients
showed increased infiltration of CD4 and CD8 expressing lymphocytes,
relative to a well matched control group (p<O.05). Infiltration of CD4, CD8
and CD56 expressing lymphocytes combined was significantly higher, as
was that of the mitochondrial antigen 7A6, expressed on cells undergoing
apoptosis (p<O.005). The activation marker CD25 was also significantly
increased (p<O.05). Flow cytometric analysis of disaggregated tumours
from 16 trial and 22 control patients, confirmed the increased expression of
CD25 on TIL in the 105AD7 group (p<O.01). Peripheral blood phenotyping
failed to show any significant increase in any lymphocyte subset, following
immunisation.
A separate analysis was performed comparing 2 year survival and
recurrence in 23 patients immunised by the previous CRC Fellow, with 97
matched controls from the Trent Audit. No significant difference was seen
between the two groups.
6
Discussion. No survival difference was seen between patients
receiving l05AD7 and placebo, in the Phase II study. This suggests that any
immune responses generated by l05AD7 are insufficient to have a
significant effect on tumour growth, in patients with advanced disease.
Work has therefore focused on immunising patients with primary
colorectal cancer. Patients receiving l05AD7 prior to resection of their
primary tumours, showed an increased number of activated lymphocytes,
and apoptosis, at the tumour site, relative to a well-matched control
group. The numbers in the survival analysis based on patients recruited ~
the previous CRC fellow, are insufficient to show whether any of these
immunological changes confer a survival advantage. This question can
only be answered in a large, prospective, placebo-controlled study in
patients with primary colorectal cancer.
7
ACKNOWLEDGEMENTS.
I am indebted to Professor JD Hardcastle, Dr Lindy Durrant and Mr.
John Scholefield for their unstinting support, and giving me the
opportunity to complete this work. I would like to thank Dr Adrian
Robins for the advice he has given me over the last two years.
This work would also not have been possible without the help of
Professor Jim Carmichael, and Professor Herb Sewell from the University
Departments of Clinical Oncology and Immunology respectively.
I would also like to acknowledge the role played by the previous CRC
Fellow, Mr Dedan Buckley. He set up the Phase II study, and recruited the
first 60 patients. He also immunised 23 patients with primary colorectal
cancer, on whom the survival analysis in Part 3 is based.
The Phase II study would also not have been completed without the
support of the other trial centres involved. These included Professor JRT
Monson and Mr. Nick Abdullah in Hull, Professor P Guillou, Mr. Shaw
Somers and Mr. Al Windsor in Leeds, and Professor H. Calvert and Kevin
Fishwick in Newcastle. Christos Pagonis in the Data Centre at CRC, and
the monitoring of Sarah Armstrong and Lucinda Light, also contributed
to the satisfactory conclusion of the study. Statistical analysis was
performed by Dr Katherine Fielding, at the Trent Institute of Health
Services Research, Nottingham University, to whom I am indebted for the
advice she has given me on all aspects of this work. I would also like to
thank the Cancer Research Campaign and Imclone systems Ltd for
funding this study. I should also acknowledge the unforgettable
contribution made by Dr Neil Rotherham at the randomisation company
'S-cubed'.
I am grateful to Rob Moss and Alison Galvin for their technical
assistance - without their help I would never have survived in the lab. I
8
would also like to thank the various secretaries involved- Carole Weaver,
Liz Reavill, Janet Duffin, and Hilary Clayton.
The immunohistochemistry staining using AP02.7 was performed
by Rula Quaitafan, and subsequently submitted to Nottingham University
as part of her MSc thesis. This work was however supervised by myself
and Adrian Robins, and funded by money I raised from the Special
Trustees of the Queens Medical Centre.
I am grateful to the following people for their help over the last 2
years: Kate Bostock collected all the tumour samples, and gathered
together innumerable pathology reports; Judy Mella whose data from the
Trent Audit was used in the survival analysis; Prof RJC Steele, and Mr
NC Armitage for permission to recruit their patients to the adjuvant
study. I would also like to thank Dr Ian Spendlove in Clinical Oncology,
and Will Hughes at the ICRF for general advice. I am grateful for the
support of the other Registrars in the Department of Surgery - Andy
Smith, Gill Tierney and Simon Parsons.
On a more personal note I would like acknowledge the support of Dr.
Anne Thomas, and to take this opportunity to formally thank my
guardians, June and Alan Parsons. lowe them a lot.
9
HYPOTHESIS
The anti-idiotypic monoclonal antibody 105AD7 mimics the
tumour-associated antigen 791T/ gp72, present on 80% of colorectal cancer
cells. Alternative presentation of this epitope should stimulate a naive
immune system, inducing T-cell responses. A Phase I study in patients
with advanced disease has shown that 105AD7 is non-toxic. In addition
9/13 patients showed evidence of IL-2 production, or evidence of a T-cell
blastogenesis against 791T/ gp72 expressing cell lines. Immunisation also
conferred a survival advantage on patients who received the vaccine,
relative to a contemporary group of patients [Denton GWL 1994].
A Phase II, double-blind, placebo-controlled survival study has been
performed, to test these results. In addition further studies on patients
with primary colorectal cancer, have assessed whether immune responses
can be seen in the peripheral blood, and at the tumour site of patients who
receive the vaccine prior to surgery.
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PO Progressive Disease.
PE Phycoerythrin.
PR Partial Response.
RPMI Rosswell Park Media Institute.
SIP Standardised Isotonic Percoll.
TAA Tumour Associated Antigen.
TBS Tris Buffered Saline.
TGFf3 Transforming Growth Factor f3.
TIL Tumour Infiltrating Lymphocyte.
TNFa Tumour Necrosis Factor.
TSA Tumour Specific Antigen.
VCAM-l Vascular cell adhesion molecule-L
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Immunotherapy of colorectal cancer.
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The history of cancer vaccines.
The concept of attempting to vaccinate against tumours was
originally proposed several hundred years ago. One of the first people to
attempt it was Louis XIV of France. He al1egedly injected himself with
fragments of tumour, in order to induce an immune response [A.
Dalgliesh 1996]. Work in the late nineteenth century by Hericourt and
Richet showed that sera could be raised against tumours in dogs and
donkeys. Further work showing that 'magic bullets', or antibodies, could
be used in the treatment of malignancy was proposed by Paul Ehrlich in
1900. It wasn't however until the work of Coley, a New York surgeon, that
the foundations of modern immunotherapy were established. He noted
that patients who recovered from severe post-operative septicaemia,
sometimes had regression of their resid ual tumours. He coined the phrase
'Coley's toxins', and went on to induce prolonged survival in a small
number of patients with osteogenic sarcoma, by means of extracts prepared
from haemolytic streptococci, and Bacillus prodigiosus [Coley 1911]. He
also established some important principles, namely that a minimum dose
of vaccine is required, and that repeated doses should be given.
It had been observed that mice recovering spontaneously from
successfully implanted tumours usual1y resist reinnoculation with the
same neoplasm. It was due to this observation that a method of active
immunization against tumours was devised [Besredka 1935]. This
consisted of innoculating susceptible animals intradermal1y with a small
amount of tumour cell suspension. In a number of cases, the resulting
tumours will regress, and the animals that recover remain immune to a
further tumour challenge. In order to eliminate the possibility that the
immunity obtained was caused by genetic differences between tumour and
recipient, work was done using in-bred mice [Gross 1943]. One hundred
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and fifteen mice of the C3H strain were innoculated i.d, with a cell
suspension of a sarcoma that had been induced by methylcholanthrene in
an animal of the same line. Spontaneous regression of the intradermal
tumours was seen in 21 animals. Repeated intradermal reinnoculation
with the same tumour was generally unsuccessful, showing that
immunity resulting from the intra-dermal dose was specifically against
the tumour, and does not depend on genetic differences. This premise was
further substantiated in work by Prehn, Klein and Old.
Despite all this work there still remained a further question to be
answered. Scientists had observed that while oncogenic mutations are
common, the development of cancer was relatively rare. This led to the
concept of 'immunosurveillance', or the abilty of the body to 'mop up'
malignant cells, before tumours developed [Burnett 1970]. In addition
spontaneous tumour regression was seen in malignant melanomas and
Grawitz tumours, further substantiating a link between the immune
system and tumour development [Fairlamb 1981][McGovern 1975].
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Tumour associated and tumour specific antigens.
There are two categories of antigen, or epitope, present on the
surface of cancer cells - tumour associated (TAA), and tumour specific
(TSA). The former may occur due to over-expression of a normally
expressed antigen, re-expression of antigens normally repressed in
differentiated tissue, or the occurrence of antigen on tissue where it is not
normally present. They are not confined to a single type of malignancy -
CEA for example is a TAA that occurs on colorectal, gastric, breast and
pancreatic. TSA's such as k-ras form either through cellular mutations or
by the expression of viral glycoprotein envelopes on cell membranes
[Lennox ES 1982].
There are a number of different immunotherapeutic strategies
currently under evaluation, all of which will be discussed. They include
active non-specific immunotherapy, adoptive immunotherapy,
monoclonal antibody therapy and active specific immunotherapy (ASI).
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Active Non Specific Immunotherapy.
Active non specific immunotherapy aims to augment the body's
immune response, without directing it against any individual TSA or
TAA. This followed on from the work of Coley, and to date a number of
approaches have been assessed.
Intraperitoneal administration of Bacille Calmette-Guerin (BCG) to
19 patients with advanced colorectal cancer showed encouraging results,
with minimal toxicity [Falk RE 1976]. A median survival of 13.2 months
was observed, though patients did in addition receive 5-FU. A significant
prolongation of disease-free interval and survival, was seen in 83 patients
with Dukes C tumours, randomised to receive BCG+/- 5-FU [Mavligit GM
1976]. The comparison however was made with a historical control group,
and results therefore need interpreting with caution. BCG has been used
prospectively in conjunction with autologous colorectal tumour cells in
patients with Dukes Band C cancers [Hoover HC 1993]. There was
however no significant difference in terms of survival or disease-free
survival between the 41 patients who received the vaccine, and the 39
unimmunised patients in the control group. Other work using BCG in
patients with Stage II and III disease, has confirmed the lack of benefit, in
terms of overall, and disease-free survival [Richards F 1979].
IL-2 is a 15.5 kDa glycoprotein that plays a central role in immune
regulation [Smith KA 1988]. Rosenberg's group administered the cytokine
alone to 155 patients with advanced malignancy [Rosenberg SA 1989].
While objective response rates of 22% and 24% were seen for renal cell
adenocarcinoma and melanoma, there was no regression of any colorectal
cancer metastases. Four patients died of therapy related complications, and
many experienced nausea, vomiting, diarrhoea, and malaise. Other side
effects noted included a decrease in peripheral vascular resistance,
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hypotension, oliguria, and increased capillary permeability. IL-2 has been
given pre-operatively to 50 patients with metastatic colorectal cancer
[Brivio F 1996]. The cytokine effectively neutralised any post-operative
lymphocytopaenia, and a prolonged survival time was seen. It should
however be noted that all patients received 5-FU and folinic acid. Murine
studies have suggested that IL-2 may act synergistically with IL-1 [Proietti E
1993]. Administration of both cytokines to 14 patients with advanced
colorectal cancer, showed objective responses in 7, with toxicities similar
to those described above [Triozzi P 1995]. A combination of IL-2 with IL-4,
and use of the killer cell growth factor IL-12 have also been proposed as
potential forms of active non-specific immunotherapy [O'Hara RJ
1997][Yamaue H 19%].
Levamisole is minimally toxic, and has been shown to augment the
immune response by potentiating T cell, macrophage and neutrophil
function. Results in the clinical setting have however been disappointing,
with 2 randomised trials showing no survival benefit, when compared
with placebo [Arnand JP 1959][Chlebowski RT 1988].
Recent work presented at the 1997 American Association of Cancer
Research, has suggested that diphtheria toxoid may act as an
immunostimulatory agent in patients with high risk cancer [Buzzi S 1997].
Significant increases in serum levels of IL-2, IL-6, IL-8 and TNF-a were
seen following administration, with only 2 of the 22 patients showing
evidence of recurrence at 5 years.
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Adoptive Immunotherapy.
Adoptive immunotherapy is a treatment approach in which cells
with anti-tumour reactivity are administered to a tumour-bearing host, in
which they mediate, either directly, or indirectly, the regression of the
established tumour [Rosenberg SA 1988]. This approach showed
encouraging results in animal tumour models, and as such was extended
to the treatment of humans [Fefer A 1976][Kedar E 1983]. There are broadly
speaking two strategies. The first involves leukapherising mononuclear
cells from the peripheral blood, stimulating them with IL-2, and
reinfusing them into the patient. The second requires lymphocytes to be
separated from fresh tumour specimens, stimulated in IL-2, and then
infused back into the patient.
Incubation of human peripheral blood lymphocytes with IL-2,
generates lymphoid cells capable of lysing fresh NK resistant tumour cells.
These have been termed LAK cells. Adoptive transfer of LAK cells in
combination with IL-2 caused regression of pulmonary and hepatic
metastases from MC-38 murine colon adenocarcinoma [Lafreniere R 1985].
Provisional work showed partial responses in 3 of 26 colorectal cancer
patients receiving LAK + IL-2 [Rosenberg SA 1987], with toxicity confined
to hypotension, weight gain, and oliguria. Further work has confirmed
these findings, with one complete, and four partial responses seen in a
total of 30 patients [Rosenberg SA 1989].
A combination of freshly isolated expanded TIL, infused with
cyclophosphamide and IL-2, caused regression of all hepatic metastases in
mice bearing the MC-38 colon adenocarcinoma [Rosenberg SA 1986]. In
view of this sixty-six patients were treated with this regime, of whom 2
had colorectal cancer. Objective responses were seen in up to 50% of
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patients, though these were generally in melanomas, and renal cell
carcinoma [Rosenberg SA 1989].
Adoptive immunotherapy suffered a setback when work was
published suggesting that expanded TIL become trapped in liver, lungs
and spleen, rather than at the tumour site [Griffith KO 1989]. Despite some
work to the contrary, suggesting that TIL could be seen in 68% of
melanomas, Rosenberg's work has now concentrated on adhesion of TIL
to endothelium [Pockaj BA 1994][Adams DH 1997].
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Monoclonal Antibody Therapy.
The work of Ehrlich was further continued in 1953 by Pressman D
and Korngald L. They showed that radiolabel1ed polyclonal sera could be
used to image rat osteosarcoma, thus showing that specific anti-tumour
antibodies could be raised in vitro. Further work along these lines was
made possible by the development of hybridomas for the production of
monoclonal antibodies [Kohler 1975]. Examples include 17-1A, a murine
IgC2a antibody against a 26kDa polypeptide tumour associated antigen,
known as CA 733-2 (or CO 17-1A), present on the surface of colorectal
cancers, and CA 19-9, now more commonly used in pancreatic carcinoma
[Herlyn M 1979][Koprowski H 1981][Ross AH 1986]. 791T/36 is a murine
monoclonal antibody against a 72 kDa glycoprotein expressed on a human
osteosarcoma cell line [Embleton MJ 1981]. Further work has shown that
this TAA is present on ovarian and bladder cell lines, and more
importantly is present on 70% of primary colorectal tumours, and 85% of
secondaries [Armitage NC 1984][Farrands PA 1982].
Hybridoma techniques have enabled antibodies against tumour-
antigens to be manufactured in unlimited quantities. Therapeutic
applications of these antibodies may centre on their use as
immunotherapy agents, in radioimaging, or as carriers of cytotoxic agents.
Antibody coated tumour cells may be destroyed by a variety of
mechanisms, including apoptosis, complement-dependent cytolysis, and
antibody-dependent cell-mediated cytotoxicity (ADCC). A review of 8 trials
using 17-1A in over 200 patients with colorectal cancer showed a response
rate of around 5%. The effect was short-lived, though associated toxicity
was low [Wadler S 1991]. A further 5 of 24 patients with metastatic
colorectal cancer showed evidence of tumour regression [Fagerberg J
1995a].As ADCC is one of the effector mechanisms for tumour cell death,
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then the action of the antibody should be potentiated by granulocyte
macrophage-colony stimulating factor (GM-CSF). This was thus tested on
20 patients with metastatic cancer. Two patients achieved complete
remission, with one showing a minor response. A further two patients
had stable disease [Ragnhammar P 1993]. 17-1A antibody has been used as
post-operative adjuvant therapy in 189 patients with Dukes C tumours.
Patients receiving 17-1A had a 30% and 27% reduction in death and
recurrence rate, respectively. Toxic side effects were infrequent, consisting
of only mild constitutional and gastrointestinal symptoms [Riethmueller
G 1994]. An update of this work was presented at the American Society of
Clinical Oncology in 1996, confirming reductions in mortality rate and
tumour recurrence by 32% and 23% respectively, after a median follow up
of 7 years [Riethmueller G 1996]. This data is currently being tested in a
randomised, multicentre Phase III study, recruiting patients with Dukes C
tumours to one of three arms 5-FU and FA, m17-1A and 5-FU and FA +
m17-1A [Pullyblank AM 1997].
Monoclonal antibodies may also be bound to radionuclides, and
used in conjunction with other imaging modalities for the detection of
colorectal malignancy. Initial work was performed on resected specimens,
in order to confirm that antibody had localised within the tumour
[Farrands PA 1982]. Imaging using the same radionuclide bound to
791T/36 demonstrated a specificity of 56% in primary tumours, and 87% in
disseminated disease [Armitage NC 1984]. Monoclonal antibodies may also
be used to deliver therapeutic doses of radiation direct to tumours -
radioimmunotherapy. The concept has been investigated primarily in
haematological malignancies, but has been extended to advanced
colorectal cancer [Press OW 1993]. A Phase I study using chimeric T84.66
(an anti-CEA IgG1) labelled with 90Y has been performed in 3 patients
[Wong JYC 1995]. They found no evidence of antibody related toxicity, and
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concluded that this was potentially a valid therapy. A recent review has
called for a multicentre study using this approach, and for further work to
optimise antigen targetting, radionucleotide, and fractionation [Bischof
Delaloye A 1995]
In a similar vein to the work outlined above, it has been possible to
use monoclonal antibodies to deliver cytotoxic agents to the site of the
tumour. In vitro experiments have been performed using the
immunotoxin XMMCO-791-RTA, a conjugate of 791T/36, and the plant
derived toxin ricin A. The immunotoxin has shown specific. effects
against gp72 expressing cell lines, and human tumour xenograft [Byers VS
1987][Embleton MJ 1986]. A phase I study on 17 patients with advanced
colorectal cancer showed evidence of response, but up to a 25 % incidence
of mental disturbance [Byers VS 1989]. An immunoconjugate of 30.6,1-1,
JCT and n-acetylmelphelan has been used in a phase I study on patients
with identical disease to above. Three patients showed minor responses,
with acceptable, minor levels of toxicity, following hepatic artery infusion
[Tjandra JJ 1989].
Antibody-directed enzyme prodrug therapy (ADEPT) is a new
treatment for cancer, in which an antitumour antibody conjugated to an
enzyme is given intravenously. The antibody causes the enzyme to
concentrate in the tumour after it has been cleared from normal tissues. A
prodrug is then given, which is converted by the enzyme to an active
cytotoxic drug within the tumour. One such enzyme is the bacterial
carboxypeptidase C2, which may be used in conjunction with the prodrug
CMDA, a monomesyl benzoic acid mustard alkylating agent, inactivated
by linkage to a glutamate. The CRC is due to launch a trial of ADEPT in
patients with advanced colorectal cancer in 1997 [Leonard PC 1997].
The majority of antibodies used in the aforementioned work are
murine in origin. These have the propensity to be recognised as foreign by
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the patients immune system, leading to HAM A (Human anti-mouse
antibodies) in 30-50% of patients [Courtney-Luk LS 1986][Larson SM 1983]
[Schroff RW 1985]. The formation of HAMA can hasten blood clearance,
and thus compromise the imaging or therapeutic efficacy of the antibody
[Klein JL 1988][Pimm MV 1985]. There are several ways of removing this
problem. The first is to link the animal variable region to the human
constant domain. These 'chimeric antibodies' are not as immunogenic,
and are thus less likely to form HAMA [Khazaeli MB 1990HLoBuglio AF
1992]. The desired specificity is however retained by the variable region
protein [Winter 1991]. Another way of reducing immunogenicity is to use
single-chain Fv antibodies. These consist of variable heavy and light
regions bound by a short synthetic peptide, and have the advantage that
protein that is not required for antigen binding is not included. There is
also the added advantage that these antibodies may penetrate further into
tumour, due to their lower molecular weight. MFE-23 is a high affinity
scFv against the tumour antigen CEA. Nine patients with colorectal cancer
were recently given MFE-23 labelled with iodine-123 [Begent RHJ 1996].All
known tumour deposits were located, and the authors conclude that this
method might be extended to encompass antibody-directed therapy, in
addition to imaging.
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Active Specific Immunotherapy (ASn.
Individual T-cell receptors are genetically determined, and are
capable of binding specifically to anyone of a large number of antigens,
which have been proteolytically cleaved and bound to cell surface
glycoproteins. These glycoproteins are encoded in a cluster of genes termed
the Major Histocompatibility Complex (MHC), and may be either Class I or
Class II. CD8+ lymphocytes recognize peptide bound to Class I MHC,
causing them to proliferate and differentiate into effector Cytotoxic T-
lymphocytes. CD4+ lymphocytes interact with antigen in association with
MHC Class II, forming either Inflammatory TH1 cells or Helper TH2 cells
(Figure 1). The former interact with Cl'L, macrophages, and NK cells, and
secrete a wide variety of cytokines including IL-2, TNFa and IFN-y. The
latter produce cytokines such as IL-4 and IL-10, that stimulate B cell
proliferation. It is T-cell responses, rather than antibody responses, that are
the most effective against tumours [Robins 1986].
Tumour antigens are incapable of eliciting an immune response
per se, for a number of reasons. To be recognised by T-cells, antigen must
be presented by specific Antigen Presenting Cells (APC), with a co-
stimulatory signal delivered through the T cell surface molecule CD28, by
its natural ligand B7.1 [Hodge JW 1994]. B lymphocytes, macrophages and
dendritic cells are all capable of acting as APCs, presenting such epitopes to
T lymphocytes. Without this co-stimulatory signal, anergy occurs, and no
immune response is generated. Colorectal tumour cells are very poor at
presenting antigen to T-Iymphocytes. This may be due to their inability to
process epitope, an absence of adhesion or co-stimulatory molecules, the
presence of inhibitory cytokines, or the fact that these tumours have low
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expression of the MHC molecules necessary for interaction with the T cell
receptor [Gimmi C 1996].
As the name suggests, ASI attempts to stimulate the immune
system to target a specific antigen, on the surface of tumour cells. A
number of different approaches have been adopted. Anti-idiotypic
antibodies mimic antigen, and elicit T cell responses. Polynucleotide
vaccines (DNA and RNA) encode the tumour antigen, while vaccines
based on viral vectors provide an alternative way of altering the host
genome. Oncogene products may act as TAAs, against which vaccines
may be developed, and autologous tumour may be processed to form
mucin or heat shock protein based vaccines. Adjuvants aiming to enhance
ASI are also discussed.
Heat Shock Proteins (HSP).
Heat shock proteins are a group of proteins present in all living
cells. HSP preparations contain a broad array of pep tides tightly bound to
HSP molecules [Li Z 1993][Udono H 1993]. They offer a number of
advantages, as cancer vaccines. If a lasting therapeutic effect is to be
conferred by a vaccine, then a cytotoxic T-cell response needs to be
generated [Leclerc IC 1973][Rouse BT 1972][Topalian SL 1990]. HSP's can
not only generate this, but can in addition can show evidence of a memory
T-cell response [Janetzki S 1994]. Vaccination with HSP-peptide complexes
circumvents the necessity for identification of the antigenic epitopes of
cancer cells, as HSP's are naturally complexed with the entire repertoire
generated in the cell. Another ad vantage of such an approach is that an
immune response will be generated against all antigens present in the
tumour. In addition they require no adjuvants in order to elicit a Cl'L
response, and the complexes can be purified rapidly. As the vaccine is
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autologous, no material is innoculated into the patient, that they haven't
already been exposed to, thus reducing the chance of toxicity.
A number of studies have shown that injection of apparently
homogeneous HSP preparations from a given tumour to syngeneic rats or
mice, renders the animal resistant to that particular tumour [Srivastava
PK 1984][Srivastava PK 1986][Ullrich SJ 1986][Palladino MA 1987]. For this
treatment modality to be successful, each vaccine would have to be
"custom built" for individual patients, using autologous tumour. Though
toxicity would be minimal with this approach, if it proves technically
difficult, excessively time consuming, or expensive, then it will not be
viable as a vaccine for colorectal cancer. Despite these limitations, Phase I
studies are currently ongoing [Srivastava PK 1996].
Mucins.
Human epithelial mucins are a family of high molecular
weight glycoproteins that lubricate and protect the underlying gastro-
intestinal mucosa. They are characterized by a large number of 0-
glycosylated tandem repeat domains which vary in length, number, and
extent of O-glycosylation [Fontenot JD 1993][Strouss CJ 1992]. Novel mucin
epitopes are expressed by tumour cells, due to aberrant glycosylation of
pre-existing mucins [Itkowitz S 1991][Jerome KR 1992]. This results in
shorter sugar side chains, with concomitant exposure of peptide antigens
(Figure 3).
Evidence has accumulated showing that T cells specific for native
epitopes on the mucin polypeptide core tandem repeat can be expanded in
vitro [Barnd DL 1989][Jerome KR 1991]. Further work has also shown that
a humoral response may be generated, with B cells recognizing the mucin
tandem repeats [Kotera Y 1994].Thus antibodies have been detected in the
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blood of patients with colonic carcinomas, breast and pancreatic tumours
[Gourevitch MM 1995}.
A vaccine has been formed by transfecting the gene for the tumour
associated antigen (MUC-1) into Epstein Barr virus immortalized B cells
[Pecher 1996}. The latter act as Antigen Presenting Cells priming cytotoxic
T-cell precursors and Delayed Type Hypersensitivity (DTH) responses in
the two chimpanzees immunized. A Phase I study using a 105uu MUC-1
peptide admixed with BCG has recently been used in 30 patients with
advanced colorectal cancer [Goydos JS 1996]. A number experienced
ulceration at the injection site, and systemic symptoms such as fever,
rigors and malaise. Immunological1y, DTH responses were seen against
mucin-specific peptides, and 7 out of 22 patients tested showed a 2-4 fold
increase in CfL [McKolanis JR 1996}. Clinically, however, only two
patients had stable disease. Eleven patients with advanced colorectal
cancer have been immunized with Theratope® sialyl-Tn-KLH cancer
vaccine in Detox™ adjuvant, following low dose cyclophosphamide
therapy [Reddish MA 1996}.This Phase II study showed that patients with
higher anti-Sialyl-Tn IgG antibody titres following vaccination survived
longer than patients with lower titres, thus suggesting an immune
response.
Recently it has been reported that the gene MUC-1 can be expressed
in baculoviruses, leading to the expression of underglycosylated mucin
molecules [Ciborowski P 1996}. This may remove the need to process
autologous tumour, making this approach more attractive.
Peptides.
Peptide vaccines can bind to MHC molecules and elicit immune
responses, as described. Generation of CfL would be further enhanced if
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the peptide was presented by an APC, such as a Dendritic cell (DC)
[Steinman RM 1993]. In vitro work using a murine model has shown
that antigen-specific Cytotoxic T-Lymphocytes may be generated following
subcutaneous administration of irradiated bone-marrow derived DC,
pulsed with OVA peptide in vitro [Young 1996]. These results have been
confirmed in a separate study, which in addition showed that RMA-S cells
and normal syngeneic adherent splenocytes were effective in eliciting CTL
in the B16/F10.9 melanoma tumour model [Nair SK 1997]. Immunisation
of mice with mutant p53 peptide-pulsed DC generated from stem cells of
other tumour bearing mice can induce effective anti-tumour CTL
responses, and lead to significant antitumour effects [Gabrilovich DI 1996].
If the T-cell epitope is as yet undefined, as is the case for a number of
cancers, then CfL can still be generated using unfractionated acid-eluted
tumour peptides in conjunction with the method outlined above
[Zitvogel L 1996].
Mutations in codon 12 of K-ras are frequently found in pancreatic
adenocarcinomas [Gjertsen MK 1995]. Mutant p21 ras is therefore a
tumour specific antigen, that can be recognised by human T-cells [Jung
1991]. Synthetic ras peptides have been used in conjunction with antigen-
presenting cells as a vaccine for pancreatic cancer, with encouraging
results. This approach could also be applied to colorectal carcinomas,
which also show mutations in codon 12 of K-ras . As with heat shock
proteins, this approach necessitates formation of vaccine from autologous
tumour, with its attendant difficulties. It clearly is advantageous when the
tumour antigen has not been identified, or is difficult to purify. One
potential drawback of immunising with unfractionated tumour material,
as compared with defined antigens is the theroretical risk of developing
autoimmune disease [Nair SK 1997].
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Polynucleotide-med iated immunisation
Intramuscular delivery of DNA or RNA vaccines has been shown to
lead to gene expression in myocytes and myofibroblasts. This will lead to a
continuous intracellular production of protein antigens that may be
presented in association with Class I MHC molecules, thus eliciting Cl'L
responses [Wolff JA 1990][Ulmer JB 1993].
The advantages of DNA vaccines are numerous. They can, for
example, be easily purified, coated on gold particles, and given directly
into tissues by gene gun (bolistics). DNA may also be combined with genes
for cytokines such as IL-2, IL-6 or IL-7, or GM-CSF, in order to enhance the
immune response generated [Irvine KR 1996][Syrengelas AD 1996].
Work has shown that mice may be immunised with a plasmid
encoding the full length of complementary DNA for CEA [Conry RM
1994]. Evidence of humoral and cellular responses against the glycoprotein
were seen in all of the 5 mice immunized, and 3 generated CEA-specific
memory T cells. In addition a further 2 had IL-2/IL-4 release in response to
CEA. Use of a minigene coding for a single antigen derived from mutant
p53 has been shown in a mouse model to elicit Cl'L [Ciernik IF 1996].
Clearly evidence exists supporting this approach as a potential vaccine
strategy. There are however no Phase I studies relating to its use in
colorectal cancer, as yet.
Viral Vectors
Viruses may be used as vectors, to transfect cells with genes encoding
tumour associated antigens. The aim of this gene therapy approach is to
co-present a weak immunogen, such as CEA, with a highly immunogenic
viral protein, in order to enhance the immune response. The DNA
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encoding CEA is inserted into viruses, such as retroviruses, adenoviruses,
baculoviruses, herpes, pox and vaccinia viruses. Cells infected express a
protein product, recognised by anti-CEA antibodies. Animal work has
shown that effective humoral and cell mediated responses can be
generated, that correlate with delayed tumour growth [Kaufman H 1991]
[Kantor J 1992][Kantor J 1993]. Phase I studies have used vaccinia encoding
CEA, in patients with colorectal cancer [Hamilton JM 1994]. Toxicity was
confined to inflammation at the injection site, and further work has
shown that cytolytic T cell responses can be generated using this approach
[Conry RM 1995]fTsang KY 1995].
The antigen 17-1A has recently been cloned, and expressed in
baculovirus [Herlyn D 1997]. Alum precipitated recombinant antigen
induced in mice, in conjunction with peritoneal macrophages as effector
cells, has shown DTH responses. This vaccine has been administered to 7
patients with pancreatic and colorectal cancer. Four developed antibody
responses.
Rosenbergs' group has recently shown that the most effective route
of administration of a viral vector is intravenous. They postulate that
once systemic, the virus is capable of infecting a larger number of cells,
especially those in the reticuloendothelial system [Irvine KR 1997]. In spite
of the interesting results in vivo, there may however be potential
problems associated with the use of live attenuated, or recombinant
vaccines, and it has been shown that immune responses generated after
the first immunisation may inhibit replication of recombinant vaccinia
virus innoculated at subsequent injections [Hodge JW 1994].
Safety and regulation are key issues in this area of gene therapy, as
highlighted in a recent editorial in the Lancet (12th July 1997). Concerns
have been raised about lymphomas developing in monkeys exposed to a
retrovirus, and spongiform encephalomyelopathy occurring in mice
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innoculated intra peritoneally with amphotropic murine leukaemia virus
[Munk 1997]. A safer alternative would be to use non-replicating viruses
such as avipox, especially if the vector is to be given IV. There is however
good evidence that viruses may be used as vectors for gene delivery, to
generate Cl'L responses against tumour cells. However unless toxicity and
regulatory issues are addressed, it seems likely that non-viral approaches,
such as liposomes, molecular conjugates, and naked DNA injection may
be more promising.
Adjuvants.
The aim of an adjuvant is to augment the intended immune
response. There have however been concerns relating to their potential
toxicity [Gupta RK 1993]. Reports of sterile abscesses, autoimmunity, and in
some cases cancer have all been documented [Hardegree. 1966][Hil1eman
1966]. An increased understanding of the properties of oil-based
formulations, and the emergence of novel vehicles such as liposomes, and
other particulate carriers, has however resurrected interest [Alving eR
1995].
In view of the fact that the adjuvant field has become progressively
more involved, a new classification has been proposed [Edelman 1990]. In
this scheme, immunostimulating formulations can be divided into three
primary categories: adjuvants, carriers and vehicles. The adjuvants
include direct immunostimulating substances such as aluminium salts,
lipopolysaccharides, lipid A, and muramyl dipeptide derivatives. The
carriers are molecules that provide T-cell help for attached antigens.
Vehicles, such as liposomes and oil-based emulsions, provide a
"substrate"or platform for adjuvant, or carrier effects. They also provide a
delivery mechanism, or depot site for entry into antigen presenting cells.
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The classification may also include the term "adjuvant formulation",
referring to mixtures of the aforementioned categories. An example would
be liposomes adsorbed onto aluminium hydroxide. As can be imagined
there is a considerable degree of overlap between the sub-divisions
described.
As advances are made in adjuvant technology, their ability to
enhance an immune response will increase. If this can be combined with
any of the vaccine strategies outlined below, then a more efficacious form
of therapy will be developed.
Anti-idiotypic antibody immunisation.
Immunisation with anti-idiotypic monoclonal antibodies may offer
an alternative immunological approach to tumour therapy. The
theoretical basis of this treatment modality is outlined in the network
hypothesis [Lindenmann J 1974]. The premise is that antibodies (Ab1)
against tumour associated antigens have specific idiotypes in their variable
regions. Ab2 is an antibody against this idiotype. The anti-idiotypic
monoclonal antibody may therefore 'mimic' the antigen on the surface of
the tumour cell (Figure 2). The concept of the anti-idiotypic antibody
acting as an 'internal image' of the antigen implies that this novel
presentation of tumour epitope should elicit an immune response
[Nisonoff A 1981][Roitt 1M 1981][Chattopadhyay P 1992]. The Ierne
hypothesis also predicts the development of anti-anti-idiotypic
monoclonal antibodies (Ab3).
This approach has a number of advantages over other forms of
immunotherapy. Anti-idiotypic monoclonal antibodies may be presented
by antigen-presenting cells in the context of Class I and II MHC, thus
eliciting both cytotoxic and helper responses. Presentation of the epitope
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in a different molecular environment may also act to break any tolerance
that may have developed to the weakly immunogenic TAA's
[Raychaudhuri 1989]. Anti-idiotypic monoclonal antibodies have a longer
half life in the peripheral blood, and are more resistant to proteolytic
digestion. They can also be used when the TAA is either unknown, or
difficult to purify in the required quantities. In addition there is evidence
that the anti-idiotypic antibody may be more effective in eliciting an
immune response than the actual antigen. Neonatal mice, incapable of
responding to a bacterial capsular polysaccharide, were able to mount an
immune response to the antigen, when vaccinated with anti-idiotypic
MAb [Stein KE 1984]. Furthermore in vitro human antigen-specific B-cell
responses were more effectively induced by anti-idiotypic antibody vaccine
than immunisation with group A streptococcal carbohydrate antigen
[Bloem AC 1988]. The framework of the anti-idiotypic antibody is unlikely
to express competing T cell epitopes, and the Fe region itself may be
preferentially internalised and processed by Fe receptors expressed 0 n
antigen presenting cells. Anti-idiotypic antibodies are also cheaper, and
less likely to give rise to autoimmune reactions [Bhattacharya Chatterjee
M 1994]. Furthermore they are free from the potential dangers of
retroviruses and genetic manipulations. Clearly the advantages to this
form of therapy are numerous.
The premise that anti-idiotypic monoclonal antibodies could
stimulate immunity has been tested. In addition to showing induction of
helper and suppressor T cells for humoral immunity [Eichmann K 1978],
various workers found that delayed-type hypersensitivity (DTH) responses
could be elicited in animal models. Such responses to p
-azobenzenearsonate (ABA) were observed in A/J mice following IV
injection of anti-cross reactive idiotypic (CRI) antibodies, providing that
the animals had been pre-treated with cyclophosphamide [Sy M-S 1980]. T
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cells from lymph nodes taken from vaccinated mice could also transfer
immunity to naive recipients. Similar resu1ts have been obtained in AIJ
mice, using 14A, an anti-idiotypic monoclonal antibody against a
determinant on anti-ABA antibody [Thomas WR 1981].
Hyperimmunisation of BALBI c mice with MCA-1490 sarcoma produced
an antibody (4.72) that could induce DTH responses upon transfer to naive
mice [Forstrum JW 1983]. This response was both antigen-specific, and
allotype restricted, confirming that it was anti-idiotypic,even though the
Ab1, or antibody against MCA-1490 hadn't been established. The work did
however add further support to the concept of anti-idiotypic
immunisation, and show that immunity could be transferred.
The abilty of anti-idiotypic monoclonal antibodies to elicit an
immune response that could be protective against a tumour challenge has
also been established [Dunn PL 1987]. HIM/1/230 is an antibody (Ab2)
against an idiotype on 111160 (Ab1). The latter is an antibody against an
epitope on the Hooded rat sarcoma HSN. Vaccination with 3 challenges of
anti-idiotype stimulated production of Ab3, indistinguishable in antigen
specificity from 11/160. Immunised animals also showed reduced tumour
take following an i.v, challenge with HSN celIs.
Polyc1onal anti-idiotypic antibodies to C017-1A and GA733 have
been developed [Herlyn D 1985][Herlyn D 1986]. When rabbits were
immunised with C017-1A, antibodies were produced which bound to
human tumour cells expressing the TAA recognised by C017-1A. In view
of these provisional results, 30 patients with advanced colorectal cancer
were immunised with between O.5mg and 4mg of alum-precipated
polyclonal goat anti-id antibody [Herlyn D 1987]. Humoral responses were
seen, and all showed evidence of Ab3 production. This antibody showed
identical binding of tumour cells as that observed with Abl. Six patients
showed partial clinical remission and a further seven showed arrest of
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metastases following treatment. Of these 13 patients, 9 also received
chemotherapy, making conclusions about the efficacy of Ab2 more
difficult. A follow up trial by the same group used a different goat
polyclonal antibody in 12 patients who had undergone resection of their
primary tumours [Herlyn D 1991]. Six of these patients developed Ab3, and
2 had antigen specific T cells, which proliferated in culture on stimulation
with the GA733 antigen. In addition 7 of the original 12, showed tumour
remissions which lasted between 1.1 and 4.1 years following
immunisation. In support of Herlyn's work, evidence of cellular
immunity has been seen in a further patient with advanced colorectal
cancer [Samonigg H 1992]. This group used SCV106, a goat anti-idiotypic
monoclonal antibody that mimics the TAA 17-1A. The patient concerned
had two lung metastases from previously resected colonic carcinoma.
These were removed after completion of the antibody course, and
subjected to analysis. Antibodies eluted from resected tissue were
confirmed to be anti tumour antigen in conventional ELISA, and
immunohistochemical analysis of tissue confirmed "massive" infiltrate of
T-helper, and cytotoxic T cells.
An anti-idiotypic monoclonal antibody mimicking the TAA GA733-
2 has been given to patients with primary colorectal cancer [Fagerberg J
1995 b]. DTH responses, IL-2 and IFNy were seen in all patients, indicating
T cell immunity. Five patients had evidence of Ab3 production, suggesting
a humoral response against the anti-idiotypic antibody.
Recent work has shown how passive immunotherapy with
unconjugated monoclonal antibodies may give rise to an idiotypic
network response, that correlates with clinical response [Fagerberg J 1995
a]. Twenty-four patients with metastatic colorectal cancer were treated with
MAb 17-1A. After completion of therapy, five of the patients had
peripheral blood T cells specifically recognizing human anti-MAb 17-1A
38
idiotypic antibodies. These same five patients were the only ones in the
study who had any objective tumour regression, following MAb therapy.
The association between the presence of anti-idiotypic reactive T cells and
clinical response was statistically significant (p=O.00002).Clearly this adds
further support to the concept of anti-idiotypic antibody immunisation.
The evidence outlined above suggests that anti-idiotypic antibodies
are capable of eliciting cytotoxic and helper T cell responses. It is likely that
following immunisation intradermally or intramuscularly, antibodies are
taken up by Langerhans cells, a subset of immature tissue Dendritic cells
(DC). Following antigenic stimulation these cells resume their migratory
behaviour, travel to draining lymph nodes, where they arrive as mature
DC. Such DC are particularly adept at antigen presentation because they
express high levels of MHC, co-stimulatory molecules, and adhesion
molecules. It was initially thought that peptides generated in the cytosol
could only be presented in association with MHC Class I molecules, and
those in intracellular vesicles with MHC Class II. More recent work has
shown . that antigen from the extracellular fluid, and on
liposomes/ adjuvants may also stimulate Cl'L [Kovacsovics-Barkowski S
1993]
The anti-idiotypic monoclonal antibody 105AD7.
The anti-idiotypic monoclonal antibody 105AD7 was originally
developed at the University of Nottingham [Austin EB 1989].A patient
with advanced colorectal cancer received the murine monoclonal
antibody C46 (Amersham), against CEA, and subsequently suffered a
Type1 hypersensitivity reaction. It transpired that he had previously been
given radiolabelled 791T/36 in order to image liver metastases. In the
ensuing search for HAMA, an anti-idiotypic antibody that inhibited
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binding of 791T/36 to gp72 positive tumour cells was discovered. This was
termed 105AD7.
Pre-clinical studies showed that 10SAD7 could induce DTH responses
to human tumour cells in experimental animals [Austin EB 1991]. In view
of these preliminary results, a Phase I study was performed. Thirteen
patients were recruited over a twelve month period beginning in
February 1990. All had liver metastases from previously resected colorectal
cancer, and two of these had evidence of extra-hepatic disease [Denton
GWL 1994].
A control group consisted of forty-five contemporary patients with
advanced colorectal cancer. These were entered into 'treatment', and 'no
treatment' arms of a multicentre Phase III study using an oral
chemotherapeutic agent. Thirty-seven of these patients had liver
metastases.
The monoclonal anti-idiotypic antibody 105AD7 was produced in
vitro according to CRC/NIBRC guidelines [Robins RA 1991]. It was
purified by affinity chromatography, and sterilised by filtration and heat
treatment. Skin test doses of lOl1g in 0.1 ml in sterile saline, and
intramuscular doses of lOOllg on aluminium hydroxide gel (Alhydrogel
85, SuperPhos Biosector a/ s Vedbaek, Denmark) were formulated.
Samples of the seed lots passed testing for viral contamination, and
sterility.
Patients were immunised with an intradermal skin test dose of lOl1g
of 105AD7. They returned 24 hours later, and 7 received lOOI1g, and 6
patients 200llg of 105AD7 in aluminium hydroxide. Patients were
admitted to hospital for the first week post immunisation.
After discharge they were seen on a weekly basis for the following
five weeks. Patients were examined at each visit, and any new symptom
investigated. In addition to this peak expiratory flow rates, urinalysis, a
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full blood count, serum urea & electrolytes, liver function tests,
complement levels , and immunological analysis were all performed. A
chest X-ray and electrocardiogram were done pre-immunisation, at 1
week, and on completion of the study. In order to demonstrate disease
progression/ regression, computerized tomography was used to image
chosen indicator lesions at trial entry, and after each treatment period.
Patients whose clinical condition was satisfactory at the end of the study
were re-entered into further six week treatment cycles. Levels of IL-2 were
measured at each treatment cycle, and blastogenesis experiments were
carried out using cryopreserved lymphocytes. Patients serum was also
screened for the development of antibodies to 105AD7.
A total of 35 immunisations were given to 13 patients recruited
. during the study period. Each had a skin test dose of 10,1g of 105AD7 with a
further 100llg, or 200llg given intramuscularly. A second skin test dose was
subsequently given several days later. The most any individual patient
received was 7 treatment cycles.
The main aim of the Phase I study was to show that there was no
toxicity associated with immunisation with 105AD7. As such a number of
clinical observations were made following 105AD7 administration. All
patients remained stable following treatment with the study drug. The
only laboratory features of note were an elevation of lymphocyte count 2
days post-immunisation with the 100llg dose, and a concomitant decrease
in serum urea. Interestingly, none of these changes were noticed in those
patients receiving 2001lg. The only adverse event however, was one
patient who presented 5 weeks post-immunisation with melaena,
secondary to a bleeding duodenal ulcer.
Despite anti-idiotypic therapy, there was no evidence of regression of
malignant disease. The survival analysis was not performed until the
study had been completed, and was done from the date of diagnosis of
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advanced malignant disease. There was no significant difference between
this date, and the time of the original operation, in the immunised and
unimmunised groups (medians of 5.5 & 6 months respectively). Survival
was significantly better in the former group for both patients with hepatic
metastases (p=O.007), and those with advanced disease ( p=O.022 ). Analysis
of the time to disease progression similarly showed a significant differance
in favour of the lOSAD7 group in the two groups with advanced disease
(p=O.023, and p=O.013 respectively).
In terms of the immunological analysis, rune out of the thirteen
study patients had a significant blastogenetic response to gp72 expressing
tumour cells, or raised levels of IL-2 in their plasma. Six of these patients
had a response in both assays, though three failed to show a rise in either.
The highest level of IL-2 was seen following the first immunisation in
five patients, the third in one, and the fourth course in a further two. IL-2
levels were seen to be raised between 1 and 3 weeks post-immunisation in
all but one patient. Peak blastogenetic responses mirrored the findings for
IL-2 in that a maximum was reached after the first dose of 10SAD7 in five
patients, and after the second in two. The five longest surviving patients
showed a response in the immunological assays, thus showing agreement
between the two sets of results.
Further analysis of plasma samples failed to show any development
of anti-anti-idiotypic antibody (Ab3), or antibody development to tumour.
There was no evidence of hypersensitivity to l05AD7 on intra-dermal
skin-testing.
The most important point raised in the Phase I study was the lack of
toxicity associated with 105AD7 immunisation. This compares with
murine monoclonal antibody administration, where flu-like symptoms,
arthralgia, and myalgia have been described [Chapman PB 1992]
[Mittelman A 1992]. In the latter paper, local toxicity was also observed, in
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the form of erythema, induration and ulceration. This was thought to be
associated with the use of BCG, as opposed to the milder aluminium
hydroxide, as the adjuvant. The lack of toxicity may also equate to the use
of allogeneic rather than xenogeneic monoclonal antibody.
A median survival of twelve months in those patients immunised
with 105AD7 was 300% higher than that obtained in the control group.
This approximates to the figure obtained by Erlichman (12.6 months)
using 5-FU and Leucovorin in patients with liver metastases from a
colorectal primary. A survival of four months was however slightly lower
than historical data suggests [Zubrod CG 1%0]. Despite this observation, it
should be borne in mind that all patients were recruited concurrently
from the same clinic, and randomised within a separate chemotherapy
trial with identical eligibility criteria.
Nine of the thirteen patients showed either a blastogenetic response,
or evidence of IL-2 production on ELISA. The blastogenesis experiments
were carried out on a time-course set of lymphocytes. The proliferative
response observed was not shown with lymphocytes from patients prior to
immunisation. The response in patients 3,4 and 5 indicated that 105AD7
induced a specific recognition event.
Interleukin-2 is a marker of in-vivo T-cell activation, and clearly,
raised levels support the fact that 105AD7 causes a significant immune
response. Work has been done showing that if 3000 units/kg/hr of IL-2 is
infused, it achieves a serum level of 5-10 units/ ml [Lotze MT 1985].
Despite the fact that patients with advanced colorectal cancer have low
levels of the Iymphokine [Lissoni P 1990], JL-2 levels of this order of
magnitude were achieved post-immunisation.
The kinetics of IL-2 production are variable, with peak levels seen
after the first immunisation in five patients, the third cycle in one patient,
and the fourth cycle in a further two patients. Generally however elevated
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levels were seen 1-3 weeks post-immunisation. It is still unclear as to
whether the intradermal dose given contributes significantly to the
immune response observed, and also what the optimum dose of 10SAD7
actually is.
No evidence of anti-anti-idiotype (Ab3), or anti-tumour antibody
responses were observed following 10SAD7 immunisation. These have
however been shown by Chapman and Mittelman following
administration of mouse monoclonal anti-idiotypic antibodies. The doses
used however in these studies were higher, and the antibody was given in
conjunction with carrier proteins, and/ or BCG vaccine. Use of xenogeneic
antibody may increase immunogenicity, due to antibody constant regions
acting as carrier determinants. However the fact that 10SAD7 is human
derived may explain the lack of toxicity associated with its use.
Despite in vitro lymphocyte proliferative responses, no evidence of
Type IV delayed hypersensitivity was observed after i.d, challenge with
10SAD7. This probably relates to either the timing of administration, or
the processing of the soluble monomeric IgG molecule.
The phase I study has confirmed most importantly that lOSAD7 is
not associated with toxicity. It also showed that immunisation caused a
significant survival difference, T cell blastogenesis, and interleukin-2
production. The aim of this thesis is in part to test the survival results of
the Phase I study in a randomised, placebo-controlled Phase II study.
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Figure 1. Presentation of epitope in association with Class I and ITMHC, to CD4+
and CD8+ lymphocytes.
Figure 2. Concept of anti-idiotypic antibody immunisation, as applied to 1OSAD7.
105AD7
791 T/36
Figure 3. Aberrant glycosylation of tumour associated mucins.
Normal Mucin Tumour Mucin
Chapter 2
Phase II Trial of l05AD7.
Anti-idiotypic induction of anti-tumour responses in Advanced
Colorectal cancer patients receiving l05AD7 therapy.
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Aim
This study aims to determine whether immunisation with the anti-
idiotypic monoclonal antibody l05AD7 confers a survival advantage on
patients with advanced colorectal cancer.
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Materials and Methods.
Trial Design.
A randomised, double-blind, study comparing treatment with the
human monoclonal antibody 105AD7 against supportive therapy in
patients with advanced colorectal cancer. Patients were recruited in one of
the following four centres - Nottingham, Hull, Newcastle and Leeds. For
105AD7 to be clinically effective, it would need to confer at least a survival
advantage of 20% on immunised patients. Assuming a power of 90%, and
significance at the 5% level, then statistically 162 patients would need to be
recruited to the study.
Ethics Committee Aproval.
Approval by local ethics committees was obtained for this study.
Informed Consent.
The responsible physician informed the patient about the
background and present knowledge of the anti-idiotypic monoclonal
antibody 105AD7, with special reference to known activity and toxicity.
The patient was informed that the treatment was experimental and that
the exact degree of activity was unknown. They were also informed that
their inclusion in the study would contribute to our knowledge further.
Patients were made aware that this was a placebo controlled study, and
that they had a 50% chance of receiving the vaccine. It was emphasised
that the patient could refuse treatment, either before, or at any point
during the study. Refusal to participate involved no penalty, or loss of
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benefits to which the subject was entitled. An explanation of whom to
contact for answers to pertinent questions about the research, and research
subjects rights, and whom to contact in the event of a research-related
injury was given to the subject. Prior to entry into the study, written
informed consent was obtained.
Patients' General Practitioners were informed that their patient had
been recruited to the study, and were given an information sheet, and
contact telephone number, should they have further enquires relating to
the trial.
Medicine-Induced Injury.
The trial was conducted under the auspices of the Cancer Research
Campaign (Phase 111I Clinical Trial Committee), who would provide
patients with compensation for adverse side-effects.
Labelling.
Individual ampoules were unlabelled, with vaccine and placebo
indistinguishable to the naked eye. I.m. (Irnl) and i.d, (O.lml) doses were
attached to each other by a label. This label carried a letter indicating the
trial centre, and the number of the course I visit ( 1,2 or 3. ). Each of the 3
'pairs' of ampoules were stored in a sealed envelope prior to use, and
refrigerated at 4°C. No reconstitution was necessary. No known
interaction existed between 10SAD7/placebo and any other medication.
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Drug Accountability.
Stocks of 10SAD7 and placebo were stored at 4 QCin the Department
of Clinical Oncology, City hospital, Nottingham. Randomised trial drug
and placebo were stored at 4°C in a locked fridge in a locked room in the
Department of Surgery, Queens Medical Centre,Nottingham, prior to
administration. The drug/ placebo was stored in the various pharmacy
departments at the other trial centres.
Treatment.
The table below details the investigations performed at trial entry,
and weeks 6 and 12.
Parameter At trial entry At week 6 At week 12
105AD7/ placebo X X X
Full blood count X X X
U&E X X X
LFT X X X
CEA X X X
cr/USS X* X*
CXR X X
Weight X X X
WHO perf X X X
* Investigation performed only if available at trial centre.
50
Study Population.
INCLUSION CRITERIA.
Histologically diagnosed primary colorectal carcinoma with at least one of
the following :
• Histologically confirmed inoperable colorectal carcinoma.
• Metastatic colorectal carcinoma, either histologically confirmed, or a
single lesion shown to be enlarging on serial investigations.
• Multiple lesions on hepatic Computerized Tomography (Cf),
Ultrasound (USS), or Chest X-ray (CXR), after resection of a colorectal
adenocarcinoma.
Life expectancy greater than 3 months.
Written informed consent.
EXCLUSION CRITERIA.
• Acute intercurrent illness.
• Autoimmune or chronic haematological disorders.
• Other concomittant anti-cancer treatment within the last 3 months,
excluding surgery, and radiotherapy within the last 1 month.
WHO performance grading 3 or 4.
Women of child bearing age, pregnancy test positive, or not taking reliable
contraceptive precautions.
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Subsequent Treatment.
No conditions existed whereby patients received more than the 3
courses of 10SAD7/ placebo. Once patients were 'off study', they were not
routinely followed up. However contact was regularly made between
General Practitioner and referring Clinician, in order to document if the
patient receives any further treatment, and their date of death.
Concomitant Therapy.
Supportive therapy necessary for the general condition of the patient
was allowed, and was recorded. Chemotherapy and radiotherapy did not
exclude patients from analysis if given at least 4 weeks following the last
dose of 10SAD7/ placebo. These were recorded on Case Report Forms
(CRF), as well as any surgery or immunotherapy that the patient has
received.
Clinical Procedures.
• Pre-Clinical assessment.
The following were carried out prior to the patient receiving
10SAD7/ placebo:
a. History and establishment of baseline disease.
b. Physical examination.
c. Height and Weight.
d. WHO performance status.
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• During treatment assessment.
The investigations carried out while the patient was on-study are
shown above.
• Post-treatment assessment.
The only investigations carried out once the patient had received
the final dose were also documented.
Safety Evaluation.
Subject evaluability for toxicity was recorded on the CRF. Assessment
of Minor and Serious Adverse Events was performed either by clinicians
at the referring centre, Family Practitioners, or Investigators at Trial
centres. These were recorded on CRFs. The following were defined as
Serious Adverse Events (SAE):
a. Death occurring within 4 weeks after the last study drug administration.
b. Life-threatening events.
c. Events which are incapacitating, or permanently disabling.
d. Events which require, or prolong hospitalisation.
e. Clinical or laboratory events which lead to withdrawl of the drug.
f. Any event resulting from a drug overdose.
g. Any event that results in secondary cancer or congenital anomaly.
All serious adverse events were reported to the CRC Phase 1/11 Data
Centre within 24 hours of them occurring. The Data Centre were then
responsible for notifying the Protocol Chairman, and the other
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investigators. An Adverse Event form was submitted to the Data Centre
within 7 days of the event occurring.
Investigators, and others responsible for patient care instituted any
supplementary investigations and treatment as was deemed clinically
necessary. The findings of any post mortem performed was attached to the
patients CRF.
Any other adverse drug reactions which were CTC grade 3 or 4,
though did not fulfill the criteria for a serious adverse event, were
reported to the Data Centre within 2 weeks, and noted on an Adverse
Event form.
All minor adverse events were recorded on the CRF. In addition,
time to onset, duration, toxicity grade, treatment and outcome were also
noted. This information was obtained following discussion with the
patient, review of the CRC Patient Diary Sheet, and from correspondence
from General Practitioners and Referring Specialists. Diary sheets graded
from 0-4 the presence or absence of the following symptoms.
1. Nausea and Vomiting.
2. Loss of appetite.
3. Pain.
4. Tiredness.
5. Constipation or diarrhoea.
6. Fever or sore throat.
7. Hair loss.
Data Collection.
Responsibility for completion of Case Report Forms (CRF) was with
investigators at the individual trial centres. The study was monitored
according to the Cancer Research Campaign Phase 1/ II Clinical Trials
Committee Standard Operating Procedure DD /010.
The CRF was divided into the following sections:
Page Contents.
1. Patient demographics and eligibility check list.
2. Treatment prior to study entry.
3. Baseline disease at trial entry.
5. Dates of immunisation and concomitant treatment.
6. Adverse events noted during trial.
7. Laboratory investigations at each visit. CXR and er results.
8. Overall response to therapy.
10. Off study form.
12. Post-study treatment for malignant disease.
13. Survival follow up, and date of last contact.
Data Management.
Patients were registered at the Data Centre, according to the Cancer
Research Campaign Standard Operating Procedure DO/ 013. The CRC Data
Centre was located at 10, Cambridge Terrace, Regents Park, London.
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Location of Study Data.
Investigators at the individual trial centres were responsible for the
storage of patients CRFs. Details of the Trial centres involved in the study
has been previously documented.
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Results
Deviations from protocol.
All patients recruited to the study were evaluable, and eligible. A
number of patients received their course of 105AD7 I placebo, either early
or late. Thirty (48%) and 31 (53%) patients received their 6 week course of
105AD7 and placebo on time, with only 12 ( 19%) and 14 (23%) patients
over 7 days early, or late. At 12 weeks, only 15 (32%) and 15 (33%) received
105AD7 or placebo respectively at the intended time, with 13 (28%) and 13
(29%) patients immunised either 1 week early, or late.
There are a number of reasons why patients did not receive a course
on time. The most common were patient convenience, and
immunisations falling on Public/ University holidays. Some patients were
too unwell to attend on a set day, and were thus seen when they were well
enough.
Patient Population.
A total of 165 patients were recruited to the study. There were 93
men, and 72 women, with a mean age of 62 and 64 respectively. The
analysis was performed on the first 162 patients, of whom 85 had received
105AD7, and 77 placebo, as defined in the protocol. These patients had a
mean age of 63.2 and 62.3 respectively. Further demographic details are
documented in Appendix 1, Table AI-I. The male: female ratio in the trial
group was 52:34, as compared with 40:37 in the placebo arm. The mean
time from diagnosis of advanced disease, and entry into the study was
277.3 days in the 105AD7 group, and 278.6 days in controls.
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The primary tumour site was coded as either colonic, or rectal. The
ratio of the two in 105AD7 patients was 49:35, and 45:32 in controls. In 1
patient, the site was not recorded. The Dukes classification for the primary
tumours were 1 'A'(1.3%), 15 tB' (19.4%), 34 'C' (44.2%) and 27 'D' (35.1%)
in patients receiving 105AD7, and where it was recorded. The figures for
the four stages in control patients were 3 (4.8%), 12 (19.0%), 23 (36.5%) and
25 (39.7%) in the cases where it was recorded.
Originally patients were stratified into two arms - 'liver mets' and
'no liver mets', The CRF however detailed disease state at the time of
inclusion in the study, as shown in Table 1. Patients may also have had
disease in more than one anatomical location. The number of sites
involved by tumour is shown in Table 2.
Subject Compliance.
A number of patients withdrew from the study, and thus did not
receive the full three courses. Number of doses received, and the
percentage of the total, in each trial centre, per patient is outlined in Table
3. These figures relate to the total number of patients recruited ie 165.
Compliance for the 162 patients used in the statistical analysis is shown in
Table 4.
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Table 1. Sites of tumour in trial and control patients at trial entry.
Treatment
105AD7 Placebo
Primary tumour 10 (12%) 6 (8%)
Local recurrence 19 (22%) 30 (39%)
Regional nodes 13 (15%) 10 (13%)
Lung metastases 27 (32%) 20 (26%)
Liver metastases 61 (72%) 50 (65%)
Bone metastases 5(6%) 1 (1%)
Skin metastases 2 (2%) 2 (3%)
Brain metastases 1 (1%) 1 (1%)
Malignant ascites 3(4%) 3(4%)
Soft tissue 0 4(5%)
Peritoneal metastases 9 (11%) 7(9%)
Other metastases 2 (2%) 3 (4%)
Table 2. Number of anatomical sites involved with tumour, in trial and
control patients.
Total number of sites 105AD7 Placebo
1 41 (48%) 36 (47%)
2 26 (31%) 26 (34%)
3 10 (12%) 7(9%)
4 2 (2%) 5 (6%)
5 4(5%) 3(4%)
6 2(2%) 0
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Table 3. Number of patients receiving 1,2 or 3 doses in each of the 4 trial
centres.
1. Dose 2Doses 3.Doses Total
Nottingham 32 (25.8%) 19 (15.3%) 73 (58.9%) 124 (75.2%)
Leeds 1 (16.6%) 0 5 (83.4%) 6 (3.6%)
Hull 2 (11.2%) 7 (38.8%) 9 (50.0%) 18 (10.9%)
Newcastle 5 (29.4%) 4 (23.5%) 8 (47.1%) 17 (10.3%)
40 (24.2%) 30 (18.2%) 95 (57.6%) 165
Table 4. Compliance for the 162 patients considered in the statistical
analysis.
105AD7 Placebo
WeekO 85 (100%) 77 (100%)
Week6 63 (74%) 59 (77%)
Week 12 47 (55%) 45 (58%)
Statistical Analysis.
SAS (version 6.0) was used for all data summary and analysis. All
statistical tests were two-sided and carried out at the 5% level. As stated in
the Protocol, survival time was measured in days from (1) randomisation
and (2) diagnosis of advanced disease. The 21st February 1997 was taken as
the censoring date for all patients in the study. Patients who were not
known to have died by this date were assumed to be censored in the
analysis.
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Univariate Analysis.
The log rank test was used to compare survival curves arising from
the two treatment groups (105AD7 and placebo). Table 5 shows the results
of a univariate analysis performed on an intention to treat basis. Median
survival from date of randomisation was 124 and 184 days, in patients
receiving 105AD7 and placebo, respectively (p=O.38), as shown in the
Kaplan Meier graphs overleaf. Survival from date of diagnosis of
advanced disease was 456 and 486 dyas for the two groups (p=O.82).
A univariate analysis was also performed restricted to those patients
receiving 2 or more doses of 105AD7/placebo (Table 6). Median survival
from the date of randomisation was 213 and 239 days for 105AD7 and
placebo patients respectively (p=O.69). The median survivals from date of
diagnosis of advanced disease were 511 and 486 days (p=O.60).
Univariate analyses were also performed for a number of subgroups
of patients in the study. These included patients with lung metastases,
liver metastases, those who had chemotherapy, and those who did not.
Analyses were performed on an intention to treat basis from date of
randomisation (Table 12), and from date of diagnosis of advanced disease
(Table 13). There was no significant difference between patients receiving
105AD7 and placebo, for any of the subgroups considered.
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Multivariate Analysis
The following variables were
analysis:
i Treatment indicator (105AD7 v placebo).
considered in the multivariate
ii Prior chemotherapy after diagnosis of advanced disease (yes/ no).
111 Prior radiotherapy after diagnosis of advanced disease (yes/no).
i v Centre (Nottingham/ Leeds,Hull and Newcastle).
v Lung, metastases (yes/no).
vi Liver metastases (yes/no).
vu Other intraperitoneal disease (yes/no).
VUI Other disease (yes/ no).
ix Number of doses (~2 versus <2).
Table 7 shows the analysis performed on an intention to treat basis,
from the date of randomisation. Patients receiving 2 doses, and those
with liver metastases, or 'other disease' do significantly worse if they
receive 105AD7. A significant survival advantage is seen in favour of
patients receiving placebo in the treatment variable. This relates to the
number of patients receiving 1 dose, who disproportionately skew the
result away from the vaccine. Hence Table 8 is included to illustrate this
point. Table 9 relates to survival from date of diagnosis of advanced
disease. Once again patients who receive 2 or more doses live significantly
longer, as interestingly do patients who receive radiotherapy or
chemotherapy. Table 10 shows the multivariate analysis from the time of
randomisation for patients receiving 2 or more doses. Patients with liver,
lung and other disease all do significantly worse in the 105AD7 arm. Table
11 considers this same group of patients, and survival from date of
diagnosis of advanced disease. Once again, survival is enhanced if
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patients receive chemotherapy or radiotherapy, and the presence of 'other
disease' decreases survival.
Overall Experience.
There were very few adverse events deemed related to
immunisation with the anti-idiotypic monoclonal antibody 105AD7, or
placebo.
Ad verse Events.
The number of deaths from the date of randomisation was 71 (84%)
and 63 (82%) in 105AD7 and placebo groups respectively.
There were 3 Serious Adverse Events - 2 in placebo patients, and 1 in
a patient who had received 105AD7. All were erc grade 3, and were felt to
be 'unlikely' to be due to the study drug. These are shown in Appendix 1,
Table Al-26. A number of other SAEs were felt to be 'unrelated' to the
study drug, and are thus not shown.
57 and 30 minor adverse events were documented in trial and
control patients, respectively. The majority were CTC grade 1 or 2. Only 1
was felt to be due to 105AD7, while a further 9 and 8 in the two groups
were classified as 'possibly' due to 105AD7. The remainder were graded as
'unlikely'. These are shown in Appendix 1, Table Al-25. The median
times between trial entry and the occurrence of the event were similar in
105AD7 and placebo patients - 22 and 26 days respectively. Median
durations of adverse events were markedly different in the 2 groups
however - 2 days and 14 days.
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Laboratory Data.
Chemical Pathology.
Results of patients' chemical pathology are tabulated in the
Appendix 1, Table Al-24. Median figures for urea and electrolytes remain
within normal limits in both trial and control patients for the duration of
the study. As anticipated there is clear derangement of liver function tests
and CEA. Alkaline phosphatase, Gamma glutaryl transferase, and CEA are
all raised both at trial entry, and throughout the duration of the study.
There is no obvious difference between the 2 groups for the alkaline
phosphatase and yGT, though clearly CEA is higher in 105AD7 patients.
This difference has not been statistically tested.
Haematology
White cell counts, platelets and neutrophil counts all remain within
normal limits. Median haemoglobin scores show that patients are
anaemic at trial entry, and throughout the study. Median lymphocyte
scores are at the lower limit of normal. There is a trend towards an
increased lymphocyte count in both groups. These are further detailed in
Appendix 1, Table Al-23.
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Table 5 Univariate analysis assuming intention to treat
observed Median RR and 95% Log rank
deaths survival and 0 test (p-95% Cl value)
From 0.38
randomisation 71 (84%) 124 (95, 206) 1.17 (0.83,1.64)
105AD7 63 (82%) 184 (119, 242) 1
Placebo
From diagnosis of 0.82
advanced disease1
69 (83%)105AD7 456 (363, 522) 1.04 (0.73,1.48)
Placebo 59 (82%) 486 (344, 659) 1
1 Date of diagnosis of advanced disease known for 83 patients
randomised to 105AD7 and 72 patients randomised to Placebo.
Table 6 Univariate analysis restricted to those patients who have
received two or more doses
observed Median RR and 95% Log rank
deaths survival and 03 test (p-
95% CI3 value)
From 0.69
randomisation1 49 (77%) 213 (168, 316) 1.09 (0.72,1.63)
105AD7 45 (76%) 239 (184, 265) 1
Placebo
From diagnosis of 0.60
advanced diseasi
48 (77%) 511 (456,656) 0.89 (0.59,1.36)105AD7
Placebo 41 (76%) 486 (334, 674) 1
1 Based on 63 patients randornised to 105AD7 and 59 patients
randomised to Placebo
Date of diagnosis of advanced disease known for 62 patients
randornised to 105AD7 and 54 patients randomised to Placebo
confidence interval (Cl), risk ratio (RR)
2
3
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Table 7 Multivariate analysis. assuming intention to treat, survival
time from randomisation
Variable Regression RR2 95% Cl for p-value
coefficient RR2
Treatment 0.0101
105AD7 0.473 1.61 1.12 to 2.31
Placebo 1
Centre 0.58
Nottingham -0.124 0.88 0.57 to 1.37
rest 1
No. of doses <0.0011
~ 2 dose -2.048 0.13 0.08 to 0.20
1 dose 1
Liver metastases 0.015
Yes 0.565 1.76 1.12 to 2.78
No 1
Other disease 0.005
Yes 0.599 1.82 1.20 to 2.75
No 1
1
2
see Table 8 for joint RRs for treatment and number of doses
confidence interval (Cl), risk ratio (RR)
Table 8 Survival time from randomisation: joint RRs for treatment
(105AD7 versus placebo) and number of doses (1 dose versus
~2 doses)
Variable Regression RR
coefficient
Placebo, 1 dose 0 1
Placebo, ~2 doses (0+(-2.0478» 0.13
105AD7,1 dose (0.473+0) 1.61
10SAD7, sz dose (0.473+(-2.048» 0.21
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Table 9 Multivariate analysis assuming intention to treat. survival
time from date of diagnosis of advanced disease
Variable Regression RRl 95% Cl for p-value
coefficient RRl
Treatment 0.30
105AD7 0.189 1.21 0.84 to 1.73
Placebo 1
Centre 0.14
Nottingham 0.326 1.38 0.90 to 2.13
Other centres. 1
No. of doses <0.001
~2 dose -0.826 0.44 0.29 to 0.65
1 dose 1
Chemotherapy <0.001
Yes -0.954 0.39 0.26 to 0.57
No 1
Radiotherapy <0.001
Yes -0.982 0.37 0.22 to 0.63
No 1
Other disease 0.004
Yes 0.561 1.75 1.19 to 2.58
No 1
lconfidence interval (Cl), risk ratio (RR)
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Table 10 Multivariate analysis. restricted to those patients who have
received two or more doses. survival time from
randomisation
Variable Regression RR1 95% Cl for p-value
coefficient RR1
Treatment 0.33
105AD7 0.213 1.24 0.80 to 1.90
Placebo 1
Centre 0.64
Nottingham 0.120 1.13 0.68 to 1.87
Other centres 1
Liver metastases 0.013
Yes 0.658 1.93 1.15 to 3.25
No 1
Other disease 0.013
Yes 0.618 1.86 1.14 to 3.03
No 1
Lung metastases 0.050
Yes 0.463 1.59 1.00 to 2.52
No 1
1 confidence interval (Cl), risk ratio (RR)
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Table 11 Multivariate analysis. restricted to those patients who have
received two or more doses. survival time from date of
diagnosis of advanced disease
Variable Regression RRI 95% Cl for p-value
coefficient RRI
Treatment 0.93
10SAD7 0.020 1.02 0.67 to 1.57
Placebo 1
Centre 0.59
Nottingham 0.135 1.14 0.70 to 1.87
Other centres. 1
Chemotherapy 0.005
Yes -0.660 0.52 0.33 to 0.82
No 1
Radiotherapy 0.011
Yes -0.761 0.47 0.26 to 0.84
No 1
Other disease 1.04 to 2.56 0.03
Yes 0.492 1.64
No 1
1 confidence interval (Cl), risk ratio (RR)
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Table 12. Univariate subgroup analysis assuming intention to treat-
survival measured from the date of randomisation.
Number Observed Median survival RR and 95% p value by
deaths & 95% CI2 (days) CI2 log rank test
Lung mets
105AD7 27 24 (89%) 90 (65,168) 1.58 (0.82-3.04) 0.16
Placebo 20 15 (75%) 151 (100,277) 1
Liver mets
105AD7 61 52 (85%) 112 (90,202) 1.17 (0.77-1.77) 0.45
Placebo 50 40 (82%) 173 (102,242) 1
Chemo 1
105AD7 30 27 (90%) 104 (71,183) 1.32 (0.70-1.43) 0.39
Placebo 21 15 (71%) 183 (68,400) 1
No Chemo
105AD7 55 44 (80%) 168 (97,250) 1.03 (0.68-1.56) 0.88
Placebo 56 48 (86%) 185 (117,242) 1
1.Chemotherapy
2.Confidence Interval (Cl), Relative Risk (RR).
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Table 13. Univariate subgroup analysis assuming intention to treat-
survival measured from the date of diagnosis of advanced disease.
Number Observed Median survival RR and 95% p value by
deaths & 95% Cl 2 (days) CP log rank test
Lung mets
105AD7 26 23 (88%) 522 (339-656) 0.91 (0.46-1.82) 0.79
Placebo 19 14 (74%) 422 (344-422) 1
Liver mets
105AD7 60 51 (85%) 418 (337-511) 1.09 (0.72-1.67) 0.68
Placebo 49 39 (80%) 475 (173-334) 1
Chemo 1
105AD7 30 27 (90%) 596 (456-679) 1.51 (0.80-2.87) 0.21 •
Placebo 21 15 (71%) 683 (560-909) 1
No Chemo
105AD7 53 42 (79%) 310 (194-488) 0.98 (0.64-1.50) 0.93
Placebo 51 44 (86%) 334 (250-475) 1
1.Chemotherapy
2.Confidence Interval
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Discussion.
Immunisation with the anti-idiotypic monoclonal antibody 105AD7
does not confer a survival advantage on patients with advanced colorectal
cancer. This study therefore does not support the findings of the Phase I
study [Denton GWL 1994]. A univariate analysis showed no significant
difference between placebo and trial group, both in the intention-to-treat,
and the analysis restricted to patients who had received 2 and 3 doses.
The study aimed to recruit 162 patients - 81 patients to both 105AD7
and placebo arms. In reality, eighty-five patients received 105AD7, and 77
placebo. The disparity between the two relates to the randomisation of the
study drug, which was in 'blocks' of 6 (3 trial, 3 placebo), and stratified
according to 'liver metastases' and 'no liver metastases' arms, in each of
the 4 trial centres. None of the 'arms' of the study finished exactly at the
end of a block of 6 in any of the centres, thus accounting for the difference
seen in terms of patients recruited. In addition, a further 3 patients were
recruited, making the total 165. These patients had agreed to be
randomised, but were still within 1 or 3 months of previous courses of
radiotherapy and chemotherapy. They were in effect waiting to become
eligible for the study. They were not included in the statistical analysis,
which was confined to the first 162 patients recruited, as defined in the
protocol.
Patient characteristics were comparable in trial and placebo groups in
terms of age, sex, site and Dukes stage of primary tumour. The time from
diagnosis of advanced disease, and inclusion in the study were also very
similar - medians of 172 and 179 days, in 105AD7 and placebo arms
respectively. Inexplicably, the time between resection of the primary
tumour and on study date was almost twice as long in the placebo arm
(13.7 months v 22.8 months).
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Therapy prior to entry into the study was comparable in the two
groups. Identical numbers of patients received radiotherapy prior to, and
following the date of diagnosis of advanced disease. No patient received
any immunological, biological, or hormonal therapy prior to the diagnosis
of advanced disease, reflecting how this treatment option has failed to
become established as an adjuvant therapy. Two patients in the lOSAD7
arm, and 4 in the control group however received Interferon, Interleukin-
2 or an Investigational drug, following the diagnosis of advanced disease,
but prior to entry into the study. Operations performed for removal of
primary tumours were similar in the 2 groups. A number of patients also
underwent further operations, as detailed in Appendix 1, Table Al-3.
Chemotherapy may be used in the treatment of colorectal cancer in
two ways - either as adjuvant therapy immediately following surgery, or as
treatment for advanced disease. Ten and fourteen patients receiving
lOSAD7 and placebo respectively fell into the former group. A number of
regimes were used, in all but one case based on S-Fluorouracil. Over a
third of patients in both groups completed 6 courses. Regimes used for the
treatment of advanced disease were more varied. In addition to schedules
based on S-Fluorouracil, Folinic Acid and leucovorin; cisplatin,
doxorubicin, raltitrexed (Tomudex), Zilascorb, and Mitomycin C were also
used. Partial responses were seen in only 2 patients. The median time
between finishing chemotherapy, and trial entry was 161 and 174 days for
10SAD7 and control patients respectively. It is possible that the
immunosuppressive effects of chemotherapy may reduce the efficacy of
immunotherapy, and if so 3-6 months may not be long enough for the
immune system to recover. It is interesting to note the results of a sub-
group analysis which showed that patients who had not received
chemotherapy lived markedly longer than those Who had. These results
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suggest that chemotherapy and immunotherapy may not be synergistic, as
has been suggested.
No significant survival advantage was seen in patients receiving
105AD7, either by univariate or multivariate analyses. The median
survival from the date of diagnosis of advanced disease in patients
receiving the vaccine was higher than that seen in the Phase I study - 456
days v 365 days. The reason for the lack of significance is that the placebo
arm lived for a median of 487 days (16 months), markedly higher than that
reported in the literature. It is important also to consider that only 34 out
of the 77 placebo patients received chemotherapy prior to inclusion,
potentially prolonging their survival. These results do not support those
of the Phase I study for a number of reasons. It is likely that the control
group in the Phase I study lived for a markedly shorter time than would
be anticipated (4 months), and the non-randomised group of trial patients
longer than would be expected for a group not receiving chemotherapy.
This combined, with the small numbers involved, almost certainly
accounted for the significant difference seen between the two groups. It is
likely also with this unblinded work that some degree of selection bias
could have taken place.
It has been shown that patients with large tumour burdens are
immunosuppressed, and thus unlikely to mount effective immune
responses when immunised with an anti-idiotypic antibody [Golub SH
1974][Eilber FR 1975]. In addition it has been shown that patients with
advanced disease have decreased amounts of t; chain in the TCR, and less
expression of MHC Class I and II on tumour cells [Guilloux Y
1994][Mizoguchi H 1992]. IFN y is a cytokine produced by activated T cells
and Natural Killer cells, that enhances antigen presentation, and induces
expression of ICAM-1 and LFA-l. Levels assayed from fresh colorectal
cancer specimens were found to decrease as disease advanced [Numata A
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1991]. Recent work has proposed that difficulties encountered generating
crt may be due to the inclusion of patients with advanced disease [Jacob
L 1997]. It is also interesting to note that the lymphocyte counts of all
patients in the study were at the lower end of normal. All of this suggests
that patients with advanced disease have compromised immune systems,
and may not be an ideal group for immunotherapy.
Recent work has shown that fas ligand is expressed on liver
metastases from colorectal cancer, and it has been proposed that fas
mediated destruction of hepatocytes may promote liver colonisation, and
that expression of fasL on primary colorectal cancers may induce apoptosis
in TIL [O'Connell J 1996][Shiraki K 1997]. It is possible that CTL stimulated
by 105AD7 to destroy gp72 expressing liver metastases, may be apoptosed
in the liver by fasL expressing tumour cells. This is further immunological
evidence that may in part explain why patients receiving the vaccine did
not live longer than controls.
The Phase I study recruited only patients with liver metastases,
whereas this study included those with multiple sites of disease, and thus
larger tumour burdens. It is likely that liver metastases will have a better
blood supply than a large mass of pelvic recurrence - if primed T cells
reach only a small proportion of disease, then it is unlikely that they will
have a significant effect on tumour growth.
Forty-one patients in the study received various chemotherapy
regimes prior to randomisation to the 105AD7 arm. In order to assess
whether this had any bearing on survival, a sub-group analyses was
performed for patients who had received either adjuvant, or
chemotherapy for their advanced disease, and those patients who had not.
Survival from the date of randomisation was markedly less in the former
group, as compared with the latter (104v168 days), supporting the view
that chemotherapy and immunotherapy may not be acting synergistically.
75
Both groups lived less than placebo, and those patients who received
chemotherapy lived generally longer, as shown in the multivariate
analysis.
The maximum number of doses of lOSAD7 that an individual
patient could receive in this study was 3. Some patients in the Phase I
study recieved up to 7 doses, and it is possible that the reason no survival
advantage was seen was that not enough courses of lOSAD7 were given.
lOSAD7 is administered with alum. It may be that patients with such
compromised immune systems require stronger adjuvants, such as BCG
or CM-CSF, to augment the immune response generated.
Patients in the study were randomised to those with liver
metastases, and those without. The actual baseline disease present at entry
into the study was recorded in the Case Report Form. Clearly from Table 2
a number of patients had disease in more than one site, and with such
large tumour burdens, would be expected to be immunologically
suppressed. These patients would be unlikely to mount an immune
response following immunisation with lOSAD7, and this in part explains
why no survival advantage was seen in the analysis. The other interesting
point to note is that twice as many patients in the placebo arm had local
recurrence. These patients live longer than those with liver metastasis,
and it is possible that this might skew the result away from lOSAD7. In
view of this a multivariate analysis was performed, taking into account
the site of baseline disease. This showed that patients with liver
metastases, and 'other disease', such as bone and brain metastases fared
worse in the placebo arm.
There was little difference between haematological and clinical
chemistry results in trial and control patients. However it is clear from the
results that mean and median lymphocyte counts fall below normal limits
in both groups. This further supports the concept of malignancy equating
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with immunosuppression, as it is likely that the low lymphocyte count
reflects of the degree of metastatic disease present.
There was no toxicity associated with the use of l05AD7 in the
Phase I study. This was confirmed in the Phase II study, where only 3
serious adverse events were documented as "unlikely" to be due to
l05AD7, by the investigator who observed them Of the three, two occurred
in the placebo arm. Of the minor adverse events, only one was felt to be
definitely due to l05AD7.
The initial entry criteria for the study stated that eligible patients
should have a life expectancy of 3 months, and should thus receive three
immunisations. Clearly this was not seen in this study, with
approximately 75% of patients receiving at least 2 doses, and only 55%
receiving all three. The most likely cause of patients not completing the
study was disease progression causing patients to die, or become too
unwell to attend hospital. It was felt that this might have implications for
the result of the study, as work done using l05AD7 suggests that the first
immunisation may act as a priming dose, with further injections
amplifying the response. An analysis was therefore performed considering
only patients who had received 2 or more doses. This effectively reduces
the number of patients in the study, and no significant difference was seen
between l05AD7 and placebo groups.
The Phase II study has shown that l05AD7 does not confer a
survival advantage on patients with advanced colorectal cancer. It is likely
that this relates to tumour-induced immunosuppression, and further
work will concentrate on use of the vaccine as adjuvant therapy.
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Chapter3.
Use of the anti-idiotypic monoclonal antibody lOSAD7 as adjuvant
therapy in patients with primary colorectal cancer.
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Aim.
The aim of this work is to assess the immunological changes that
occur in the peripheral blood, and at the tumour site of patients who
receive the anti-idiotypic monoclonal antibody 105AD7 prior to resection
of their primary colorectal tumours. In addition an assessment will be
made as to whether this confers a survival advantage on these patients.
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Materials and Methods.
Human monoclonal anti-idiotypic antibody
Clinical grade monoclonal antibody was produced as previously
described [Robins RA 1991] using the guidelines of the Cancer Research
Campaign [Working Party on the Clinical use of antibodies 1986]. Samples
of the seed Jots passed testing for sterility and viral contamination.
Antibody was prepared as 1OI1gin 0.1 ml of saline, and lOOl1g in Iml of
aluminium hydroxide. With a relative molecular mass of 150 KDa, the
former dose of antibody, for example, contains 1.33 x 10 13 molecules, and
is a 6.6 x 10 -6 M solution.
Patients.
Twenty-four patients were recruited prospectively from surgical out-
patients by the author between August 1995 and December 1996 (fable 14).
All had primary colorectal cancer, either diagnosed on biopsy, or double-
contrast barium enema. The group consisted of 17 men, and 7 women,
with a mean age of 71.3 years (range 56-87 years). There were 16 rectal
tumours, 1 recto-sigmoid tumour, 3 sigmoid and 4 caecal cancers.
Twenty-three patients had already been recruited to the 105AD7
adjuvant study by the previous Cancer Research Campaign Fellow,
between May 1993 and August 1995. These patients are considered in the
survival analysis, as described in Part 4.
Trial patients were selected arbitrarily from the total number of
patients obeying the inclusion and exclusion criteria outlined below.
There was no selection bias, though due to the time constraints of
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processing specimens, only a limited number of patients were "on-study"
at anyone time.
Inclusion Criteria
• Patients with primary colorectal cancer.
Exclusion Criteria
• Pre-operative radiotherapy
• Women of child bearing age not taking reliable contraception.
• Normal hepatic and renal function.
• Haemoglobin > 109! dl, Platelets> 50xl09/ I and White blood count >
2xl09/1.
• Chronic haematological, autoimmune or intercurrent illness.
Clinical Protocol.
This study was performed under the auspices of the Cancer Research
Campaign UK Phase I! II clinical trials committee, with local ethical
committee approval. Informed consent was obtained in writing prior to
treatment with 105AD7.
Eligible patients were registered with the Data Centre, at the Cancer
Research Campaign prior to inclusion. Details of patients initials, date of
birth, and hospital number were recorded.
Patients received varying doses of 105AD7, at different time-points
prior to surgery, as detailed in Table 14. This was as part of ongoing work,
aiming to optimise dose and route of administration. Seven patients
received 10~g of antibody i.d. followed 48 hours later by 50l-tg i.m. One
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patient (no. 5) received this regime twice. Ten patients were given 50!lg
i.m, followed by a further 50!lg i.m. 1 week later. One patient was
administered with 20~tg i.m. followed 7 days later by another 20~lg i.m.
Three patients were given 10!lg i.d. with a further 20!lg i.m. 48 hours later,
and two received two courses, 1week apart, of lO!lg i.d. with 50!lg i.m. at
the same time. All 23 patients immunised by the previous CRC fellow
received 10!lg i.d, followed by 100~lg i.m.
In order to phenotype peripheral blood lymphocyte sub-sets, 20mls of
venous blood was taken pre-immunisation, and on several occasions
before surgery.
A mean of 16.8 days following immunisation, patients attended and
underwent resection of their primary tumours. Two samples were taken
from the resection specimen. One was snap frozen in liquid nitrogen,
prior to immunohistochemical analysis. The other was suspended in
RPMI, disaggregated, and TIL analysed by flow cytometry.
Six and twelve weeks following resection, patients attended the
Department of Surgery, to receive booster doses of l05AD7. During the
study, the protocol changed, and some received further doses. Six patients
were referred for adjuvant chemotherapy, and were randomised into the
QUASAR study. They were contacted three months after their last course,
and offered 105AD7. Three patients underwent adjuvant post-operative
radiotherapy. Dukes stage of the primary tumour, and further treatment is
shown in Table 15.
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Table 14. Demographics of patients recruited to the 105AD7 Adjuvant
study, by the author.
No Initials Agel. Sex Primary 2 On-Study+ Dose4 Qe_s
1. OT 75 F Rectum Aug '95 10 id + 50 im 18 days
2. EN 79 F Sigmoid Sept '95 10 id + 50 im 14days
3. ER 82 M Caecum Sept '95 10 id + 50 im 11 days
4. HT 86 F Rectum Oct '95 10 id + 50 im 14days
5. JC 64 M Rectum Oct '95 10 id + 50 im 31 days
6. ET 87 M Caecum Oct '95 10 id + 50 im 20 days
7. MF 63 F Rectum Nov '95 10 id + 50 im 19 days
8. MB 75 M Rectum Nov '95 10 id + 50 im 26days
9. OH 56 M Rectum Nov '95 50 im + 50 im 9days
10. VMcC 63 M Rectum Dec '95 50 im + 50 im 21 days
11. JK 76 M Sigmoid Jan '96 50 im + 50 im 14days
12. JCa 58 M Rectum Jan '96 50 im + 50 im 13 days
13. TB 62 F Rectum Feb'96 50 im + 50 im 20days
14. CB 75 M Caecum Mar '96 50 im + 50 im No op
15. FCl 67 F Rectum Mar '96 50 im + 50 im 14days
16. JH 69 M Rectum Apr' 96 50 im + 50 im 15 days
17. FH 73 M Rectum M'!Y_'96 50 im + 50 im 29 d'!Y_s
18. FCh 70 M Rectum M'!Y_'96 50 im + 50 im 13 day_s
19. PT 72 M Rectosig May'96 20 im + 20 im 12days
20. CF 75 M Rectum Nov '96 10 id + 20 im 8days
21. DP 69 M Rectum Nov'96 10 id + 20 im 14 day_s
22. AC 65 M Sigmoid Nov '96 10 id + 20 im 20days
23. JF 81 ~1 Caecum Dec '96 10 id + 50 im x2 12 d'!Y_s
24. MW 69 F Rectum Dec '96 10 id + 50 im x2 20days
Key to Table 14.
1.Age at resection of primary tumour
2·Site of primary tumour.
3.Month that patient was recruited to the adjuvant study.
4. Dose of 105AD7 that patient received. Several dosing schedules were
employed, as part of ongoing work aiming to establish the optimal regime.
All intradermal (i.d.) doses were followed 48 hours later by an
intramuscular (i.m.) dose, except for patients 23 and 24, who received i.d,
and im doses at the same time. If an i.m. dose was administered at the
outset (Nos 10-19), then the next i.m. dose was 7 days later.
5.Number of days between receiving first dose of 105AD7, and resection of
the primary tumour.
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Experimental Procedures involved in the adjuvant study.
In order to achieve the aim of this work, three scientific techniques
were employed. These included immunohistochemical analysis of
cryopreserved tumour sections, flow cytometric analysis of tumour
infiltrating lymphocytes, and peripheral blood lymphocyte phenotyping.
For logistical reasons, not all 24 patients recruited by the author had all 3
performed. The analyses performed on individ ual patients is shown in
Table 16.
To assess whether 10SAD7 conferrred a survival advantage, when
used as adjuvant therapy, it was necessary to follow up the 23 patients
recruited by the previous CRC fellow, and compare their survival with a
contemporary group of patients undergoing surgery at the same time. This
survival analysis is described in Part 4.
Part 1. Immunohistochemistry.
Analysis of tumour sections was performed at three different times
throughout the two year period. Sections from thirteen trial patients
immunised by the author, and a further three recruited by the previous
CRC Fellow were labelled with MAb against C04, COS, C056 and C02S
lymphocyte antigens.
At a later date specimens from twelve of the above patients were
labelled with MAb against C068, CD69, and CD3 l; chain. Tumour from S
patients was available for labelling with AP02.7 MAb, at a still later date.
Immunohistochemical analysis was also performed on
cryopreserved tumour specimens from control patients who had not
received 10SA07 pre-operatively. These were matched to trial patients
according to tumour site, stage and differentiation, as well as sex, and
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approximate age of patient. Such a close match was possible as specimens
are taken from all colorectal tumours resected at the Queens Medical
Centre, and cryopreserved.
Part 2. Venous blood phenotyping.
Venous blood was taken from 17 trial patients, pre-immunisation,
and at various time points prior to surgery. Lymphocytes were separated
out, labelled with MAb, and analysed by flow cytometry. Analysis was
performed assessing whether peripheral blood lymphocytes were affected
by immunisation with 105AD7.
Part 3. Tumour Infiltrating Lymphocytes.
Fresh tumour specimens from 19 immunised and 35
unimmunised patients were disaggregated, and separated lymphocytes
labelled with MAb, and analysed by flow cytometry.
Part 4. Survival analysis.
Twenty-three patients were immunised by the previous CRC
Fellow, between May 1993 and August 1995. Survival and recurrence data
at 2 year follow up was collected, and compared with matched controls
from the Trent Audit. The Trent Audit contains data relating to the
management of 3520 patients with colorectal cancer. Each patient who had
received 105AD7 was matched to between 2 and 5 controls, according to
Dukes stage, site, differentiation, sex, age, ASA, and whether or not they
had chemotherapy or radiotherapy.
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Table 15. Pathological stage and outcome of recruited patients.
No. Initials Primary 1 Stage 2 Diff3 Chemo 4 RTHS 10SAD76
1. DT Rectum C Mod. Yesx4 Yes 3
2. EN Sigmoid B Mod. Mort 7 0
3. ER Caecum C Mod. No No 1
4. HT Rectum
- - No Yes 2
S. JGr Rectum D Mod. No Yes 2
6. ET Caecum B Mod. No No 2
7. MF Rectum B Mod. No No 0
8. MB Rectum A Mod. No No 1
9. DH Rectum B Mod. No No 2
10. VMcC Rectum C Mod. Yes No 3
11. JK Sigmoid A Mod. No No 2
12. JGa Rectum A Mod. No No 1
13. TB Rectum C Poor Yes No 1
14. CB Noop - - No No 0
15. FCI Rectum A Mod No No 3
16. JH Rectum A Mod. No No 2
17. FH Rectum C Mod. No No 0
18. FCh Rectum B Mod. No No 0
19. PT Rectosig C Mod. Yes No 1
20. GF Rectum B Mod. No No 0
21. DP Rectum C Mod. No No 0
22- AG Sigmoid C Mod. Yes No 0
23. JF Caecum B Mod. No No 0
24. MW Rectum C Mo/Po Yes No 0
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Legend to Table 15.
I·Site of primary tumour.
2.Modified Dukes stage of primary tumour.
3.Differentiation of primary tumour.
4.Adjuvant chemotherapy administered post-operatively.
5 Adjuvant radiotherapy received by patient post-operatively.
6.Number of doses of 10SAD7 received by patient post-operatively.
7.This patient died within 30 days of surgery.
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Table 16. Experiments performed on individual patients.
No. Initials. Pheno 1 CD4,8,56 CD68,69, AP0274 TILS5
&252 &l;3
1. DT Yes Yes No No Yes
2. EN Yes Yes Yes Yes Yes
3. ER Yes Yes Yes Yes Yes
4. HT Yes No No No No
5. JC No Yes Yes No Yes
6. ET Yes Yes Yes Yes Yes
7. MF Yes No No No Yes
8. MB Yes Yes Yes Yes Yes
9. DH Yes Yes Yes Yes Yes
10. vxrec Yes No No No Yes
11. JK Yes Yes Yes Yes Yes
12 JC Yes Yes No No Yes
13. TB Yes Yes Yes Yes Yes
14. CB Yes No No No No
15. rei Yes Yes Yes No Yes
16. JH Yes No Yes No Yes
17. FH Yes Yes Yes No Yes
18. Feh Yes Yes Yes Yes No
19. PT No No No No Yes
20. CF No No No No Yes
21. DP No No No No Yes
22 AC No No No No No
23. JF No No No No No
24. MW No No No No No
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Key to Table 16.
1.Phenotyping of lymphocyte subsets in venous blood.
2. Immunohistochemical analysis of section of tumour from trial patients
using MAb against CD4, CD8, CD56 and CD25.
3. Immunohistochemical analysis of tumour sections from trial patients
using MAb agaainst CD68, CD69, and f; chain. Note this work was
performed later than 2, and thus less tumour specimens were available
from patients who had received 105AD7.
4.A number of sections from trial patients were available for labelling with
the MAb AP02.7, directed against 7A6 antigen. This was the last
immunohistochemical analysis performed, and thus specimens were only
available on 8 trial patients.
5 TIL were assessed by disaggregating fresh tumour from immunised
patients, labelling with MAb, and analysing by flow cytometry.
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Part 1.
Lymphocytic Infiltration of primary colorectal tumours
in patients receiving 105AD7, as measured by immunohistochemistry.
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Aim.
The aim of this work is to assess immunological changes occurring at
the tumour site of patients with primary colorectal cancer who receive
10SAD7 prior to surgery. In order to do this sections from trial patients, and
their matched controls will be immunohistochemically labelled with a panel
of antibodies against specific CD antigens expressed on tumour infiltrating
lymphocytes. These include MAb against CD4, an antigen expressed on
helper / inducer T cells, CDS on cytotoxic T cells, and CDS6 expressed on
Natural Killer cells. In addition MAbs against the a subunit of the
Interleukin-2 receptor (CD2S), an antigen expressed on macrophages (CD6S),
and the 2S/34 KDa transmembrane glycoprotein activation marker CD69
(Activation Inducer Molecule). Apoptosis at the tumour site was assessed
using the MAb AP02.7 against 7A6, a mitochondrial antigen. Tumour
samples were also labelled with an MAb against the t chain of the T cell
receptor, in order to assess whether immunisation with lOSAD7 up or down
regulated its expression.
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Materials and Methods.
Patients.
Twenty-four patients were recruited prospectively from surgical out-
patients by the author, of whom 13 had tumour samples taken for
immunohistochemical analysis. Tumour from 3 of the 23 patients
immunised by the previous CRC Fellow, were also analysed.
The group consisted of 10 men, and 6 women, with a mean age of
71.3 years (range 56-87 years). The control group was composed of
cryopreserved samples from patients, matched with trial patients
according to site,stage and differentiation of tumour, as well as age and sex
of patient. All patients had normal hepatic and renal function, and no
patient received pre-operative radiotherapy. These details are summarised
in Table 18.
The majority of the tumours were rectal (n=10), with the
remainder either caecal (n=2), or from ascending (n=L), and sigmoid colon
(n=3). All but two were classified on routine histopathology, as being
moderately differentiated. There were equal numbers of Dukes stage A,B
and C (n=5), with the remaining case being stage D.
Clinical Protocol.
Five patients received a test dose of 1DIlg of 105AD7 given
intradermally. A further dose of 5DIlg intramuscularly was administered
to those patients who showed no evidence of hypersensitivity on review
of the initial injection site 24-72 hours later. One patient, in whom a pre-
existing medical condition delayed operation, received this course twice -
10 and 3Ddays prior to surgery. A second dosing schedule consisted of
50~g of 105AD7 intramuscularly, followed 7 days later by a further 50~lg
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intramuscularly. Seven patients were recruited into this group. The 3
patients recruited by the previous CRC fellow received 10~g i.d. of 105AD7,
followed 48 hours later by 100~lg i.m. The mean number of days between
first dose of 105AD7, and operation was 19.3 days for these patients.
Immunohistochemistry.
Immunohistochemical analysis of sections was performed on three
occasions over two years. The initial analysis was performed using MAb
against CD4, CD8, CD56 and CD25. The second used MAb against CD68,
CD69 and 1; chain, and the third AP02.7, an MAb against the
mitochondrial antigen 7A6. Due to the limitations of processing blocks of
tumour tissue, less patients samples were available for each analysis (Table
19).
Resection specimens were retrieved, and samples taken from two
edges, the centre of the tumour, and from normal bowel, at least 20cm
from the lesion. Tumour tissue was stored in liquid nitrogen, prior to
cutting into Slim sections. Sections were mounted on Vectabond™
(Vector Laboratories) coated slides, air-dried for 5 minutes, and then placed
in acetone for 10 minutes. They were air-dried again overnight, before
bathing for S minutes in Tris buffered saline (TBS). Sections were blocked
with 100111of 20% rabbit serum, and left for 20 minutes. 100111of mouse
MAb, optimally diluted in TBS, were added to each section. MAbs used,
source, and dilutions used are shown in Table 17. TBS and JgG1 were
added as negative controls. Specimens of human tonsil were used as a
positive control, and labelled with identical dilutions of MAb. After
Ihour, slides were washed for a further 5 minutes in TBS. One hundred
microlitres of rabbit anti-mouse biotin (Dako), in 4% human serum, was
then added for 30 minutes. Following further washing, as previously
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described, 100111of strep-avidin complex (Dako) was added for 30 minutes.
This solution was washed off, and bound enzyme visualised using 1 ml of
horseradish peroxidase in 3,3' diaminobenzidinetetrahydroc1oride (DAB-
Sigma Chemical Company). After 10 minutes, slides were transferred to a
0.5% copper sulphate bath for 10 minutes, and then stained with
hematoxylin. Finally, slides were dehydrated in alcohol and mounted.
Table 17 Monoclonal Antibodies used for Immunohistochemical staining.
CD Antigen Clone Dilution Manufacturer
rn4 SK3 1:40 Becton Dickinson 1
rns RFT-S 1:20 Gift of Dr G King 2
coss MY31 1:40 Becton Dickinson 1
rn25 ACf-1 1:10 Dako 3
CD68 Ki-M6 1:S0 Serotec 4
CD69 TPI/55.3.1 1:100 Serotec 4
t Chain TIA-2 1:20 Coulter 5
AP02.7 2.7A6A3 1:S0 Immunotech 5
IgGl W3/25 1:10 Serotec 4
1Becton Dickinson, Between Towns Rd, Cowley, Oxford OX4 3LY
2 Dr George King, Dept of Pathology, Aberdeen University, Scotland
3 Dako A/S Produktionsvej 42.DK-2600 Glostrup, Denmark.
4 Serotec Ltd. 22 Bankside, Station Approach, Kidlington, Oxford, OX5 1JE
5 Immunotech (Coulter), BP 177-13276 Marseille Cedex 9- France
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Image Analysis
Sections were viewed under x200 magnification, and the image
digitised and transferred by camera to an Apple Macintosh Quadra 660AV
computer. Using the NIH image programme it was possible to quantify the
degree of brown staining relative to the blue Haematoxylin background,
and express it as a pixel count. This count is a reflection therefore of
expression of that CD antigen analysed on invading lymphocytes.
Each section was analysed in five different, randomly selected areas,
and a mean pixel count obtained. All sections except those labelled with
AP02.7 were analysed by the author. Analysis of sections labelled with
AP02.7 was performed blindly by one observer (RQ), who analysed each
section 15 times, producing 3 mean values. Pixel counts for individual
patients are shown in Appendix 2, Tables 2-1 to 2-11.
In order to assess intra-observer variation, samples from 2 trial and 2
control patients analysed by the author, were reanalysed. This second
analysis used an identical technique, and took place 9 months later.
An assessment of inter-observer variation was also performed. The
sections from one patient were analysed by two observers (CMA and RM),
using identical techniques. The results obtained for identical sections are
shown in Appendix 2, Table 2-13.
Statistical analysis.
Median scores are given, and a two-tail Wilcoxon Signed Rank test
was used to test for statistical significance, which was taken at the 5% level.
98
Table 18. Tumour sections from trial patients analysed
immunohistochemically.
No. Init. Agel Sex Dose Op2. Site3 Stage Diff
1. DT 75 F 10+50 18 Rectum C Mod
2. EN 79 F 10+50 14 Sigmoid B Mod
3. ER 82 M 10+50 11 Caecum C Mod
5. JGr 64 M 10+504 31 Rectum D Mod
6. ET 87 M 10+50 20 Caecum B Mod
8. MB 75 M 10+50 26 Rectum A Mod
9. DH 56 M 50+50 9 Rectum B Mod
11. JK 76 M 50+50 14 Sigmoid A Mod
12- JGa 58 M 50+50 13 Rectum A Mod
13. TB 62 F 50+50 20 Rectum C Poor
15. ret 67 F 50+50 14 Rectum A Mod
17. FHa 73 M 50+50 29 Rectum C Mod
18. FCh 70 M 50+50 13 Rectum B Mod
AS AC 67 F 10+100 29 Asc. B Poor
B S HS 67 M 10+100 17 Sigm A Mod
Cs AGe 83 F 10+100 30 Rectum C Mod
1.Age at time of removal of the primary tumour.
2.Number of days between first immunisation, and operation
3·Site of primary tumour
4. Patients received two courses of 10~lgi.d. followed by 50~g i.m.
S Three patients were recruited to the adjuvant study by the previous CRC
fellow. Cryopreserved samples from these patients were also stained
immunohistochemically.
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Table 19. MAb labelling of tumour sections.
No. Initials. CD4,CD8, CD68,CD69 AP027
CD56&CD25 CD3l; chain.
1. m Yes No No
2. EN Yes Yes Yes
3. ER Yes Yes Yes
5. JGr Yes Yes No
6. ET Yes Yes Yes
8. MB Yes Yes Yes
9. DH Yes Yes Yes
11. JK Yes Yes Yes
12 JGa Yes No No
13. TB Yes Yes Yes
15. Fe} Yes Yes No
17. FHa Yes Yes No
18. FCh Yes Yes Yes
A 1 AC Yes No No
B 1 HS Yes No No
C 1 AGe Yes No No
1 Patients recruited by the previous CRC fellow.
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Results.
Patients were reviewed on several occasions between first
immunisation, and operation. No side-effects related to the use of 105AD7
were observed. This finding confirms the results of the Phase I and Phase
II studies, in a cohort of patients with primary colorectal cancer.
Samples of normal bowel, tumour centre, and two tumour edges,
from sixteen trial patients, and their controls, were analysed
immunohistochemically, Each section was analysed randomly 5 times,
and a mean pixel count obtained. This raw data is shown in Appendix 2,
Table 2-1 to 2-11. In practice, however, not all patients had two edges
analysed. If the original tumours were small then only one sample would
be taken from the tumour edge, in order to allow sufficient tissue for
routine histopathological analysis.
Insufficient numbers of patients were present in the individual
dosing regimes, to allow comparison, so results were combined to give
figures for all patients who had received 105AD7. The analysis was
perfomed to assess infiltration into the centre and edge of the tumour, and
also for the tumour edges alone. In addition, a ratio of tumour infiltration
to that of normal bowel infiltration was calculated. This is expressed as
Tumour/Normal (T /N) ratios. No assumptions were made about the
distribution of the data, and medians and interquartile ranges for the two
dosage schedules, and combined results are shown.
Human tonsil was used as a positive control, and the results
obtained shown in Table 22. Lymphocytic infiltration was markedly higher
than in tumour tissue, as would be expected, and the findings confirm that
the MAbs label lymphocytes at the dilutions used.
Infiltration at the tumour centre and edge is shown in Table 20 for
all patients results combined. Median infiltration of CD4, CDS and CD56
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expressing lymphocytes was higher in trial patients than controls, when
results were combined (0.92vO.65: p=0.021). Infiltration by CD4 expressing
lymphocytes was similarly significantly higher in the 16 trial patients
(1.17vO.81: p<O.OS).This is shown graphically in Figure 16. Median scores
for trial patients sections labelled with MAb against CD8, CD56, CD25,
CD69, CD68, and CD3~ chain were 0.81, 0.82, 0.75, 0.51, 1.10, and 0.56
respectively. The corresponding median infiltrations for control patients
were 0.75, 0.44, 0.50, 0.79, 1.02, and 0.62. There was no difference between
pixel scores for trial and control sections labelled with the negative control
antibody IgG1 (0.20vO.18) or TBS (0.23vO.lB). Median pixel score for AP02.7
labelling was significantly higher in trial patients than controls (2.B6v1.77:
p<0.005). The IgG1 negative control used for these sections was 0.37 for
both trial and control patients.
Median pixel scores were also calculated for figures from the edge of
the tumour alone. These are also shown in Table 20. When results of CD4,
CDB and CDS6 were combined, scores were significantly higher in trial
patients when compared with controls (0.B5vO.SB:p=0.028). Expression of
the a subunit of the Interleukin-2 receptor was also significantly higher in
trial patients (0.76v0.33: p<0.025). Median scores for trial patients labelled
with MAb against CDB, CD4, CD56, CD69, CD68, and CD3~ chain were O.Bl,
1.02, 0.85, 0.51, 0.99, and 0.56. There was no significant difference between
these figures and the controls, whose scores were 0.75, O.Bl, 0.43, 0.B3, 1.01,
and O.BO,respectively. Pixel counts for trial patients labelled with IgGl and
TBS were 0.24 and 0.29 respectively. The corresponding scores for their
controls was O.1B and 0.20. Neither of these differences was statistically
significant.
Ratios of pixel scores obtained from the edge and centre of the
tumour, and normal bowel, in trial and control patients are shown in
Table 21. The first column considers results of both centre and edge of the
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tumour. The ratio for the combined results of CD4, CD8, and CD56 was
once again significantly higher in trial patients (O.93vO.78:p=0.04), as was
expression of CD25 (1.12vO.42: p<0.05). There was no significant difference
between trail and control ratios in sections labelled with CD8, CD4, CD56,
CD69, CD68, CD3<;'and AP02.7. Scores in trial patients were 0.91, 1.04, 0.62,
0.59, 0.86, 0.55 and 0.56 for each respective MAb. Corresponding scores in
controls were 0.64, 0.90, 0.40, 0.82, 0.81, 0.48 and 0.55. Values for IgGl and
TBS were higher in trial patients than controls, though not significantly so
(0.61v0.50 and 0.90vO.46).
The ratio of tumour edge to that of normal bowel was also calculated,
and also shown in Table 21. A significant difference was seen in favour of
trial patients for the combination of CD4, CD8 and CD56 (l.00vO.80: p=0.04).
Pixel counts for CD8 were also significantly higher in trial patients
(1.03vO.65: p<0.05), as was CD25 expression (1.08v0.41: p<0.05). The former
result is shown graphically in Figure 17. There was no significant
difference in ratios of edge to normal bowel when sections were labelled
with CD4, CD56, CD69, CD68, CD3<;'chain. Figures for trial patients were
1.04, 0.67, 0.59, 0.76, and 0.51, compared with 0.91, 0.37, 0.88, 0.82, and 0.51.
There was no difference for scores for IgG1 and TBS. These were 0.65 and
0.65 in trial patients, and 0.49 and 0.48 in controls, respectively.
Median pixel counts are also shown, when figures from the tumour
edge alone were considered. Significantly higher values were once again
seen for overall infiltration, and T / N ratios for CD25 (p<0.025 and p=0.05),
and when results from CD56, CD4, and CD8 were combined (p=0.028 and
p=0.041). In addition the T /N ratio for CD8 was significantly higher in
immunised patients (p<0.05).
Sections from 2 trial and 2 control patients were analysed twice by
the same observer, to test for intraobserver variation. The concordance
between individual mean pixel scores is shown in Appendix 2, Table 2-12.
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Median pixel counts were 0.62 and 0.50 for first and second assessments
respectively. Interquartile ranges were comparable, 0.19-1.02 and 0.23-0.SS,
and there was no significant difference between the two groups. The
correlation coefficient was +0.36 (covariance 0.11). Figures for the
tumour:normal ratios showed a median of 0.71 and 0.62 for first and
second analyses respectively. Relative IQR were 0.42-1.1S and 0.40-1.23,
with a correlation co-efficient of +0.27, and covariance of 0.14.
Slides from one patient were analysed blindly by a further
observer, in order to assess the degree of interobserver variation. Mean
scores for edge and centre of the tumour, for CD2S, CDS, CDS6, and CD4
MAbs, and TBS control, are shown in Table 13, Appendix 2. Mean and
median pixel counts of all the results were 0.34 and 0.14 (IQR 0.07-0.60),
and 0.71 and 0.S6 (IQR 0.95-1.56), respectively for Observer 1 and Observer
2. This difference was statistically significant ( p<O.OOS),and the correlation
coefficient was +0.69 (covariance 0.13). The ratio of tumour:normal bowel
pixel counts were also calculated. Mean and median scores for Observer 1
were 0.47 and 0.40 (lQR 0.14-0.49), as compared with 0.76 and 0.71 (0.S1-1.03)
for Observer 2. This difference was once again statistically significant
(p<O.OS),with a comparable correlation coefficient (+0.6S).
Statistical analysis was performed in order to assess whether the
effect of 10SAD7 was the same across all four Dukes stages, for CD4, CDS
and CD56 expression combined (Table 23). Of the 16 patients, 5 were Dukes
A,B and C, with the remaining 1 a stage D tumour. Clearly the number of
patients is small, so the results need interpreting with a degree of caution.
Median pixel counts were 0.99, 1.13, 0.79 and 0.24 for stages A-D in trial
patients, and 1.04, 0.60, 0.60 and 0.75 in controls. The only significant
differences were between stage B (p<0.005) and stage D (P<O.025). When
tumour infiltration was compared with that of normal bowel, the ratios
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obtained were 1.12, 1.04, 0.66, and 0.33 in trial patients, and 1.04, 0.77, 0.51
and 0.29 in controls. Only stage B was significant (p<O.Ol).
A further analysis was performed to assess whether CD3l; chain
expression varied with Dukes stage. Pixel counts in trial patients were 0.42,
0.59 and 0.53 for stages A-C, as compared with figures of 0.35, 0.54 and 0.99
in controls. Insufficient numbers precluded any analysis of the patient
with a Dukes D tumour. The tumour: normal bowel ratios were 0.41, 0.51,
and 0.44 for the three stages respectively in patients who had received
105AD7. Figures for controls were 0.24, 0.54 and 0.83.
Eight tumour specimens from immunised and unimmunised
patients were analysed immunohistochemically for AP02.7 expression.
Individual pixel scores for edges, and tumour centres are shown in the
Appendix, Table 2-11. Median, and mean scores are shown in Table 20 for
both AP02.7, and the negative control. Median scores for the negative
control (IgG1) are very similar in both trial and control patients, both for
absolute labelling of 7A6 antigen by AP02.7, (0.37vO.37), and the tumour:
normal bowel ratios (0.70vO.89). Median pixel scores were higher in trial
sections stained with AP02.7 than controls (2.86 v 1.77: p<0.005). The
median tumour: normal ratios were however essentially the same
(0.56v0.55).
In order to assess in which part of the tumour apoptosis was highest,
median figures for tumour edge and centre were calculated. Absolute
labelling by AP02.7 in trial patients was 2.36 (1.82-3.68) at the centre, and
3.42 (2.07-4.41) at the edge. This compared with figures of 1.94 (0.94-2.59)
and 1.77 (1.64-2.00) respectively, in controls. The ratios of tumour:normal
bowel labelling were also calculated, for centre and edge. The figures in
trial patients were 0.57 (0.50-1.09) and 0.52 (0.35-0.95), as compared with 0.59
(0.46-0.78) and 0.46 (0.44-0.60). None of the differences between centre and
edge were statistically significant.
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Table 20. Lymphocytic infiltration at tumour edge & centre 1, and at edge 2
alone.
Trial I. Control I Trial2• Control s
CD56,4 0.92 0.65 <][ 0.85 0.58 •
&8. (0.59-1.41 ) (0.24-1.35) (0.60-1.49) (0.25-1.27
CDS 0.81 0.75 0.81 0.75
(0.49-1.16) (0.24-1.36) (0.60-1.22) (0.24-1.36)
CD4 1.17 0.81 * 1.02 0.81
(0.76-1.87) (0.32-1.41) (0.59-1.87) (0.27-1.43)
CD56 0.82 0.44 0.85 0.43
(0.51-1.27) (0.18-1.29) (0.62-1.30) (0.20-0.97)
CD25 0.75 0.50 0.76 0.33 §
(0.40-1.27) (0.15-0.94) (0.46-1.11) (0.14-0.78)
CD69 0.51 0.79 0.51 0.83
(0.43-0.95) (0.52-1.19) (0.44-0.92) (0.54-1.18)
CD68 1.10 1.02 0.99 1.01
(0.79-1.31) (0.83-1.56) (0.57-1.24) (0.65-1.39)
t chain 0.56 0.62 0.56 0.80
(0.37-0.87) (0.39-0.95) (0.44-0.93) (0.36-0.92)
AP02.7 2.86 1.77 r - -
0.89-3.99) (1.54-2.21)
IgGl 3 0.20 0.18 0.24 0.18
(0.12-0.40) (0.11-0.27) (0.15-0.40) (0.13-0.25)
IgGl 4 0.37 0.37 - -
(0.02-0.92) (0.08-0.85)
TBS 0.23 0.18 0.29 0.20
(0.11-0.62) (0.06-0.48) (0.13-0.58) (0.09-0.96)
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Key to Table 20.
1.Lymphocyte infiltration at the tumour edge and centre.
2. Lymphocyte infiltration at the tumour edge only.
3.Negative control for sections labelled with CD69, CD68, and CD3l; chain.
4.Negative control for sections stained with AP02.7.
S. TBS as negative control for labelling with MAb against CD4, CD56, CD8
andCD25.
Figures in parentheses denote Interquartile Ranges
.. p<0.05; 1p=0.021; .. p=0.028; §p<0.025; L p<0.005
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Table 21. Ratios of tumour edge and centre 1 to normal bowel, and of edge
alone to normal bowel 2.
CDAg Trial!· Control! Trial2• Control s
CD56,4 0.93 0.78 !J. 1.00 0.80 !J.
&8. (0.48-1.48) (0.36-1.18) (0.59-1.48) (0.33-1.13)
CD8 0.91 0.64 1.03 0.65 ©
(0.50-1.90) (0.30-1.47) (0.64-2.14) (0.27-1.11)
CD4 1.04 0.90 1.04 0.91
(0.69-1.46) (0.49-1.13) (0.69-1.37) (0.39-1.13)
CD56 0.62 0.40 0.67 0.37
(0.38-1.39) (0.20-1.30) (0.49-1.36) (0.28-1.36)
CD25 1.12 0.42 © 1.08 0.41 ©
(0.67-1.82) (0.21-1.10) (0.61-1.39) (0.16-0.97)
CD69 0.59 0.82 0.59 0.88
(0.38-0.91) (0.56-1.30) (0.45-0.80) (0.55-1.29)
CD68 0.86 0.81 0.76 0.82
(0.54-1.00) (0.64-1.10) (0.53-0.86) (0.69-1.05)
t chain 0.55 0.48 0.51 0.51
(0.39-0.80) (0.25-0.63) (0.42-0.76) (0.26-0.76)
AP02.7 0.56 0.55 - -
(0.45-0.99) (0.44-0.77)
IgG! 3 0.61 0.50 0.65 0.49
(0.43-1.79) (0.26-0.82) (0.41-2.06) (0.26-0.94)
IgGl 4 0.70 0.89
- -
(0.53-1.20) (0.60-1.57)
TBS 0.90 0.46 0.65 0.48
(0.38-1.82) (0.21-1.44) (0.38-1.10) (0.17-1.58)
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Key to table 21.
1.Lymphocyte infiltration at the tumour edge and centre.
2.Lymphocyte infiltration at the tumour edge only.
3.Negative control for sections labelled with CD69, CD68, and CD3~ chain.
4. Negative control for sections stained with AP02.7.
5. TBS as negative control for labelling with .MAb against CD4, CD56, CD8
andCD25.
© p<0.05; ~ p=O.04
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Table 22. Infiltration of Tonsil by lymphocytes expressing various m
antigens - Positive control.
CDAg 1. 2. 3. 4. 5. Mean
TBS 0 0.01 0 0 0 0.005
IgG 0.66 0.01 0 0 0.02 0.14
CD4 3.03 3.52 6.73 2.34 6.77 4.48
CDS 2.24 1.68 1.28 1.43 1.22 1.57
CDlS 1.36 1.36 1.27 1.27 2.45 1.54
CD68 1.29 1.09 2.12 1.96 0.25 1.34
CD69 1.44 2.51 0.85 0.60 3.31 1.74
t 0.89 0.20 0.98 3.13 0.57 2.89
CD56 1.43 0.01 2.07 0.64 5.32 1.89
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Table 23. Variation in pixel count with Dukes stage of trial and
control patient. Combined results of CD4, CD8 and CD56 MAb labelling.
Stage Trial patient Control patient Trial patient Trial patient
Pixel count Pixel count TIN ratio 1 TIN ratio 1
A 0.99 1.04 1.12 1.04
n=5 (0.73-1.56) (0.27-1.73) (0.75-2.08) (0.41-1.42)
B 1.13 0.60 p<O.OO5 1.04 0.77 p<O.Ol
n=5 (0.78-1.78) (0.19-1.24) (0.72-1.66) (0.38-1.19)
C 0.79 0.60 0.66 0.51
n=5 (0.57-1.26) (0.23-1.20) (0.43-1.09) (0.30-0.85)
D 0.24 0.75 p<O.03 0.33 0.29
n=l (0.19-0.33) (0.37-0.85) (0.25-0.47) (0.18-0.63)
1.Ratio of tumour to normal bowel infiltration.
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Figure 4. Immunohistochemical staining of human tonsil with IgGl
negative control monoclonal antibody (xlOO). Lymphoid follicles are
clearly visible within the photomicrograph. The section is blue due to the
background hematoxylin counter-stain.
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Figure 5. Immunohistochemical staining of sections of human tonsil by
CD4 monoclonal antibody (x200). The brown stain within the fol1icles
labels lymphocytes expressing the CD4 surface antigen. As would be
expected this is greater than that of the negative control (Figure 4).
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Figure 6. Immunohistochemical staining of tumour centre by CD4
monoclonal antibody, in a patient who received l05AD7 pre-operatively
(x200). The brown stain represents stromal infiltration of lymphocytes
expressing CD4 surface antigen. Tumour cells are stained blue with
counter-stain.
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Figure 7. Immunohistochemical staining of tumour edge by CD4
monoclonal antibody, in a patient who received 105AD7 pre-operatively
(x200). Brown stain can clearly be seen at the interface between normal
bowel and the leading edge of the tumour. Once again there is stromal
infiltration of lymphocytes expressing CD4.
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Figure 8. Immunohistochemical staining of tumour centre by CDB
monoclonal antibody, in a patient who received 105AD7 pre-operatively
(x200). Once again infiltration is predominantly stromal.
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Figure 9. Immunohistochemical staining of tumour edge by CDS
monoclonal antibody, in a patient who received l05AD7 pre-operatively
(x300). Higher magnification view showing the leading edge of the
tumour, with normal villi visible at the bottom-right hand corner of the
photomicrograph.
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Figure 10. Immunohistochemical staining of tumour centre by CD56
monoclonal antibody, in a patient who received l05AD7 pre-operatively
(x200). Stromal infi1tration of NK cells between nests of tumor. White
areas represent artefact introduced on cutting sections.
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Figure 11. Immunohistochemical staining of tumour edge by CD56
monoclonal antibody, in a patient who received l05AD7 pre-operatively
(x300). Photomicrograph shows predominantly normal villi, with leading
edge of tumour to the left of the picture. Clearly this is where lymphocytic
labelling predominates.
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Figure 12. Immunohistochemical staining of tumour centre by CD25
monoclonal antibody, in a patient who received 105AD7 pre-operatively
(x300). Stromal infiltration of activated lymphocytes.
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Figure 13. Photomicrograph of tumour centre labelled with CD25. Section
taken from matched unimmunised control patient for patients shown in
Figure 12. Clearly less brown stain seen, suggesting fewer activated
lymphocytes at the tumour site of the patient who did not receive 105AD7
pre-operatively.
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Figure 14. Immunohistochemical staining of tumour centre by IgG1
monoclonal antibody, in a patient who received 105AD7 pre-operatively
(x300). Blue staining is indicative of the background hematoxylin.
122
Figure 15. Photomicrograph of normal bowel immunohistochemically
labelled by CD4 monoclonal antibody, in a patient who received lOSAD7
pre-operatively (x300). The brown stain predominates in the connective
tissue between the villi.
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Figure 16. Immunohistochemical staining of normal bowel by IgG1
monoclonal antibody, in a patient who received 105AD7 pre-operatively
(x300). Photomicrograph shows normal colonic villi stained blue by the
negative control.
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Figure 16. Infiltration of centre and edge of tumour from trial patients and
their matched controls, by CD4+ lymphocytes.
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Figure 17. Ratio of CD8 expression between tumour edge and normal
bowel, in trial patients and their matched controls.
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Discussion
Immunohistochemical analysis of tumour sections from immunised
and unimmunised patients showed a significant infiltration of CD4+ and
CD8+ lymphocytes in the former group. CD4, CD8 and CD56 subsets were
combined to reflect overall lymphocytic infiltration. A statistically
significant difference in favour of patients who received 105AD7 prior to
surgery was seen. The benefit of lymphocytic infiltration of colorectal
cancer was first noted in 1931 by WC MacCarthy, and has subsequently
been shown in a number of other papers [Murray D 1975][Zhou X-G
1983][Carlon CA 1985][Svennevig JL 1984][Jass JR 1986 a][Jass JR 1986 b[Jass
JR 1987][Jass JR 1996][Kubota Y 1992][Secco GB 1990]. This work suggests
that vaccination with 105AD7 is capable of inducing changes at the
tumour site.
A computer-assisted method was used to analyse individual sections.
The results are semi-quantitative, as the computer in effect 'counts' areas
of brown staining consistent with lymphocytic labelling, relative to the
background blue haematoxylin counter stain. Interobserver variation was
assessed by two observers analysing one patient's sections twice. A
correlation coefficient of +0.65 and +0.69 was obtained. Intraobserver
variation however showed correlation coefficients of +0.36 and +0.27.
These results suggest that two observers can analyse the sections, and get
broadly similar results. When the same samples are analysed twice by one
observer, nine months apart, the correlation is not high. This may be due
to samples fading with time, or the settings on the microscope being
inadvertantly different.
The variation in lymphocytic infiltration with Dukes stage has also
been assessed (fable 23). These results should be interpreted with caution
in view of the small numbers. Comparable infiltration was seen between
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trial and control for Dukes stage A. Median scores obtained for Dukes B
and C were however higher in trial patients, significantly so in the former.
With only 1 stage D tumour, it is dificult to draw firm conclusions. Ratios
of tumour to normal bowel were higher in trial patients for all four stages.
In addition infiltration was clearly higher in early stage disease, an
observation that has been borne out by other authors [Watt AC
1978][JacksonPA 1996][HakanssonL 1997].
Infiltration of CD4 and CD8 lymphocytes.
A number of lymphocyte subsets were independently raised in trial
patients as compared with controls. Infiltration of the tumour centre and
edge by CD4+ lymphocytes was significantly higher, as was the ratio of
tumour edge to normal bowel, for CD8+ cells. This is consistent with other
studies, which have shown that tumours are infiltrated predominantly by
T-cells [Werkmeister J 1979][Hutchinson CH 1981].The results also suggest
that 105AD7 is inducing a cellular response, and that stimulated
lymphocytes may be targetting gp72 expressing cells at the tumour site.
Previous work has shown that 105AD7 can stimulate both helper
and cytotoxic T-cell responses, leading to autologous tumour cell killing
[Durrant LC 1994].These results add further support to these findings. Pre-
clinical research has shown induction of delayed-type hypersensitivity
responses in mice, rats and rabbits immunised with anti-idiotypic
antibodies against gp72 and CEA [Irvine K 1993], and evidence of T cell
responses have also been seen in patients with advanced colorectal cancer
receiving anti-idiotypic monoclonal antibodies, as described in Chapter 1
[Herlyn D 1991)[Samonnigg H 1992]. Anti-idiotypic antibodies mimicking
CEA have been shown to stimulate T cell responses [Foon KA 1995][Pervin
S 1997]. In the former study, twelve patients with advanced colorectal
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cancer were immunised with the Ab2, 3Hl. Seven showed idiotype
specific proliferative T cell responses, and 4 patients had evidence of T cell
proliferation to CEA. The same group in the latter study showed that
cellular anti-CEA immunity could be induced by 3Hl, in mice previously
injected with the colorectal cancer cell line MC-38. Importantly,
immunised mice were protected against a challenge with lethal doses of
MC-38. A goat polyclonal anti-idiotypic antibody mimicking the TAA
GA733 has been administered as adjuvant therapy to 13 patients with
colon cancer. Two patients developed CD4+ MHC class II dependent T
cells, that specifically proliferated in culture in response to stimulation
with either anti-Id, or GA733 antigen. A further two patients had evidence
of lymphocytes that suppressed the proliferative responses of cultured pre-
therapy lymphocytes to stimulation with anti-Id or GA-733 antigen
[Somasundaram R 1995].There is evidence suggesting that anti-idiotypic
antibodies are capable of eliciting T cell responses. The
immunohistochemistry results shown suggest that T cells stimulated in
the peripheral blood are capable of targetting tumour cells expressing gp72.
A number of mechanisms have been proposed for the ways in which
TIL might control tumour growth. These have included cytokine release,
cytotoxicity, and helper/suppressor activity [Itoh K 1986][TopalianSL 1989].
Conflicting reports exist regarding the ability of freshly isolated TIL to
exhibit cytotoxicity, however. Some workers have, for example, barely
detected Cl'L using conventional assays [Rabinowich H 1987)[YooYoung-
Kul 1990]. Werkmeister et al however showed evidence of ill vitro CTL
responses against autologous tumour cells in 18 of the 60 cases of
colorectal cancer studied [Werkmeister J 1979]. Ostenstad et al develped a
system for testing T cell capacity to induce DNA fragmentation, one of the
hallmarks of apoptosis. They found that TIL were highly active effectors,
killing the target cells at least as efficiently as control lymphocytes derived
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from the peripheral blood of the same patients [Ostenstad B 1994]. Work
from the same group also demonstrated a limited heterogeneity in the V-
gene usage of TIL from seven patients with colorectal cancer, suggesting a
local antigen-driven immune response at the tumour site. There is
therfore evidence suggesting that TIL may be capable of destroying tumour
cells.
Infiltration of Natural Killer Cells.
Natural Killer cells have been shown to infiltrate tumours such
as malignant melanomas, squamous cell carcinomas, keratocarcinomas,
and malignant breast lesions. The proportion of invading cells may
however be as low as 2% [Kernohan NM 1990][Markey AC 1989][Teisa A
1987][Itoh K 1986]. Immunohistochemistry results confirm labelling of
lymphocytes bearing CDS6, in both trial and control patients, as pixel
counts obtained in both are higher than sections stained with the negative
control IgGl MAb. Tumour from patients who had received 10SAD7 had
consistently higher scores than their matched unimmunised controls,
though the differences do not reach statistical significance.
Killer Inhibitory Receptors (KIR), such as pS8, p70/NKBl, and CD94,
interact with HLA molecules, sending inhibitory signals to the NK cell
[Brooks AG 1997]. Unlike Cf'L, NK cells are capable therefore of lysing
vitally-infected, and malignant cells that down-regulate expression of
Class I and IIMHC molecules. Such killing may occur by a direct cytolytic
effect, be cytokine or antibody mediated, or by interaction between the cells
and macrophages/T-cells/B-cells.
Murine and rat studies have shown that NK activity may be
augmented by innoculation with certain viruses, or immune adjuvants
such as BCG or C parvum. Increased infiltration of primary colorectal
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tumours has also been seen in humans receiving pharmacological doses
of L-Arginine [Heys SD 1997].These results show increased levels of CDS6
on TIL in patients immunised with 10SAD7 prior to surgery. The
implications of this will be discussed in a further section.
Expression of the activation markers CD2S and CD69.
This work demonstrates that the a subunit of the IL-2 receptor is
increased in patients who receive 10SAD7, suggesting that the enhanced
numbers of TIL seen, are activated, and potentially capable of tumour cell
killing. Expression of the early activation marker CD69 was not however
significantly increased in trial patients.
Interleukin-2 is a cytokine that plays a key role in T-cell proliferation
and differentiation, mediating its various effects by binding to specific
receptors [Robb 1984][Waldmann TA 1991]. CD2S is the alpha chain,
present in both high and low affinity receptors on CD4 and CD8 cells
[Wang HM 1987]. Contact of naive T lymphocytes with epitope induces
synthesis of IL-2, and its receptor. Released IL-2 has been shown to
promote activation, growth and differentiation of T lymphocytes, B cells,
NK cells and monocytes, and in addition further promote receptor
formation [Henney CS 1981][Trinchieri G 1984] [Waldmann TA 1984]. The
autocrine/ paracrine expression of this receptor therefore suggests
lymphocyte activation [Harel-Bellan A 1986][Smith KA 1989].This work
shows that the lymphocytes previously seen at the tumour site of patients
who received 10SAD7 pre-operatively are expressing CD2S, and are thus
activated. Immunohistochemical labelling of tumour sections for the a
subunit of the IL-2 receptor is consistently higher in trial patients, relative
to controls, when tumour edge and centre were considered together, and
when pixel scores for edge were analysed independently. Ratios of tumour
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expression to that of normal bowel are similarly higher in patients who
receive 10SAD7 prior to surgery.
Interleukin-2 receptor expression has however been demonstrated
on human solid tumour cells in situ. Weidmann et al (1992) showed that
human squamous cell carcinomas of the head and neck expressed the fl
subunit, as did gastric and renal carcinomas [Weidmann E 1992][Yasumura
S 1994]. Presence of the a subunit (CD2S) was not however seen. A recent
immunohistochemical analysis of 52 cryopreserved solid tumour
specimens has confirmed that while the fl subunit is seen on tumour cells,
the a subunit is not [McMillan DN 1995]. These results suggest therefore
that CD25 MAb is labelling IL-2 receptor present only on infiltrating
lymphocytes. This is consistent with other authors who have confirmed
the presence of CD2S immunohistochemically on lymphocytes in
cryopreserved tumour sections [Hakansson L 1997][Allen C 1987].
The advantage of immunohistochemistry is that it enables a
topographical assessment of the tumour, allowing a comparison between
edge and centre. In our department we have cryopreserved a large number
of tumour samples from unimmunised patients, enabling us to select a
well matched control group for patients who have received 10SAD7.
A trend towards increased infiltration of CD25 expressing lymphocytes
with earlier stage disease was seen. The numbers are however small, and
the differences not statistically significant. It is also possible that the
increased CD25 expression with early stage disease may be due to increased
activation, associated with less immunosuppression. Trial patients
showed increased infiltration of the tumour edge relative to the avascular
centre, though numbers were once again too small to allow statistical
analysis. The converse was true for control patients, suggesting that
10SAD7 may be enhancing infi1tration of activated lymphocytes at the
leading edge of the tumour.
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Thirteen patients with advanced colorectal cancer have been
immunised with 105AD7, as part of a Phase I study. Of these, 6 had
evidence of IL-2 production in their peripheral blood [Denton GWL 1994].
Immunohistochemical analysis of tumour sections from 6 patients
immunised with 105AD7 pre-operatively has also shown increased
expression of CD25 in all samples relative to stage-matched controls
[BuckleyTJD 1995]. Results outlined here in a different cohort of patients,
confirm our original results, and show that patients immunised with
105AD7 prior to resection of their primary tumours have a higher tumour
: normal ratio, and an increased number of CD25 expressing lymphocytes
relative to controls. This suggests a higher proportion of activated effector
T-cells at the tumour site in patients who have received the vaccine.
In addition to CD25, tumour sections were labelled with an MAb
against CD69 (Activation Inducer Molecule), another activation marker.
This is a 28/34 kDa type II transmembrane glycoprotein expressed on
Natural Killer cells and other lymphocytes [Ullman KS 1990].It is one of
the earliest cell surface surface antigens to be induced on T cells by cross-
linking of the TCR/ CD3 complex. Levels peak well before CD25, at
between 30 and 60 mins post-stimulation. They return to normal, as Soon
as the stimulus is withdrawn. The exact function of CD69 is not known,
though it has been suggested it serves as a signalling receptor for T-cell
activation. It is absent from resting lymphocytes, but has been shown on
in vivo activated cells infiltrating sites of chronic inflammation, and
recent evidence suggests that ligation of CD69 by MAb may be sufficient to
induce apotosis in GM-CSF cultured eosinophils [Walsh GM 1996].
Attempts have been made to measure the presence of CD69 on
lymphocytes following administration of various forms of
immunotherapy. Peripheral blood lymphocyte expression of CD69 in
cancer patients was increased following administration of anti-CD3
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monoclonal antibodies, without changes in CD25 levels [Urba WJ 1992].
Further work has confirmed this in patients with metastatic ovarian and
breast cancer receiving TF-KLH and STn-KLH respectively, and shown
that >50% increased expression on PBL correlates with prolonged survival
[Bowen Yacyshyn MB 1995]. Activation markers on TIL have similarly
been measured using immunohistochemistry. Expression of CD69 and
HLA-Dr is increased on lymphocytes infiltrating melanomas, following
immunisation with autologous vaccine modified by the hapten DNP
(Dinitrophenyl) [Berd D 1994]. There was however no increase in CD25
expression, which, the authors suggest, was a consequence of recruiting
patients with advanced disease, who have been shown to have defective
lymphokine production, reduced l; chain and MHC molecule expression,
as well as decreased Cl'L activity [Jacob L 1997]. They are not therefore an
ideal group for immunotherapy, as highlighted in the discussion of the
Phase II study. Of the 16 patients receiving 105AD7 prior to surgery, all but
1 underwent a curative resection. These patients were potentially less
immunsuppressed than the group recruited by Bird. This may explain
why our results show an increase in CD25 expression, whereas his do not.
Immunohistochemistry results suggest that there is no significant
difference in expression of CD69 betweeen patients receiving 105AD7, and
their controls. It should be noted however that pixel scores are consistently
higher in the immunised group. The fact that CD25 is significantly higher
in trial patients, and that CD69 is not, may be due to levels of the latter
returning to normal at the tumour site, as described. The autocrine nature
of CD25 expression may act in a positive feedback loop promoting further
expression, as discussed. This phenomenon has not been described for
CD69.
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CD68 expression
The aim of this work was to assess infiltration of macrophages at the
tumour site of trial and control patients, using an MAb against CD68.
Macrophages are monocyte-derived cells, with stimulatory, suppressive
and phagocytic potential [Tormey VJ 1997].They are strongly positive for
CD68, as well as CD14, acid phosphatase, and occasionally MHC class II
markers. They are morphologically large, rounded cells lacking
cytoplasmic protrusions [Kerrebijn JD 1994].
The role of macrophages at the tumour site is contentious. Despite
their cytotoxic effect when activated by lymphokines, or bacterial prod ucts,
work in head and neck malignancy has shown that 50% of the patients
studied had macrophages that were not cytotoxic towards tumour cells in
vitro [Kerrebijn JD 1994][Cameron DJ 1984].This has been confirmed in
colorectal cancers, and it has been hypothesised that tumour cells become
insensitive to cytolysis in vivo by macrophages, by building up resistance
to tumour necrosis factors [Allen C 1987].Other authors have suggested in
a rat model that macrophages may be assisting, rather than preventing
tumour growth [Evans 1979]. In addition, lysosomal enzymes of
stimulated macrophages might promote metastasis by causing detachment
of cells from the tumour mass [Fulton AM 1984].
Immunohistochemical analysis of tumour sections for macrophages
has produced conflicting results. Some authors report very little
infiltration, while others suggest it is widespread, increasing from normal
bowel to tumour, and further as disease advances [Allen C 1987][EbertEC
1989].Recent work has confirmed the presence of CD11c+ macrophages in
large numbers at the tumour site [Hakansson L 1997]. Conversely, there
were more present with earlier stage disease, and they tended to be present
round areas of cytodestruction, suggesting a cytotoxic role.
134
Analysis of sections showed higher pixel counts for tumour samples
stained for CD68, than for the negative control. This suggests the presence
of macrophages at the tumour site, in part confirming some of the results
above. There was however no difference between trial and control
patients, and the ratios of tumour: normal bowel infiltration were less
than 1 for all the analyses performed, refuting the work of Allen and
Hogg. CD68 is highly expressed on macrophages. It is likely that these
results are more reflective of the true picture at the tumour site, as other
authors use MAb against antigens such as CD11c, which is also present on
monocytes and granulocytes [Hakansson L 1997]. It has further been
suggested that the reason early work failed to show infiltration of tumour
by macrophages was that the surface antigens being assessed were lost
during the preparation process [Hakansson L 1997].
A balance is thought to exist between three macrophage subsets
(stimulatory, suppressive and phagocytic), in normal tissues, and certain
pathological conditions [Hutter 1992][Poulter LW 1994]. Recent work has
shown that cytokines released by T cells may influence which macrophage
phenotype predominates. IL-4 and IFN-y has been shown to induce
stimulatory macrophages, while IL-I0 promotes suppressor cells [Tormey
VJ 1997]. Immunohistochemical analysis clearly shows there is no
difference in terms of absolute infiltration of macrophages between
immunised and unimmunised patients, using an MAb against CD68. It
would have been interesting to use this MAb in conjunction with RFDl
and RFD7 MAb, which may be used to distinguish the three macrophage
subsets. In this way it might have been possible to assess if stimulatory
macrophages, for example, predominated at the tumour site of patients
who had received 105AD7. Having shown enhanced infiltration of CD4
expressing lymphocytes we might have expected to have seen increased
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infiltration of macrophages as a result of cytokine release by activated
Helper T cells. This was clearly not seen.
CD3t chain expression
Signal-transducing molecules associated with the CD3/TCR complex
include the t chain- a 16KDa disulphide linked homodimer [Weissman
AM 1988].The cytoplasmic domain of the CD3 t subunit is involved in
signal transduction, and the subsequent activation of T-cells [Irving 1991].
Work has shown a decrease in CD3 t chain levels on T cells from mice
bearing an experimental colon carcinoma [Mizoguchi H 1992]. NK cells
and TIL from patients with colorectal carcinomas have similarly been
found to have significantly fewer t chains than peripheral blood
lymphocytes (PBL),which themselves had less than normal [Nakagomi H
1993]. Expression on PBL has also been found to decrease as disease
becomes more advanced, though our immunohistochemisty results do
not suggest any decrease in t chain with increasing stage, and if anything
show the opposite [Matsuda M 1995]. It is likely that this reflects the small
numbers involved. Matsuda also showed that levels of t chain were
higher in normal bowel, with a direct relationship between amount of
signal-transducing molecule, and distance from the tumour. This
observation is consistent with this work in that tumour : normal bowel
ratios of t chain were less than 1 in both trial and control patients.
Immunohistochemical analysis of tumour sections failed to show
any difference between trial patients who had received l05AD7, and their
matched controls, suggesting that the vaccine is having no effect on t
chain expression. This is at variance with work by Finn's group, who have
shown that t chain levels are increased following immunisation with a
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synthetic peptide containing five mucin antigenic epitopes [Finn OJ 1996].
Patients received 3 doses of vaccine, 3 weeks apart - markedly more
vaccine, over a longer time course than in this study. It is possible that
increased doses of 105AD7 prior to surgery might have an effect on t; chain
expression, thus reducing the inhibitory effect of the tumour on signal
transd uction.
AP02.7 MAb labelling of tumour sections.
Programmed cell death, or apoptosis, is a selective process of
physiological cell deletion. It has a number of roles including destruction
of tumour cells by CTL and NK cells [Apasov S 1993]. It has been shown to
be accompanied by certain characteristic morphological changes, and the
degradation of internuc1eosomal DNA [Zhang C 1996]. Before death occurs
apoptotic cells undergo alterations in phenotype, and various functional
properties. These include activation of endogenous endonucJeases,
molecular marker expression, and a loss of protein expression. Apoptotic
cells also have abnormal mitochondria, and reductions in their
membrane potentials [Castedo M 1995]. Recently workers have observed
that a 3SkDa mitochondrial antigen is expressed on cells undergoing
apoptosis, against which an MAb (AP02.7) has been raised [Zhang C 1996].
It has been shown to be expressed early in apoptosis, rather than as a final
product of dead cells, and it has been suggested that it may be present on
the cellular membrane in addition to that of the mitochondria.
This work uses the MAb AP02.7 to assess degree of apoptosis
immunohistochemically, in patients receiving 105AD7, and their controls.
Previous work has shown increased infiltration of CD4, CDS, and CD56
expressing lymphocytes at the tumour site of trial patients, and up-
regulation of CD25. These results suggest that apoptosis is increased
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significantly at the tumour site of patients who receive 105AD7 prior to
surgery, possibly reflecting tumour cell killing by infiltrating lymphocytes.
A comparison was made between trial and control patients, in terms
of AP02.7 expression at the edge and centre of the tumour. No significant
difference exists between the two areas. The results need interpreting with
caution in view of the small numbers involved, and the fact that statistical
analysis is based on relatively few pairs.
There is evidence that colorectal cancer cells express Fasl., and may
be capable of killing TIL by apoptosis, thus evading the patients immune
system [Hahne M 1996].These results should be interpreted with caution,
as it is not as yet clear whether the increased labelling with AP02.7 is a
reflection of an increased numbers of lymphocytes undergoing apoptosis
as a result of FasL expression on the tumour cells, or whether invading
TIL are causing death of tumour cells by apoptosis.
Work is currently ongoing aiming to address this issue. Using 2-
colour flow cytometric analysis of disaggregated tumour specimens
labelled with BerEP4 and CD3, in conjunction with AP02.7 MAb, we hope
to assess tumour cell and lymphocyte apoptosis, separately. In addition we
are using Annexin V, a calcium and phospholipid binding protein, to bind
phosphatidylserine, a negatively charged phopholipid expressed on the
surface of apoptotic cells. This change precedes DNA fragmentation
[Martin SI 1995]. Using these techniques it will be possible to determine
which cells are undergoing apoptosis, and hopefully show that the
apoptosis seen at the tumour site immunohistochemically is due to
increased cancer cell killing in patients who receive 105AD7. This work is
currently being performed by an MSc student in the University
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Conclusion.
Infiltration of CD4, CD8 and CD56 expressing lymphocytes is
significantly increased in patients receiving 105AD7 prior to surgery, when
results of the three subsets were combined. Retrospective pathological
assessments of tumour sections would suggest that this might confer a
survival advantage on immunised patients. Infiltration of CD4+ and
CD8+ lymphocytes are independently higher in trial patients relative to
wen matched controls, supporting the premise that 105AD7 is stimulating
cytotoxic and helper T cell responses. Increased expression of the Cl subunit
of the Interleukin-2 receptor (CD25) implies that these TIL are activated,
and potentially capable of releasing cytokines such as IFNy, TNF~, IL-4, IL-
5, IL-6 and IL-10. These are potential1y chemotactic and tumoricidal. In
addition they could cause an alteration in expression of cell-surface
adhesion molecules, such as L-selectin, ICAM-1, VCAM-1 and LFA-1, all of
which might promote NK cell trafficking through the vascular
endothelium [Rothlein R 1988]. This might account for the observation
that CD56 is increased in trial patients.
If the hypothesis outlined above were true, then apoptosis at the
tumour site would be higher in immunised patients, as tumour cells were
lysed by the increased, infiltrating, activated lymphocytes. A significant
increase in apoptosis at the tumour site in patients who received 105AD7,
as denoted by AP02.7labelling might suggest that this were true. However
it is not as yet clear whether activated infiltrating lymphocytes are causing
tumour cell apoptosis, or whether the TIL themselves are being apoptosed
by FasL bearing malignant cells. Work is currently ongoing using flow
cytometry to address this issue.
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Aim.
The aim of this chapter is to assess whether immunological
changes seen at the tumour site of patients receiving l05AD7, can be seen
in the peripheral blood.
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Materials and Methods.
Patients.
A total of 17 patients with primary colorectal cancer were recruited
prospectively from surgical out-patients. All had had their diagnosis made
either at endoscopy and biopsy, or on double-contrast barium enema.
Patient demographics are shown at Table 25.
Clinical Protocol.
Patients attended the Department of Surgery, where consent for
enrollment in the study was obtained, as described. Thirty millilitres of
venous blood was then taken prior to immunization with the vaccine.
Patients received varying doses of 105AD7, as outlined in Table 25. Further
blood samples were taken following immunisation, and prior to resection
of primary tumour.
Phenotyping.
Thirty microlitres of blood were added to labelled Falcon ( FACS )
tubes containing 5,,1 of FITC, PE or PE-Cy5 directly labelled monoclonal
antibody (MAb). The MAb's used are detailed in Table 24. Samples were
then incubated at room temperature, in the dark, for 15 minutes. One
millilitre of FACS lysing solution ® (Becton Dickinson) was added to each
tube, and left for 10 minutes. Vials were then centrifuged for 5 minutes at
200g (1200rpm), and the ensuing supernatant removed. Cells were
resuspended by vortexing the tubes. One millilitre of PBS/Azide was
added and the sample centrifuged for a further 5 minutes at the
aforementioned speed. A further 1 ml of PBS/ Azide was added, and the
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centrifugation repeated. Three hundred microlitres of FACS Fix® (Sysmex,
Tarpen 15A, Hamburg, Germany) were added, and the sample introduced
into the FACScan (Becton Dickinson). Lymphocytes were gated, and
checked for non-lymphocyte contamination. The absolute counts were
therefore obtainable from the haematological white cell count differential.
Table 24. Monoclonal antibodies used to phenotype whole blood
lymphocyte subsets, by flow cytometry.
Cluster Clone. Manufacturer
Designation
CD45/CD141 2DII M8P9 Becton Dickinson 2
JgG1 / Jg G2a - Becton Dickinson 2
CD3/CD4 SK71 SK3 Becton Dickinson 2
CD3/CD8 SK71 SKI Becton Dickinson 2
CD3/HLADR SK71 L243 Becton Dickinson 2
CD3/CD25 SK7/ ACT/1 Becton Dickinson 2 and Dako 3
CD4/CD25 MT3101 ACTI1 Dak03
CD8/CD25 DK25 1 ACf/1 Dak03
CD8/CD56 DK251 MOC-1 Dako3
CD3/CD16+56 SK7/ B73.1+MY31 Becton Dickinson 2
CD3/CD19 SK7/4G7 Becton Dickinson 2
CD3/CD69 UCH 311 T1L78 Dako3
1.All MAbs were used undiluted. The first Cluster Designation is directly
conjugated with fluoroscein isothiocyanate, and the second with
phycoerythrin.
2Becton Dickinson, Between Towns Road, Cowley, Oxford. UK
3Dako, 16 Manor Courtyard, Hughendon Avenue, High Wycombe, UK.
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Table 25. Demographics of patients whose venous blood was phenotyped
following immunisation with ·105AD7.
Pt no. Sex Age Site 1 Stage 2 Oiff 3 Samples 4. Time s.
1.0T F 75 Rectum C Mod 1,6,13,18 18
2.EN F 79 Sigmoid B Mod 1,4,14 14
3.ER M 82 Caecal C Mod 1,4,6,11 11
4.HT F 86 Sigmoid - Mod 1,10,14 14
6.ET M 87 Caecum B Mod 1,8,13,20 20
7.MF F 63 Rectum B Mod 1,9,14,19 19
B.MB M 75 Rectum A Mod 1,9,14,20,26 26
9.0H M 56 Rectum B Mod 1,5,9 9
10. VMcC M 63 Rectum C Mod 1,8,11,15,20 20
11.JK M 76 Sigmoid A Mod 1,9,14 14
12.JGa M 58 Rectum A Mod 1,8,12 12
13. TB F 62 Rectum C Poor 1,10,20 20
14.eB M 75 Caecum Mod *- 1,8,12 -
15. Fe} F 67 Rectum A Mod 1,7,13 13
16.JH M 69 Rectum A Mod 1,8,12,15. 15
17. FH M 73 Rectum C Mod 1,7,14,19,28 28
18. Feh M 70 Rectum B Mod 1,6,13 13
1 Site of primary tumour.
2 Modified Dukes stage of tumour (Turnbull RB, 1967).
3 Differentiation of primary tumour.
4 Days on which venous blood samples were taken. Day 1 denotes the pre-
immunisation sample.
S Number of days between first immunisation and surgery. Patient 14
refused further sampling, and ultimately did not have tumour resected.
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Statistical analysis.
This data presents several analytical difficulties. The number of
venous blood samples, and the duration of time over which they taken
vary for individual patients, making comparison difficult. In the first
instance, a Wilcoxon signed rank test was performed comparing values for
each phenotype prior to immunisation with those at day 7, and
immediately pre-operatively.
A new approach to this problem of serial data involved calculating
the area under the curve per unit time [Matthews et al 1990]. This is
achieved by adding the areas under the graph between each pair of
consecutive observations. For measurements Yl and Y2 at times tl and t2,
then the area under the curve between these two times is the product of
the time difference and the average of the two measurements. Thus we
get (trtl)(Y1+Y2)/2. This is known as the trapezium rule, because of the
shape of each segment of the area under the curve. Therefore if we have
n+ 1 measurements Yi at times ti ( i = 0,1,2...n), then the area under the
curve (AVC) is calculated as:
AUC= 1/2
n-l
L (t;+I- t;) (y; + y;+1)'
i=O
The AVC score obtained is then standardised by dividing the figure
obtained by the number of days between first and last measurements. If
there is no response to immunisation, then the overall AVC/ day will be O.
Clearly a positive score indicates a response. The way in which this test
was applied to the phenotyping data is shown in Figure 19. A paired t-test
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was then performed comparing AVC/ day for trial patients against scores
of 0, the theroretical AVC that would be obtained from an unimmunised
group, for each leucocyte phenotype.
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Results.
A total of 17 patients were recruited to this arm of the adjuvant
study. There were 6 women and 11 men, with a mean age of 71.5 years
(range 56-S7). Eleven had rectal tumours, 3 caecal, and 3 sigmoidal. All
patients had pre-immunisation venous blood samples taken, and a mean
of 3.65 samples (range 3-5) were taken overall prior to surgery. The mean
time between first immunisation and pre-operative blood sample/surgery
was 16.63 days (range 9-2S). Of the 17 patients, 15 had resection of their
primary tumours. In all but one case they were moderately differentiated.
Five tumours were Dukes A, five Dukes Band 5 Dukes C. Patient
numbers 4 and 14 did not have their tumours removed. In the first case
the tumour was unresectable, while the second refused operation, when
he was found to have lung metastases.
Table 26 shows mean and median values for all the lymphocyte
subsets analysed. Statistical analysis was performed, comparing the pre-
immunisation scores with those obtained at approximately 7 days, and
samples taken immediately before surgery. Figure IS shows graphically for
patient number 1, how phenotypes varied with time between
immunisation, and surgery.
Mean peripheral blood phenotypes higher at day 7, than pre-
immunisation included CD3/4, CD3, B cells, CD3/HLA Dr, CD4/25 and
CD3/69. Those lower included CD3/S, NK cells, CD3/25, CD56, CDS/56,
and CD69with lymphocytes, CD3/S, CDS/ 25,CD3/16+56 phenotypes being
unaffected by immunisation. None of these differences reached statistical
significance on a two-tailed Wilcoxon Signed rank test, assuming
significance at the 5% level. Mean, median, SO, IQR, and range for all
phenotypes are shown in Table 26.
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A similar comparison was performed between phenotypes pre-
immunisation and those taken immediately before surgery, approximately
17 days later. Those phenotypes showing an increase after receiving
105AD7 included lymphocytes, CD3, CD3/4, CD3/8, CD3/16+56, CD69 and
CD3/69. No difference was observed between B cells and CD8/25. Those
phenotypes showing a decrease included CD3/HLA Dr, CD3/25, CD4/25,
CD56, and CD8/56. Once again there was no significant difference between
the two groups.
Paired analysis is one way to answer the question of whether a
particular lymphocyte subset is influenced by immunisation with 105AD7.
Another statistical technique employed involved calculating the Area
under the Curve (ADC) per unit time. This principle is shown graphically
in Figure 19, and described in the preceeding section. Patients showed
either positive or negative scores- the former denoting an overall
response to immunisation, the latter no response. The number of patients
showing positive scores for the various phenotypes is shown below, with
figures for individual patients shown in Table 27.
Lymphocy_tes 11/17 (65%) B cells 11/15 (73%) CD3 9/15(60%)
C03/CD4 10/15 (67%) CD3/COB 8/15 (53%) NK cells 9/15 (60%)
CD56 10/14 (71%) C03/HLA Dr 8/15 (53%) C03/16+56 7/15 (47%)
C04/25 8/14 (57%) COB/25 10/14 (71%) C03/25 7/14 (50%)
COB/56 7/14 (50%) C03/69 6/12 (50%) CD69 7/12 (58%)
Table 27 shows the analysis of the area under the curve data for all
patients, and for the two dosing schedules used. The only lymphocyte
subsets when all patients were grouped together to show an overall
negative response to immunisation were NK cells, CD3/25, CD56, and
CD8/56. The others were all positive. If there was no overall response then
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the mean score would be 0 ie no effect of immunisation. Paired analysis
was therefore performed comparing scores obtained with O. No significant
difference was however seen using a Wilcoxon Signed Rank test.
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Figure 18. Venous blood phenotypes measured pre-immunisation, and on
three further occasions before surgery.
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Figure 19. Venous blood phenotyped for CD3/CD81ymphocytes, prior to
immunisation, and on three further occasions before surgery. Graph
indicates how the area above and below a line drawn across from the pre-
immunisation value can be calculated. An average value per day can then
be calculated.
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Table 26. Pre and post immunisation peripheral blood phenotypes.
Lymphocytes Pre-im- Post-im3 Pre-im- Pre-opt
( 1500-4500 x 106/1 ) T=7.41 T=16.35
n=17 mean 1510 1520 n=17 1510 1530
median 1460 1500 1460 1600
SO 360 340 360 320
IQR 1250- 1300- 1250- 1300-
1740 1680 1740 1810
Range 940-2210 1060- 940-2210 860-1970
2350
CD3 Pre-Im- Post-im? Pre-im Pre-opt
(1000-2100 x 106/1) T=7.53 T=16.13
n=15 mean 982 997 n=16 1002 1030
median 967 972 1011 998
SO 243 214 248 306
IQR 835-1121 878-1090 847-1133 834-1191
Range 573-1525 649-1485 573-1525 516-1756
CD3/CD4 Pre-im- Post-im! Pre-im Pre-opt
(500-1700 x 106/1) 1 T=7.53 T=16.13
n=15 mean 545 567 n=16 552 572
median 544 515 550 544
SO 156 129 154 150
IQR 423-634 499-648 423-657 476-666
Range 332-870 389-883 332-870 353-888
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Table 26. Pre and post immunisation peripheral blood phenotypes.
CD3/CD8 Pre-im2 Post-im-' Pre-im Pre-op+
(200-1000 x 106/1) 1 T=7.53 T=16.13
n=15 mean 437 434 n=16 455 462
median 470 420 473 371
SO 189 193 196 248
IQR 278-562 298-511 282-620 309-613
Range 169-796 209-941 169-796 146-1119
CD16+56 Pre-im2 Post-im? Pre-im Pre-opt
(60-240 x 106/1) 1 T=7.43 T=15.93
n=14 mean 265 240 n=13 222 213
median 267 209 207 211
SO 127 117 128 120
IQR 168-370 161-357 116-335 126-288
Range 69-465 74-442 12-420 39-471
CDl9 Pre-im- Post-im3 Pre-im Pre-op+
( 40-400 x 106II )1 T=7.53 T=16.13
n=15 mean 160 171 n=16 159 161
median 171 170 161 140
SO 84 101 81 92
IQR 85-237 95-231 96-237 97-213
Range 25-262 23-389 25-262 36-389
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Table 26. Pre and post immunisation peripheral blood phenotypes.
CD56 Pre-im- Post-im- Pre-im Pre-opt
x 106/1 T=7.43 T=16.BO
n=14 mean 346 317 n=15 364 349
median 333 295 351 312
SO 140 101 153 153
IQR 261-420 247-405 241-442 264-482
Range 122-622 154-461 122-622 77-698
CDB/CD56 Pre-im- Post-im'' Pre-im Pre-opt
x 106/1 T=7.43 T=16.BO
n=14 mean 182 165 n=15 195 189
median 175 178 208 187
SO 81.8 75.7 88.3 101
IQR 122-247 101-220 123-265 110-264
Range 47-319 32-279 47-332 32-388
CD3/16 + 56 Pre-im- Post-im- Pre-im Pre-op4
x 106/1 T=7.50 T=16.50
n=14 mean 80.2 79.8 n=15 70.4 80.9
median 73 57 70.0 58.5
SO 59.6 75.6 47.6 86.4
IQR 24-112 21-123 20-99 23-105
Range 16-218 11-281 16-175 13-347
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Table 26. Pre and post immunisation peripheral blood phenotypes.
CD3/CD25 Pre-im- Post-imf Pre-im Pre-op+
x 106/1 T=7.43 T=17.14
n=14 mean 269 252 n=14 269 243
median 241 248 241 281
SO 162 140 162 105
IQR 150-388 138-351 150-388 136-312
Range 74-641 56-495 74-641 79-403
CD4/CD25 Pre-im- Post-im- Pre-im Pre-opt
x 106/1 T=7.43 T=16.BO
n=14 mean 306 315 n=15 301 295
median 303 291 262 324
SO 126 134 123 107
IQR 220-354 223-340 220-354 205-360
Range 123-611 127-614 123-611 98-462
CDB/CD25 Pre-im! Post-im3 Pre-im Pre-cps
x 106/1 T=7.43 T=16.8
n=14 mean 47.8 47.6 n=15 45.4 45.4
median 33.5 46.5 33.5 32.5
SO 41.7 34.0 41.1 32.1
IQR 14-67 16-70 14-62 19-70
Range 9-155 11-120 9-155 9-99
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Table 26. Pre and post immunisation peripheral blood phenotypes.
C03/HLA Dr Pre-im/ Post-im'' Pre-im Pre-opt
x 106/1 T=7.S3 T=16.60
n=1S mean 293 314 n=16 309 295
median 234 255 285 238
SO 171 208 177 204
IQR 145-415 139-458 153-437 174-373
Range 94-663 99-759 94-663 80-888
CD69 Pre-im! Post-im'' Pre-im Pre-cps
x 106/1 T=8.4S T=17.1S
n=11 mean 160 154 n=13 159 205
median 142 141 142 177
SO 73.6 97.1 67.7 111
IQR 104-237 81-196 108-206 139-253
Range 66-264 74-396 66-264 92-502
WSR NS p=0.0549 1 tail
C069/C03 Pre-im- Post-im3 Pre-im Pre-opt
x 106/1 T=7.7S T=17.15
n=12 mean 80.1 83.5 n=13 80.5 104
median 69 58 77 80
SO 62.2 95.3 56.8 113
IQR 50.3-91.8 35-81 50.8-89.3 51-96
Range 19-250 27-363 19-250 26-463
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Key to Table 26.
1 Normal range for lymphocyte sub-set, on FACScan used for
phenotypic analysis. In a number of cases this range has not as
yet been established.
2 Sample taken prior to immunisation.
3. First sample taken after immunisation. T denotes mean number
of days since immunisation.
4. Sample taken before surgery. T denotes time since
immunisation.
5. Two-tailed WSR test performed at the 5% level. NS denotes Not
Significant.
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Table 27. Area under the curve data for phenotyped patients.
Patient Lym CD3 C03/4 C03/S C016/56 CD56 CDS/56 CD19
number 106/1/ day 106/ 1/ day 106/ 1/ day 106/1/ day 106/ 1 / day 106/1/ day 106/ 1/ dav 106/1/ day
1.0T -110 -105 -94.3 -30.7 -7.3 10.3 15.9 0.56
2. EN 100 55.8 50.5 23 -4.6 -22.1 -19.3 40.7
3. ER 90 97.9 69.7 14.7 -30.8 20.8 13 8.5
4.HT 100 61.8 39.1 38 13.9 0.07 -9.25 41.1
6. ET 80 60 72.5 -0.70 6.6 -227.6 -26 14.4
7.MF 260 223.7 129 54.8 54.6 152.5 21.7 7.3
S.MB -60 -8.10 99.1 -73.5 -106.7 -155.7 -82.8 2.0
9.0H -130 - - - - - - -
10. VG 120 - - - - - - -
11.JK 260 288.2 133.7 194.4 14.6 - - 7.2
12JGa -100 -92.7 -108.6 -8.6 11.5 8.6 1.0 -24.8
13. TB 70 32.6 39.1 8.7 20.1 12.4 -6.8 15.2
14.CB 20 -219 -8.3 -14 6.4 4.8 1.3 -2.7
15. FCI -200 111.9 -45.2 -76.2 -77.1 -82.4 -20.5 -12
16.JH 140 65.8 15.9 31 27.4 42.8 27 28.4
17. FH 100 111.9 74.2 28.1 -31.2 88.1 10.5 9.0
1S. FC -260 -219 -125 -115 3.1 28.3 -2.04 -32.8
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Table 27. Area under the curve data for phenotyped patients.
Patient CD3/25 CD4/25 CDB/25 CD3/16+56 CD69 CD3/69 CD3/HLADr
number 106/ I / day 106/1 I day 106/ 1/ day 106/11 day 106/ II day 106/1/ day 106/ II day
1.DT -94.9 -96.7 -15.6 -1.2 - - -25.4
2. EN -2.96 24 0.70 -14.3 - - -B.21
3. ER 50.8 93.2 21.6 6.9 - - 11.4
4.HT 55.9 41.3 10.6 17.5 -15 -3.6 15.6
6.ET 36.0 71.7 6.6 -3.6 16.1 1.45 42.2
7.MF 3B.3 103.2 19.2 3.9 2.5 -2.97 10.8
B.MB -23 -10.4 -22.B -47.6 -105.6 -36.2 -51.3
9.DH - - - - - - -
10.VG - - - - - - -
11.JK - - - 80.6 104.4 90.5 2BO.l
12JGa -29.8 -56.2 4.3 -5.6 -10.8 -12.5 -7.7
13. TB 10.8 26.3 13.6 0.73 5.B5 4.5 26.4
14.CB -21.5 -35.9 -7.9 1.2 42.7 2B.7 -4.96
15. FCl -22.2 -71.8 1.B -0.92 -B.77 -4.2 -99.7
16.JH 9.3 37 1.67 -1.5 33.7 10.5 10.6
17.FH 67.1 36.9 21.2 4.38 35.B 19.2 25.3
IB.FC -lBO.B -23.7 -44.9 -7.4 -6.5 -15.7 -114.5
160
Table 28. Statistical analysis of Area under the Curve data.
Mean Median IQR SO WSR 1
Lymphocytes 2 28.0 80 -100 to 110 149 NS
cm 29.96 60 -71.6 to 108.4 130.6 NS
CD3/CD4 22.8 39.1 -36.0 to 73.8 83.0 NS
CD3/CDS 4.93 8.7 -26.5 to 30.3 70.8 NS
CD16+56 -6.63 6.4 -24.9 to 14.4 40.9 NS
CD19 6.80 7.3 -1.9 to 15.0 20.7 NS
CD3/HLA Dr 7.38 10.6 -21.1 to 22.9 22.7 NS
CD3/CD25 -7.64 3.17 -23.0 to 38.3 65.9 NS
CD4/CD25 9.92 25.2 -35.9 to 41.3 61.0 NS
CDS/CD25 0.72 3.05 -7.9 to 13.6 18.6 NS
CD56 -8.1 9.5 -22.0 to 28.3 94.9 NS
CDS/56 -5.5 -0.52 -19.3 to 13 27.4 NS
CD3/16+56 2.21 -0.92 -5.1 to 4.26 25.9 NS
CD69 9.0 4.18 -9.8 to 34.8 48.5 NS
CD3/CD69 6.64 -0.76 -8.4 to 14.9 31.2 NS
1. Two-tailed Wilcoxon signed rank test comparing AVC/ unit time
against values of 0, the theoretical mean AVC for a control group.
Significance was taken at the 5% level. NS denotes Not Significant.
2 All lymphocyte subsets in units x 106 1-1 day -1.
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Discussion
These results demonstrate that 105AD7 has no measurable effect on
peripheral blood lymphocyte subset levels. There are several explanations
for this observation. The easiest conclusion to draw is that the anti-
idiotypic antibody does not elicit an immune response. This is clearly at
variance with the results of the Phase I study, and work done using the
vaccine as adjuvant therapy. It is more likely that other factors are
contributory towards the lack of any change in lymphocyte subset levels,
with immunisation.
Flow cytometry is a technique whereby a large number of cells can be
analyzed, and divided into functional subsets based on expression of
surface antigens. A number of lymphocyte subsets were increased
following immunisation, though differences were not statistically
significant. It seems likely that this technique is not sensitive enough to
detect the small changes in lymphocyte subsets that would occur following
immunisation.
Statistical analysis of the results used a two-tailed Wilcoxon signed
rank test, thus not assuming any particular frequency distribution, or
direction of presumed effect. While unimpeachable, this is not as
powerful as a students t test, and is therefore less likely to show any
significant difference should there be one.
Venous blood samples were taken at various time points following
immunisation. It is possible that the paired analysis performed between
pre-immunisation phenotypes, and those at days 7 and 16 failed to detect
a rise occurring at day 3, or day 12 for example. Previous work has also
shown blastogenesis responses, and increased plasma IL-2 levels not
occurring until2-3 weeks after immunisation [Robins RA 1991]. Clearly it
would not be ethical to delay a patients operation in order to take more
blood samples to confirm or refute these findings. In order to compensate
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for this, the area under the curve per unit time was calculated. NK cells
(C016+56), C03/25, CD56 and C08/56 were the only lymphocyte subsets
that showed overall negative mean AUC scores, with all others showing a
positive response.
Parallels can be drawn between this work, and that done in the field
of transplant immunology. Unsuccessful attempts have previously been
made to measure a variety of peripheral blood immunological parameters,
such as T cell subsets and activation markers, in order to predict organ
rejection. If a blood test can show rejection is occurring, then the graft need
not be biopsied [ColesM 1987].Expansion of peripheral blood Cl'L with IL-
2 proved similarly fruitless, even though Cl'L were found to be present at
the site of the organ undergoing rejection [Vaessen LMB 1992].
Immunohistochemical analysis of tumour sections from patients who
also had venous blood phenotyped, has shown increased infiltration of
C04,C08 and C056 positive lymphocytes, with enhanced expression of the
Interleukin-2 receptor. Based on these observations in transplant patients,
it is possible that lymphocytes primed by 105AD7 are localising to the
tumour site, and therefore no changes are seen when peripheral blood is
phenotyped.
Two colour MAb labelling has also been performed, assessing the
number of cells expressing CD16 and CD56 receptors. There is evidence
that peripheral blood levels of this phenotype are higher in patients with
colorectal cancer, as compared with controls [Takii Y 1994]. Our results are
consistent with this, in so much as peripheral blood NK cell levels are just
above the normal range. There was however no significant increase in
this phenotype with 105AD7 administration.
Expression of the activation markers CD69 and HLA DR has been
assessed on PBL following administration of active specific
immunotherapy, in patients with metastatic breast and ovarian cancer.
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There was no increase in levels of the latter, though CD69 levels were
found to be raised [Bowen Yacyshyn MB 1995]. A separate study has also
shown that CD25 levels are not increased following administration of
anti-CD3 MAb [Urba WJ 1992]. It seems therefore that flow cytometry is not
sensitive enough a technique to measure subtle changes in activation
markers on lymphocytes, and that our negative findings are consistent
with those of other authors.
It is likely that 105AD7 is stimulating a very small population of the
total number of T cells in the peripheral blood. As such it is unlikely that
flow cytometry is sensitive enough to detect any slight increase. Peripheral
blood phenotyping is therefore not a sensitive, or viable tool for assessing
responses to the vaccine. In retrospect it might have been more
appropriate to measure IL-2 or TNFa, for example. Work has shown a
correlation between clinical response and levels of the latter in patients
receiving active non-specific immunotherapy, and one could hypothesise
that these might be expected to increase in a patients receiving an
immunotherapy agent, rather than anticipating a significant increase In
specific T cell subsets [Blay JY 1990].
164
Part 3.
Flow Cytometric analysis of Tumour Lymphocytic Infiltration in
Patients receiving 105AD7and their controls.
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Aim.
The aim of this work is to use flow cytometry to assess the
phenotypes of lymphocytes at the tumour site of patients receiving
105AD7, and their controls. Using a panel of monoclonal antibodies it is
possible to quantify the percentage of lymphocytes expressing different
surface antigens, and thus determine if certain subsets are stimulated by
the vaccine, in preference to others.
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Materials and Methods.
Patients.
A total of 19 patients with primary colorectal cancer were recruited
prospectively from surgical out-patients, as described. Patient
demographics are shown in Table 29.
Clinical Protocol.
Patients attended the Department of Surgery, where consent for
enrollment in the study was obtained. They received varying doses of
105AD7, as previously outlined, and underwent resection of their primary
tumours, a mean of 16.9 days (range 9-31 days) following initial
immunisation. Samples were taken from the specimen, immediately
following removal, and stored in RPMI, at 4°C. Disaggregation was
performed within 12 hours of removal, as outlined below.
Control Group.
Tumour disaggregation and flow cytometry were also performed on
fresh samples from 35 unimmunised patients. Patient demographics for
this control group are also shown in Table 29.
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Table 29. Trial and control patients undergoing tumour disaggregation.
No Initials Hosp no 105AD71. Date 2. Sex Age Site 4 Stage 5 Diff6
1. RS 5825068 Control Feb95 M 64 Sigmoid B Mod
2. KG 5263116 Control Mar95 F 58 Caecum B Mod
3. GE 5270734 Control Mar95 F 80 Ascend B Mod
4. JH 5999126 Control Mar95 M 75 Caecum C Mod
5. IB S362759 Yes 3 Mar95 F 71 Caecum B Mod
6. RS S56716A Yes 3 Apr95 M 71 Rectum C Mod
7. GB 5819486 Control May95 M 64 Sigmoid B Mod
8. MS 5975702 Control May95 F 66 Caecum B Mod
9. HS S856235 Control May95 F 82 Caecum B Mod
10. MR 5305334 Control [un 95 M 74 Rectum C Poor
11. m 707357A Yes (1) Sept95 F 75 Rectum C Mod
12. MH 306326 Control Sept95 F 48 Ascend C Poor
13. EN 598383 Yes (2) Sept95 F 79 Sigmoid B Mod
14. ER 5289263 Yes (3) Sept95 M 82 Caecum C Mod
15. VH 640270 Control Nov 95 M 64 Rectum C Mod
16. JG S927425 Yes (5) Nov 95 M 64 Rectum D Mod
17. - - Control Nov 95 - - - - -
18. MF 675748 Yes (7) Dec95 F 63 Rectum B Mod
19. ES 75923A Control Dec95 F 74 Ascend B Mod
20. DH S541069 Yes (9) Dec95 M 56 Rectum B Mod
21. MB 750439 Yes (8) Dec95 M 75 Rectum A Mod
22. IS 752730 Control Dec95 F 68 Sigmoid C Mod
23. JA 50887A Control Dec95 F 55 Rectum B Mod
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Table 29. Trial and control patients undergoing tumour disaggregation.
No Init. Hosp no 105AD71• Date2• Sex Age Site4 Stage 5 Diff6
24. WL 992911 Control Dec95 M 68 Caecum D Mod
25. VMc 214994 Yes (10) Dec95 M 63 Rectum C Mod
26. NW 294189 Control Jan 96 F - - - -
27. DY 65473 Control Jan 96 F - - - -
28. JGa 367716 Yes (12) Feb96 M 58 Rectum A Mod
29. JKirk 327877 Yes (11) Feb96 M 76 Sigmoid A Mod
30. TB 5990904 Yes (13) Mar96 F 62 Rectum C Poor
31. RF - Control Mar96 M 73 Anus - -
32. JW 97622A Control Apr96 M 82 Rectum A Mod
33. FC} 5521022 Yes (15) Apr96 F 67 Rectum A Mod
34. GCI 920255 Control Apr96 M 82 Caecum B Mod
35. ID 419952 Control Apr96 M 78 Caecum B Mod
36. JHa 5330368 Yes (16) May96 M 69 Rectum A Mod
37. MD 92836A Control May96 M 74 Caecum C Poor
38. KK 48175A Control May96 F 75 Caecum B Mod
39. FP 51963A Control May96 M 57 Rectum B Mod
40. WC 972566 Control May96 M 64 Caecum C Mod
41. FHa 5808637 Yes (17) May96 M 73 Rectum C Mod
42. TS 98283A Control [un 96 F 82 Spl flex A Poor
43. PT 5823729 Yes (19) Jun96 M 73 Rectum C Mod
44. JB 08536B Control Jul % F 56 Caecum B Mod
45. TD 985934 Control Jul % M 51 Rectum C Mod
46. 1M 959247 Control Aug96 F 72 Colon C Mod
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Table 29. Trial and control patients undergoing tumour disaggregation.
No Init, Hosp no 105AD71• Date2• Sex Age Site4 Stage 5 Diff6
47. AP 58589A Control Sept 96 M 56 Rectum C Poor
48. JB 475592 Control Sept96 F 65 Rectum C Mod
49. WA 19669B Control Sept 96 M 75 Rectum C Mod
50. EB - Control Oct96 M 61 Sigmoid A Well
5I. DW - Control Nov 96 F 70 ReSig 7 B Mod
52 GF 5442424 Yes (20) Nov 96 M 75 Rectum B Mod
53. DP 5433883 Yes (21) Nov 96 M 69 Rectum C Mod
54. DR - Control Nov 96 F 70 Rectum B Mod
1 Patients immunised with 105AD7 by the author, followed by their trial
number in parentheses (see Table 14). These patients are shown in bold.
Tumours were also disaggregated prospectively from control patients
who did not receive 105AD7 prior to surgery.
2 Month and year that tumour separation occurred.
3 Patients recruited by the previous CRe Fel1ow. These patients received
10J.lgof 105AD7 i.d. followed by 100~lg i.m. 48 hours later.
4 Site of primary tumour
5 Modified Dukes stage of tumour
6 Differentiation of primary tumour, as determined by routine
histopathological examination ( Well, Moderate or Poor ).
7 Rectosigmoid tumour
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Tumour Disaggregation.
Icm- of tumour was finely chopped in a Petri dish using a scalpel,
and added to 20mls of 5% Collagenase A (Sigma, Fancy Rd, Poole, Dorset).
After 10 minutes incubation at 37°C, the solution was filtered through a
coarse filter, and the resultant mixture centrifuged at 1909 (1100rpm) for 10
minutes. Residual unfiltered tumour was once again mixed with 20 mls of
RPMI, and the procedure repeated. After centrifugation, the cells were
treated with 200111of DNAase (Sigma), washed by centrifugation, and
resuspended in RPMI.
Separation of lymphocytes from epithelial cells and red cells was
achieved using a discontinuous Percoll gradient (Pharmacia, Sweden). The
gradient was made using SIP. The SIP consisted of Percoll diluted in
HEPES (Sigma) buffered Hanks balanced salt solution. The osmolarity of
the SIP was made up to 2S5mOsm/l, and its density calculated. Varying
densities (1.044,1.055 and 1.077) of gradient were made by adding RPMI.
Five ml of each density was layered in a Universal container in order to
create the discontinuous gradient.
Ten millilitres of disaggregated tumour suspension in RPMI was
added to the top of the gradient, and centrifuged for 30 minutes at 4°C and
SOOg(2000rpm). The resultant band of lymphocytes was harvested from
the interface between 1055 and 1077 densities, and washed in RPM!, prior
to resuspension. Five millilitres of unlabelled cell suspension was
aliquoted into a FACS tube, and run through the FACScan (Becton
Dickinson), to check for the presence of lymphocytes
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Flow cytometry of tumour infiltrating lymphocytes.
Two hundred microlitre samples of cell suspension were stained
with a panel of MAbs. These MAbs included CD45/CD14, an isotype
matched control (IgGl and IgG2a), CD3/CD19 (B cells), CD4/CD8,
CD3/CD16+56 (NI< cells), CD4/HLA-Dr, CD4/CD25, and CD3/CD69.
Monoclonal antibodies were used undiluted, and obtained from the same
sources, as outlined in Table 24. In addition CD4/ CD45RA/ CD45RO and
CD8/CD45RA/CD45RO MAb (Dako) were used. Samples were incubated
in the dark, on ice, for 30 minutes. Following this, they were centrifuged at
1200 rpm for 5 minutes, and washed twice with RPMI/1% Fetal Calf
Serum (FCS). Supernatant was removed, and 300111of FACS Fix added.
Samples were then analysed on the FACScan cytometer (Becton
Dickinson).
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Results.
A total of 54 fresh tumours were disaggregated, and analysed, as
described. Of these, 35 were from unimmunised patients, while the
remaining 19 were from patients who had received varying doses of
105AD7. TIL obtained from disaggregation and separation on the Percoll
gradient were only labelled and analysed by flow cytometry, if at least 1000
lymphocytes were obtained. Results were therefore available on 16/19
patients who had received 105AD7, and 26/35 of the controls. Three of the
42 available results were lost because patients details were inadequately
recorded, and one patient was excluded, as the pathology from his
resection specimen confirmed squamous cell carcinoma of the anus.
Thirty-eight sets of results were therefore available from patients, for
statistical analysis (16 immunised, and 22 unimmunised). There were 11
men, and 5 women in the immunised group, with a mean age of 69.6
years. Twelve tumours were rectal, 2 caecal, and 2 sigmoid. AU but 1 were
moderately differentiated adenocarcinomas, and 3 were stage A, 5 stage B,
7 stage C, and 1 stage D.
Twenty-two patients had not received 105AD7 prior to surgery, and
acted as the control group. This group consisted of 10 men, and 12 women,
with a mean age of 67.7 years. Seven tumours were rectal, 8 caecal, 3
sigmoid, 1 colonic, 1 rectosigmoid, 1 ascending colon, and 1 at the splenic
flexure. The majority of tumours were moderately differentiated, on
routine histopathological examination. Two cancers were Dukes stage A,
10 stage B, and 10 stage C. There were no stage D tumours in the control
group.
Individual results for trial and control patients are shown in
Appendix 2, Table 2-14. Figures in parentheses represent percentages as
recorded from the FACScan, while those without brackets are corrected for
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contamination, and represent the percentage of the total number of
lymphocytes expressing the surface antigen assayed. It is the latter figures
that are used in the statistical analysis.
Contamination of TIL by epithelial cells and erythrocytes was similar
in both trial and control groups. Median figures clearly approach 70%, and
in some cases a 95% pure population of lymphocytes was obtained.
A comparison was initially made between all trial and control
patients irrespective of any confounding variables. Median percentages,
and interquartile ranges, are shown in Table 31. Immunised patients had a
higher percentage of their lymphocytes expressing CD3, CD4, and CD19
surface antigens at the tumour site, and an increased presence of
activation markers such as CD4+/- HLA Dr, CD4+/- 25, CD3+69. None of
these differences were however statistically significant. Percentage
expression of various activation markers was also combined. CD3-/69 and
CD4+ /25 was higher in trial patients. The percentage of lymphocytes
expressing CD25 (CD4+ and CD4-) was significantly higher in patients who
had received 105AD7 prior to surgery (Figure 20). Percentage expression of
CDS+ cells was however slightly lower in trial patients.
A further analysis was performed whereby the two groups were
matched by site, stage and differentiation of the tumour, and patient sex
(Table 30). The ages of trial and control groups were comparable, being 66.S
and 62.7 years, in the two groups respectively. Trial patients had greater
numbers of TIL expressing CD3, CD4, CD4+/-25, and CD3/69. A number of
phenotypes were lower in trial patients. These included CDS, CD16+56,
CD4/HLADr,CD19andCD3-/69.The combination of CD3-/69 and CD4/25
was also higher in control patients. The only difference to reach statistical
significance was for CD4+/ - 25, once again suggesting an activated
population of TIL in patients receiving 105AD7 (Figure 21: p<O.Ol).
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Figure 20. Expression of CD25 on CD4+ and CD4- lymphocytes in all trial
and control patients.
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Figure 21. Expression of CD25 on CD4+ and - TIL, in trial and control
patients matched according to Dukes stage, site and differentiation of
tumour, sex and approximate age of patient.
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Table 30. Trial patients and controls matched, where possible, according to
tumour site, stage,differentiation and sex and approximate age of patient.
Patient demography:
Pair TIL no. Site3 Stage 4 OH£. 5 Age Sex
1. Trial (9)1 20 Rectum B Mod 56 M
Control 39 Rectum B Mod 57 M
2 Trial (10) 25 Rectum C Mod 63 M
Control 45 Rectum C Mod 51 M
3. Trial (17) 41 Rectum C Mod 73 M
Control 49 Rectum C Mod 75 M
4. Trial (1) 11 Rectum C Mod 75 F
Control 48 Rectum C Mod 65 F
5. Trial (7) 18 Rectum B Mod 63 F
Control 51 ReSig B Mod 70 F
6. Trial2 5 Caecum B Mod 71 F
Control 2 Rectum B Mod 58 F
1. Patients immunised with 105AD7 by the author, followed by their trial
number in parentheses (see Table 14). Tumours were also disaggregated
prospectively from control patients who did not receive 105AD7 prior to
surgery.
2. Patients recruited by the previous CRC Fellow. These patients received
10~tgof 105AD7i.d. followed by 100~lgi.m. 48 hours later.
3. Site of primary tumour.
4. Modified Dukes stage of tumour.
s. Differentiation of primary tumour, as determined at routine
histopathological examination (Well, Moderate or Poor).
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Table 31. Statistical analysis of TILS results
Trial 1. Control 1. Trial 2. Control 2
Lymph. 71.5 66.5 64.0 73
(63-84) (65-76) (48.5-84.8) (61.0-84.5)
%CD3+ 78 70 84.5 76.5
(59-89) (69-80) (63.0-88.5) (64.0-89.0)
%CD4+ 38 35 60.0 36.0
(29-52) (27-48) (43.0-82.0) (29.0-48.0)
%CD8+ 35.5 42.5 34.5 36.0
(23-42) (36-46) (22.0-39.0) (22.0-51.8)
%CD19 7.5 14.5 9.5 11.5
(7-27) (11-18) (5.5-21.5) (4.0-18.00
% CD16 2.5 4.0 3.0 2.0
+CD56 (1-10) (2.5-5) (2.0-5.0) (1.0-5.0)
%CD4+ 16 22 26.0 23
HLADr (12.8-25.3) (19.8-28.5) (12.5-35.0) (15.5-27.5)
% CD4- 51 61 54.0 48.0
HLADr (45.8-56) (32.5-63.3) (40.5-57.5) (36.5-61.8)
% COt 37 29 39 32.5
+/- (14.5-49.5) (22-61) (26-56) (23-52)
HLADr
1. Analysis of 6 trial, and six control patients matched according to
site, stage and differentiation of tumour , sex and approximate
age of patient. Two-tailed Wilcoxon Signed Rank test used.
2 Statistical analysis of all trial and control patients, using a Mann-
Whitney U test. Figures in parentheses represent interquartile
ranges.
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Table 31. Statistical analysis of TILS results.
Trial1• Control 1. Trial 2. Control 2
%CD4+ 12 8 10.5 8.0
25+ (10-20) (4.5-9.5) (8-18) (4.8-11.3)
%CD4- 6.5 1 4.5 3.0
25+ (4-19) (0-3.8) (2.5-9.0) (1.0-4.8)
%CD25 10.5 4.0 p<O.Ol 8.0 3.5 p=o.OO3
(CD 4 +/-) (7-16.5) (1-8) (4.0-16.0) (3.0-8.0)
%CD3+ 70.5 61 66.0 58.0
CD69+ (52.3-66.5) (65-77) (35-76)
%CD3- 6.0 14 10.0 14
CD69+ (13.5-17.3) (6.0-16.5) (6.25-23.3)
%CD69 35.5 34.0 29.5 26.0
(CD3 +/-) (6-71) (14-61) (10.0-66.0) (14.0-59.5)
CD3-/69 10.5 11.5 10.0 10.5
C04/25 (7-16.5) (8-14) (7.8-16.5) (S.D-lS.0)
C04/ - - 94.5 95.0
RO% (92.5-96.5) (88.3-97.8)
COS/ - - 88.0 95
RO% (84.5-94.5) (84.8-96.8)
CD4 & 91 94 93.0 95.0
COBRO (84-93) (83-97) (87.0-96.0) (88.0-97.0)
1. 6 trial and control patients matched by site, differentiation and
stage of tumour, sex and age. 2-tailed Wilcoxon Signed Rank test
2 Analysis of all trial and control patients, using a Mann-Whitney
U test. Figures in parentheses represent interquartile ranges.
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Discussion.
Analysis of all tumours disaggregated showed a significant increase
in expression of the activation marker CD25 (p=0.003) in patients who had
received 105AD7 pre-operatively. This is consistent with results obtained
by immunohistochemical labelling of tumour sections. Other activation
markers were raised in trial patients (CD4+HLA DR, CD4-HLA DR and
CD3/69), though differences did not reach statistical significance. The
percentage of lymphocytes expressing CD4 was also higher in immunised
patients.
Matching trial and control patients for the same variables as used in
the immunohistochemistry analysis, confirmed the findings above, for
CD25 expression (p<O.Ol).The activation markers CD4+HLA DR, CD4-
HLA DR and CD3/69 were also increased, though not significantly so.
It is reassuring to see results obtained immunohistochemically are
confirmed by flow cytometry. The advantage of the former technique is
that it allows multiple analyses to be performed, by separate observers in
some cases, and comparisons to be made between different areas of the
tumour. Flow cytometry is capable of quantifying the percentage of
lymphocytes expressing various markers in a much larger amount of
tumour tissue. Both techniques are subjective. Analysis of
immunohistochemically labelled slides relies on the observer defining
brown stain relative to the blue background. Determination of 'gates' on
the FACScan is similarly subjective. The strength of the work lies in the
close matching of trial and control patients, and analysing tumours blind.
A disadvantage of tumour disaggregation and flow cytometry, is that
it is prospective. This means that a large number of tumours need to be
'processed', before adequate matching can occur. The separation is also
techniqually difficult. If less than 1000 'events' (CD45+CD14- lymphocytes)
were recorded from the tumour digest, then the computer analysis
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software (Consort 30 and Lysys) would not run. As such only 42 out of 54
patients tumours were available. Flow cytometric analysis of tumour
sections was performed blind by one observer (AG). Each dot plot is
analysed separately and 'gates' inserted subjectively. This explains why
results do not always add up to 100%. If percentage of lymphocytes
expressing CD4 and CD8 were summed, this should broadly equal the
percentage of lymphocytes expressing CD3. This is clearly not always the
case.
The results obtained in trial and control patients are consistent with
those in the literature. Work in colorectal cancer has also shown that
there are more CD4+ cells in TIL than CD8+ cells [Balch CM 1990].This is
consistent with results presented here. A further study compared frozen
sections from 14 normal colons with 14 colorectal adenocarcinomas.
Sections were stained using antibodies to the T-cell associated antigens
CD2, CD7, CD4, CD8, and the (l~ and y(, subunits of the T-cell receptor
[Banner BF 1993]. The distribution of cells was similar to that in small
bowel, with CD8 expressing cells present in both the lamina propria and
the epithelium. CD4 cells were concentrated in the luminal half of the
mucosa. It was found that the major components of the immune response
are Th cells, macrophages and HLA-DR+ cells [Banner BF 1993].
Analysis of sections from 58 large bowel adenocarcinomas, and 20
adenomas has recently been performed [Jackson PA 1996].They found that
the phenotype of the inflammatory infiltrate remained constant
irrespective of intensity. The infiltrate was predominantly made up of
CD4+ and CD3+ cells, with fewer CD8+ lymphocytes. HLA changes,
notably ABC loss, A2 loss and DR gain, were commoner in poorly
differentiated tumours. Further work has shown that the majority of TIL
are CD4+, with the remainder being CD8+ [Keller H 1995][MoyP 1985].
Analysis of all tumours disaggregated, showed that 60% of all lymphocytes
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were CD4+ in trial patients, as compared with 36% in controls. This is
consistent with the results of our immunohistochemical analysis of
tumour sections. Expression of CD8 however at the tumour site is
essentially equal in the two groups. The proportion of NK cells in TIL is
thought to be low, and our results confirm this, with <5% of CD45+ cells
expressing CD16and CD56.
Lymphocytes were labelled with a monoclonal antibody against the
low molecular weight (180 kDa) isoform of the Leucocyte Common
Antigen (CD45). The external domain of the molecule may be expressed in
a number of different isoforms. Alternate mRNA splicing-out of exons 4,5
and 6, which encode products termed A,B and C could in theory produce 8
CD45R isoforms (ABC, AB, AC, BC, A, B, C and the null isoform 0),
ranging in molecular weight from 180kDa to 220 kDa [Hargreaves M 1997].
CD4+ T cells may be functionally subdivided based upon expression of
either high molecular weight CD45 RA+CD45RO- isoform or the low
molecular weight CD45RO+CD45RA-.Expression of these two phenotypes
is thought to reflect overall cell maturation, with the former representing
the 'naive' or resting population, and the latter the 'memory' or activated
lymphocyte population. Upon stimulation, T cells are thought to switch
from synthesis of CD45RAmRNA to CD45RO mRNA within 24 hours of
stimulation, and expression of the RO glycoprotein within 24-48 hours.
CD45 RA glycoprotein has been shown to remain on the cell surface for 48-
72 hours, and then disappear [Deans JP 1989]. The difference
phenotypically between RA an RO relates to cytokine production. CD4+ T
cells expressing CD45RO+are capable of producing cytokines such as IL-l,
lL-2, IL-5, lL-6, IFN-y, TNF-a and TNF-~, when stimulated. CD4+
lymphocytes with the RA+ phenotype however, are only able to produce
lL-2 and TNF-~ in any quantity [Adamthwaite 1994]. In assessing
expression of CD45RO at the tumour site of immunised and
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unimmunised patients, an attempt was being made to semi-quantify the
number of stimulated/memory lymphocytes at the tumour site.
Expression of CD45RO however at the tumour site of all patients tumours
was approximately the same in immunised patients as controls, on both
CDS+ and CD4+ lymphocytes. This labelling was performed only on
tumours disaggregated in the second half of the study, and insufficient
numbers were available to match according to stage, site, differentiation
age and sex.
The activation markers CD69 and HLA DR were also assessed at the
tumour site of trial and control patients. There was no significant
difference in expression of the former in the two groups, consistent with
results obtained by immunohistochemical labelling of tumour sections.
The significance of this has been discussed in this section. MHC Class II
expression, which has been shown to increase on T cells following
activation, was also similar on CD4 + and - TIL in trial and control patients
[Pichler WJ 1994].
In conclusion, this work shows that expression of CD25 is increased
following immunisation with 105AD7. This is consistent with the results
obtained immunohistochemically, further sugesting a population of
activated lymphocytes at the tumour site of patients receiving the vaccine.
There is however no significant difference in terms of expression of other
activation markers, such as CD69, HLA DR and CD45RO. This technique is
slightly flawed in that while it may be ideal for expressing the percentage
of activated lymphoctes, it does not compare infiltration of CD4 or CDS
cells per se, as the numbers quoted are percentage of all TIL. In future it
might be more appropriate to assess more definitively absolute cell
numbers.
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Aim.
Previous chapters have attempted to assess the immunological
changes that occur at the tumour site following pre-operative
immunisation with 105AD7. The aim of this work is to assess whether
these have any effect on overall survival.
A total of 23 patients were recruited to the 105AD7 adjuvant study
between June 1993 and April 1995, by the previous eRe fellow Mr T.J.D.
Buckley. This analysis was performed in March/ April 1997, when all of
these patients were at least 2 years following operation. The main
outcomes were time to recurrence, and death within 2 years. The aim was
to compare these outcomes in trial patients, with a well matched group,
randomly selected from the Trent Colorectal Audit.
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Materials and Methods.
Patients and Clinical Protocol.
A total of 23 patients were recruited to the 105AD7 adjuvant study
between June 1993 and April 1995 by the previous CRC Fellow, Mr. T.J.D.
Buckley (Table 32). All patients had colorectal cancer, either diagnosed at
endoscopy and biopsy, or on Double Contrast Barium enema. There were
18 men, and 5 women, with a mean age of 69.7 years (range 55 to 82 years).
Fourteen were rectal tumours, while the remaining nine were colonic.
Patients attended the Department of Surgery, where they received
10~lg of 105AD7 intradermally, followed 48 hours later by a 100~g
intramuscularly. Patients then underwent resection of their primary
tumours. At 6 and 12 weeks after operation patients were boosted with the
same treatment course.
Follow up post-operatively was in the Department of Surgery
Colorectal Clinic, by five Surgical Research Registrars, according to a set
protocol. All patients were seen 3 monthly for the first year, and then 4
monthly thereafter. At each visit, History and Physical Examination were
performed, and a venous blood sample assayed for Carcinoembryonic
Antigen (CEA). Patients underwent flexible sigmoidoscopy at 6 months,
and 3 years, if their anastomosis was within reach of the endoscope. A
persistently raised CEA was investigated by cr, Chest X-ray and
colonoscopy. Other investigations were performed if clinically indicated.
Control Group.
The control group consisted of patients randomly selected from the
Trent Colorectal Cancer Audit. This data base was originally established on
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the 1st August 1992, to document outcome in patients with colorectal
cancer, seen in the ensuing 12 months, in hospitals in the Trent region.
The audit was extended to cover patients treated in Wales between
January 1993 and December 1993, and in total 52 hospitals were covered,
and the notes of 3520 patients scrutinised. Funded by the Department of
Health through the Royal College of Surgeons of England, it involved an
independent notes review by six trained research assistants, and ongoing
GP contact. Patients were identified using a number of approaches,
including hospital record systems, histopathology records, audit derks,
operation notes, and consultant secretaries. The only patients not included
in the various centres were those who had had previous colorectal cancer.
Trial patients were matched to controls for the following eight
variables:
Dukes stage of tumour.
Tumour site ( colon v rectum ).
Tumour differentiation.
Sex.
ASA 1.grade.
Chemotherapy
Radiotherapy
Approximate A_ge.
1.American Society of Anaesthesiologists.
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Table 32. Patient Demographics. Survival analysis.
No. Sex Age.1• No Age Dukes Diff.4 Site 5 ASA Chemo 6. RTH6.
Con2 Con3 Stage.
1. M 64 5. 55.6 C Mod. Rectum. 1. No No
2. M 55 2. 59.0 D Poor. Rectum. NK. 5-FU+FA No
3. M 66 5. 59.4 C Mod. Rectum. 2. No No
4. F 82 5. 68.0 C Mod. Rectum. 3. No No
5. F 67 5. 75.8 B Poor. Colon. 3. No No
6. M 64 1. 50.0 C Mod. Rectum. 2. 5-FU+FA No
7. F 60 5. 64.8 C Mod. Colon. NK. No No
8. F 75 5. 71.8 C Mod. Colon. 3. No No
9. M 74 2. 74.0 D Mod. Rectum. 3. No No
10. F 64 5. 69.6 B Mod. Colon. NK. No No
11. M 81 5. 63.2 B Mod. Rectum. NK. No No
12. M 71 5. 74.2 B Mod. Rectum. NK. No No
13. M 71 2. 63.0 C Poor. Rectum. 2. No No
14. M 76 5. 69.8 B Mod. Rectum. 2. No No
15. M 71 5. 73.2 B Mod. Rectum. 1. No No
16. M 77 5. 73.6 A Mod. Rectum. 2. No No
17. M 79 5. 63.2 A Mod. Rectum. NK. No No
18. M 70 5. 66.4 A Mod. Rectum. 1. No No
19. M 65 5. 68.0 C Mod. Colon. NK. Gastr 7. No
20. M 70 2. 74.5 B Poor. Colon. 3. No No
21. M 72 2. 54.5 C Mod. Colon. 2. 5FU+FA No
22. M 67 5. 72.2 A Mod. Colon. NK. No No
23. M 61 5. 67.2 C Mod Colon. 1. No No
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Legend for Table 32
1 Age of patient (years) at time of resection of primary tumour.
2 Number of control patients selected from Trent Audit for trial
patient.
3 Mean age of control patients at time of operation.
4 Degree of differentiation of primary tumour (well, moderate or
poor).
5 Site of primary tumour (colon v rectum).
6 A number of patients received adjuvant chemotherapy or
radiotherapy, following resection of their primary tumours.
7 Patient received Gastrimmune™ for advanced disease, as part of
a Phase I study.
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Results.
From the database it was possible to obtain between 1 and 70
potential controls for each of the patients who had received 105AD7. It was
decided, following consultation with a statistician, to use a maximum of 5
randomly selected controls for each, where possible. Having more than 5
controls per patient would have little effect on the power of the analysis.
Ultimately, 96 controls were used for the 23 trial patients.
Twenty-three patients were recruited by the previous CRC Fellow,
over a 23 month period, ending April 1995. The group consisted of 18
men, and 5 women, with a mean age of 69.7 years. Fourteen of the primary
tumours were rectal, and 9 colonic. Four (17%) tumours were Dukes stage
A, 7 stage B (31%)~10 stage C (43%)~and the remaining 2 (9%)~stage D. All
were described as moderately differentiated on routine histological
assessment, except for 4 tumours, which were classified as poorly
differentiated. Patient demographics are shown in Table 32.
The survival, and recurrence data for these patients is shown in
Table 33. Sixteen of the 23 (69.6%) patients who had received 105AD7 were
alive and disease free at 2 year follow up. Five patients had died (21.7%),
and a further 2 (8.7%) had developed liver metastases. Of the patients who
died, 2 had Dukes D primary tumours. The remaining 3 died at between 60
and 209 days following operation. All had Dukes C tumours originally. A
diagnosis of carcinomatosis was made on each. The mean time to death
was 180 days. The two patients who had recurrences at 2 year follow up
had a Dukes Band C at original presentation. It was not clear on reviewing
these patients notes whether any treatment in terms of chemotherapy or
radiotherapy was given for these recurrences.
Ninety-six control patients were matched to patients who had
received 105AD7, according to the aforementioned 8 variables. Between 1
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and 5 control patients were available for each trial patient (mean 4.2). The
group as a whole consisted of 71 men, and 25 women, with a mean age of
67.4 years. Fifty-seven tumours were rectal, and 39 colonic. Eighty-five and
11 tumours were moderately, and poorly differentiated, respectively.
Twenty tumours (21%) were Dukes stage A, 32 (33%) stage B, 40 (42%) stage
C, and 4 (4%) stage D.
Survival and recurrence data for patients in the control group is
shown in Table 33. There were 96 patients in the control group, of whom
67 (69.8%) were alive and disease free at 2-year follow up. A total of 15
(15.6%) patients had died, while 14 (14.6%) had evidence of local
recurrence, or distant metastases. The mean time to death in this group
was 403 days. Of the fifteen patients who died, 1 had a Dukes A primary
tumour, 5 Dukes B, 6 Dukes C and 3 Dukes D tumours. Fourteen patients
had evidence of local recurrence, or distant metastases at 2 year follow up
of whom 2 were originally Dukes A tumours, 3 Dukes B, 8 Dukes C, and 1
Dukes D.
A log rank test was performed to assess if there was any difference
between trial and control patients in terms of death, or recurrence. No
significant difference existed between the two groups at the 5% level.
A Cox proportional hazards model was used to adjust for Dukes stage
of disease. The risk ratio in the 105AD7 arm was 1.080 (Cl 0.473-2.466),
suggesting that overall survival in the 105AD7 arm is worse than controls.
The 95% confidence intervals do however span I, suggesting that no firm
conclusions can be drawn. Analysis of Dukes A and B tumours relative to
those graded C and D showed a risk ratio of 0.376 (Cl 0.188-0.751), as one
would expect, indicating that patients with the former tumours have a
better survival than the latter. When the multivariate analysis was
performed for Dukes stage AlB as one group, and CID as another, a
relative risk ratio of 0.387 (Cl 0.050 to 2.998) was seen in the 105AD7 arm.
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The corresponding figure for stages C and D was 1.532 (Cl 0.607-3.866).
These are shown in Table 34. Once again the 95% confidence intervals
span 1, suggesting that no firm conclusions can be drawn.
Kaplan-Meier curves for trial and control patients is shown overleaf.
The upper graph shows the time to a negative outcome (death or
recurrence) for all patients, while the lower graph considers Dukes stages
A and B versus C and D, for the two groups.
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Table 33. 2 Year Follow up data for 23 patients immunised by the
previous CRC fellow between June 1993 and April 1995, and their matched
controls from the Trent Audit.
No 1. Status 2. Control P, Ref no.4 Status of controls
1. Alive. 1. 3136 Died 409 days.
2. 4328 Alive
3. 4400 Alive
4. 4653 Died 375 days.
5. 4661 Loc ree 6 730 days.
2. Died 273 days. 1. 4173 Died 160 days.
2. 4499 Died 561 days.
3. Alive. 1. 1681 Alive.
2. 719 Alive.
3. 4104 Loe rec 730 days.
4. 1879 Alive.
5. 2537 Alive.
4. Died 209 days. 1. 947 Alive.
2. 1647 Loe. ree 365 days.
3. 4218 Died 365 days.
4. 4581 Alive.
5. 6230 Alive.
5. Alive. 1. 246 Died 157 days.
2. 508 Died 730 days.
3. 4556 Alive.
4. 5651 Alive.
5. 8625 Died 387 days.
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Table 33. 2 Year Follow up data for 23 patients immunised by the
previous CRC fellow between June 1993 and April 1995, and their matched
controls from the Trent Audit.
No 1. Status 2. Control P. Ref no 4. Status of Controls.
6. Alive. 1. 4104 Loc rec 730 days.
7. Alive. 1. 1081 Loc rec 76 days.
2. 1301 Alive.
3. 4624 Alive.
4. 6178 Alive.
5. 6221 Alive.
8. Died 149 days. 1. 2808 Alive.
2. 4502 Alive.
3. 4236 Alive.
4. 2842 ' Recurr 435 days.
5. 4290 Alive.
9. Died 210 days. 1. 5282 Died 373 days.
2. 8825 Recurr 60 days.
10. Alive. 1. 1321 Alive.
2. 2174 Alive.
3. 2113 Alive.
4. 3585 Alive.
5. 1890 Alive.
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Table 33. 2 Year Follow up data for 23 patients immunised by the
previous CRC fellow between June 1993 and April 1995, and their matched
controls from the Trent Audit.
Not Status 2 Con P Ref no 4 Status of Controls
11. Alive 1. 4406 Died 428 days.
2. 8111 Alive.
3. 4455 Alive.
4. 4151 Alive.
5. 6130 Alive.
12. Alive 1. 765 Alive.
2. 8550 Loc rec 365 days.
3. 838 Alive.
4. 885 Alive.
5. 5300 Alive.
13. Died 60 days. 1. 2236 Died 339 days.
2. 4715 Loc rec 730 days.
14. Alive. 1. 1278 Loc rec 730 days.
2. 2365 Loc rec 365 days.
3. 230 Alive.
4. 1086 Alive.
5. 4260 Alive.
15. Alive 1. 6160 Alive.
2. 6012 Alive.
3. 4216 Alive.
4. 4049 Alive.
5. 3183 Alive.
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Table 33. 2 Year Follow up data for 23 patients immunised by the
previous CRC fellow between June 1993 and April 1995, and their matched
controls from the Trent Audit.
No 1. Status 2. Control f Ref no 4 Status of Con 5.
16. Alive. 1. 1150 Alive.
2. 764 Alive.
3. 2599 Alive.
4. 2324 Alive.
5. 744 Alive.
17. Alive. 1. 5742 Alive.
2. 775 Alive.
3. 4109 Alive.
4. 1185 Alive.
5. 6359 Alive.
18. Alive. 1. 2659 Loc rec 365 days.
2. 3252 Alive.
3. 4240 Alive.
4. 1783 Alive.
5. 8585 Alive.
19. Recurrs 400 days. 1. 2773 Alive.
2. 5690 Died 533 days.
3. 6379 Alive.
4. 4516 Alive.
5. 2822 Died 369 days.
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Table 33. 2 Year Follow up data for 23 patients immunised by the
previous CRC fellow between June 1993 and April 1995, and their matched
controls from the Trent Audit.
Not Status 2 Control P. Ref no 4. Status of Control s.
20. Recurrs 707 days 1. 5254 Died 373 days.
2. 49 Alive.
21. Alive. 1. 4412 Alive.
2. 1448 Alive.
22. Alive. 1. 1058 Alive.
2. 6156 Died 480 days.
3. 361 Alive.
4. 4746 Alive.
5. 8815 Recurrs 365 days.
23. Alive. 1. 4514 Alive.
2. 8631 Alive.
3. 2773 Alive.
4. 3313 Alive.
5. 2433 Recurrs 228 days.
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Key to Table 33.
1 Patients recruited to study by the previous eRe fellow. The
patient number corresponds to that in Table 32.
2 Status of the patient at 2-year follow up. Patients were either
alive and presumed disease free, dead (all causes), or were alive,
but had evidence of recurrent disease.
3 Number of controls matched to each trial patient from the Trent
Colorectal Audit.
4 The reference number corresponds to the number allocated to
the patient in the Trent Colorectal Audit. This should enable
comparison of immunised patients with controls at 3 and 5
years.
5 Status of control patient at 2-year follow up. Patients may be
alive, and presumed disease free, dead, or alive, but with
evidence of recurrent disease.
6 Local recurrence.
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Table 34 Multivariate analysis adjusting for Dukes stage.
Covariate Risk ratio 95% Confidence Interval
105AD7 1.080 0.473-2.466
Control 1
Dukes stage
105AD7 0.376 0.188-0.751
Control 1
Table 34. Effect of 105AD7 by Dukes Stage.
Dukes Stage Treatment Risk ratio 95%CI
AlB 105AD7 0.387 0.050 to 2.998
Control 1
C/O 105AD7 1.532 0.607 to 3.866
Control 1
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Discussion.
This work has attempted to assess whether any of the
immunological changes described, confer a survival advantage on patients
receiving 105AD7 as adjuvant therapy. A comparison is made with a
historical control group, that is well matched to trial patients according to
8 different variables. It differs from the Phase II study in that it is not
prospective, randomised or blind, and these are the major criticisms of the
analysis. In addition, trial and control patients were not operated on at
exactly the same period in time - 1993/1995 in the former, and 1992/1993 in
the latter group.
This analysis also takes no account of the treatments patients may
have received for their recurrent disease. This data was not available from
the Trent Audit, and was not reliably obtainable from Nottingham
patients immunised with 105AD7. The post-operative follow up of
patients receiving 105AD7 is likely to have been better than that of patients
in the control group. Patients in the former group were seen every three
months for the first year, and every 4 months in the second. Physical
examination and CEA were performed on each occasion, with flexible
sigmoidoscopy at 6 months, in cases where the anastomosis was visible.
The follow up regimes used by the various consultants whose patients
were included in the Trent Audit, and thus constituted the control group,
has recently been documented [Mella J 1997]. There was wide variation in
the regimes employed. Approximately 15% of all patients undergoing
operation were followed up for only 1 year. As well as potentially closer
follow up, more specific data relating to time taken to death or recurrence
was available in the 105AD7 group. In some control patients exact dates of
recurrence were known, though in others it was only known from the
data base that they had recurred at 2 years, when in fact it may have been
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earlier. In these cases the time to a negative outcome had to be assumed to
be 2 years.
At the time of performing this survival analysis, only 2-year follow
up data was available from the Trent Audit database, and this time point
was therefore chosen as the censuring point. There is evidence however to
suggest that 80% of all recurrences will occur within the first 2 years of
surgery. Seven out of 23 patients (30%) receiving 105AD7 had either died
or recurred, as compared with 29/96 (30%) in the control group. Ideally an
analysis should be performed at a follow up of 5 years. If 50% of all patients
with colorectal cancer ultimately die of their disease, then it is possible that
more patients will die or recurr, in the 3 years after this analysis was
performed. This may be the case. The caveat however is that the original
23 patients immunised with 105AD7 have earlier stage disease than would
be expected. This observation is reflected in the control group which is
stage-matched. Approximately 20% of tumours were Dukes stage A, and
4% stage D in the two groups, and the literature suggests that these figures
should be 5% and 30% respectively [Gill P 1978]. It is likely that patients
receiving 105AD7 had their tumours diagnosed as part of the faecal occult
blood screening study that was running at the time in Nottingham.
Tumours detected by screening have been shown to be detected at an
earlier stage [Hardcastle JD 1996].
The ultimate role of a colorectal cancer vaccine is in the treatment of
patients with primary disease. These patients have low tumour burdens,
and are more likely to mount an effective immune response than patients
with advanced disease. 40-45% of patients will have either Dukes A or B
tumours and are unlikely to be referred for chemotherapy. These patients
may benefit from a non-toxic adjuvant therapy, that has a small, but not
insignificant effect on 5-year survival. It is interesting to note, that of the
11 immunised patients with Dukes A or B tumours, only 1 had recurred at
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2 year follow up (9.1%). This compared with 11 of the 52 controls (21.2%),
and was reflected in the relative risk ratio of 0.387. The difference was not
however statistically significant, and the 95% confidence intervals
spanned 1.0 (0.050 - 2.998), suggesting that 105AD7 could not be assumed to
be conferring a survival advantage.
This analysis does nothing towards answering the question of
whether 105AD7 prolongs survival when used as adjuvant therapy. Too
few patients were immunised 2-3 years ago, and thus with wide
confidence intervals, firm conclusions cannot be drawn. A prospective,
randomised, placebo-controlled study recruiting over 200 patients is the
only satisfactory way to answer this question.
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Chapter4.
Conclusion.
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Conclusion.
There were two aims of this work. The first was to test the survival
results of the Phase I study in a randomised, placebo-controlled, double-
blind, Phase II study, in patients with advanced colorectal cancer. The
second aim was to use 10SAD7 as adjuvant therapy in patients with
primary malignancy, and assess the immunological changes that may be
occurring in the peripheral blood, and at the tumour site. A comparison
was also made in terms of survival, and local recurrence between 23
patients who had received 10SAD7 from the previous CRC Fellow, and a
matched control group.
No significant survival difference was seen between patients
receiving 10SAD7 and placebo, in the Phase II study. It is likely that any
immunological responses generated in these patients were insufficient to
have any major effect on tumour growth. This was felt to be due to a
number of factors, including the number of immunisations given, the
adjuvant used, the site of disease, and whether sufficient time was left
after completion of chemotherapy. The patient population was different
from the Phase I study, in so much as patients with local recurrences, and
multiple disease sites were included. The argument that tumour burden
may equate to immunosuppression is persuasive, and it is likely that
recruited patients failed to develop sufficiently effective immune
responses to cause slowing of tumour growth, and prolongation in
survival.
A number of encouraging results were however shown in the Phase
II study. The effect of chemotherapy and radiotherapy in prolonging
survival was seen in the multivariate analysis, consistent with the results
of a number of other published studies. Survival of patients who received
chemotherapy and 10SAD7 was appreciably worse than other groups,
206
contradicting the hypothesis that immunotherapy and chemotherapy may
act synergistically. The toxicity profile of 105AD7 was encouraging, with
only one serious adverse event felt potentially due to immunisation. In
view of this, and the fact that patients with advanced disease are not an
ideal group for immunotherapy, work has concentrated on immunising
patients with primary colorectal cancer, as part of an adjuvant study.
In contrast to the Phase II study, the adjuvant study has shown a
number of interesting, and encouraging results. The toxicity profile was
once again confirmed, with none of the 24 patients recruited by the author
showing any side effects. Immunohistochemical analysis of tumour
sections showed statistically significant infiltration of CD4, CDS and CD56
expressing lymphocytes in patients who had received 105AD7 pre-
operatively, as compared with a control group matched according to site,
stage and differentiation of tumour, sex and age of patient. Evidence has
been presented suggesting that such lymphocytic infiltration may confer a
survival advantage on patients with colorectal cancer. Results for labelling
with MAb against CD4 and CDS lymphocyte subsets were also
independently significantly higher in trial patients. This work also showed
higher levels of the activation marker CD25 on lymphocytes at the
tumour site of immunised patients. This latter observation was confirmed
by disaggregating fresh tumour from 16 trial and 22 control patients,
labelling the lymphocytes obtained with CD25 and analysing by flow
cytometry.
These results suggested an enhanced population of activated
lymphocytes at the tumour site of patients who received 105AD7 prior to
surgery. Having established this, the aim was to assess whether these
lymphocytes were functional, and capable of killing tumour cells by
apoptosis. Tumour sections from trial and control patients were therefore
labelled immunohistochemically with AP02.7, an MAb against a
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mitochondrial antigen (7A6) expressed only on apoptotic cells. Results
showed higher levels of apoptosis at the tumour site of trial patients. It
was not however clear whether this reflected enhanced kiling of tumour
cells by invading lymphocytes, or the converse; ie Fas mediated
destruction of lymphocytes by tumour cells. Work is currently ongoing to
address this issue.
Peripheral blood samples were taken from patients, prior to
immunisation with 105AD7, and at various time points up until
operation. Analysis by flow cytometry failed to show any significant
increase in any of the lymphocyte subsets considered. This may reflect the
fact that stimulated lymphocytes are accumulating at the tumour site, or
that the technique is not sensitive enough to detect small changes in
lymphocyte numbers.
An attempt was made to assess if any of the immunological changes
described after immunisation, correlated with a survival advantage.
Twenty-three patients were immunised with 105AD7 by the previous eRe
Fellow, between June 1993 and April 1995. The survival and recurrence
data at 2 year follow up was compared with 97 controls from the Trent
Colorectal Audit, matched according to stage, site and differentiation of
tumour, age, sex and ASA of patient, and whether they had chemotherapy
or radiotherapy. No significant difference was seen between the two
groups, almost certainly reflecting the small numbers involved in the
analysis.
These results suggest that 105AD7 is capable of inducing immune
responses in patients with primary colorectal cancer, with minimal if any
associated toxicity.
Future work using the anti-idiotypic monoclonal antibody 105AD7
needs to concentrate on several different areas. The premise that the
vaccine is capable of mimicking the antigen needs further substantiation.
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With current advances in molecular biology it should be possible to clone
and sequence the CDR3 region of l05AD7. In addition gp72 could be
affinity purified, and protein sequenced. Ultimately, nieve lymphocytes
could be stimulated with gp72, and then further re-stimulated with
l05AD7 to confirm that the primed lymphocytes are specific for the
antigen/ anti-idiotypic antibody. This work is currently ongoing.
Clinical studies need to concentrate further on immunising
patients with primary tumours, who are likely to get better immune
responses than those with advanced disease. Work using AP02.7 MAb to
immunohistochemically label tumour specimens was encouraging,
though debate still exists as to the nature of the apoptotic cells concerned.
In order to address this important issue, one or both of two techniques
could be employed. These include either 2-colour immunohistochemical
staining of tumour sections, or flow cytometric analysis of distinct
apoptotic populations of disaggregated TIL/ tumour epithelium. No
significant increase post-immunisation could be seen when peripheral
blood was phenotyped, as discussed. If future work is going to look at this
area, then it should concentrate on assaying cytokines such as IL-2, IL-4,
TNFa and (3.
The ideal method for assessing whether any of the immune
responses seen in this thesis have any effect on patient survival would be
a randomised, placebo-controlled survival study, whereby patients are
immunised pre-operatively, and for up to two years after resection of
primary tumours. An alternative approach would be to perform a further
survival analysis of all patients recruited to the adjuvant study by the
author, and the previous CRC Fellow, and compare it with controls from
the Trent Audit. In addition future work should concentrate on the
efficacy of combined adjuvant chemotherapy and l05AD7, and optimising
the dose of the vaccine.
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Table 1-1 Patient Demography
Treatment
105AD7 Placebo
n=85 n=77
Age Mean (sd) 63.3 (11.9) 62.2 (11.2)
Median 64 62
Min 27 33
Max 85 85
n 85 77
Sex Male 51 (60%) 40 (52%)
Female 34 (40%) 37 (48%)
Time from diagnosis Mean (sd) 277.1 (303.4) 278.6 (271.1)
of advanced disease Median 172 179
to entry into the Minimum 0 5
study Maximum 1629 1131
(in days) n 83 72
Missing 2 5
Grade Well 3(5%) 4(7%)
Moderate Iwell 3(5%) 2 (3%)
Moderate 43 (78%) 42 (71%)
Mod I Poor 1 (2%) 3(5%)
Poor 5(9%) 8 (14%)
Missing 30 18
Dukes stage A 2(3%) 2 (3%)
B 14 (18%) 13 (18%)
C 35 (45%) 33 (45%)
D 26 (34%) 26 (35%)
Missing 8 3
Primary site of Colon 48 (58%) 46 (60%)
tumour Rectum 36 (42%) 31 (40%)
Unknown 1 0
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Table 1-2 Initial surgery for resection of the primary tumour
Surgery for resection Treatment
of primary tumour 105AD7 Placebo
n 77 74
Time from surgery Mean (sd) 640.8 (579.4) 803.7 (720.1)
to entry into the Median 465.0 666.5
study Min 20 41
(in days) Max 3475 3615
n 77 74
Operation Colectomy 17 (22%) 9 (12%)
Colectomy+debulk 0 1 (1%)
Resection 5(6%) 4(5%)
Hartmann's 4(5%) 6(8%)
Right hemicolectomy 19 (25%) 15 (20%)
Left hemicolectomy 4(5%) 5(7%)
Subtotal colectomy 0 1 (1%)
Anterior resection 21 (27%) 22 (30%)
Abdomino-perineal 7(9%) 11(15%)
resection
Site Colon 44 (57%) 37 (50%)
Recto-sigmoid 2(3%) 0
Rectum 26 (34%) 34 (46%)
Rectum+small bowel. 0 1 (1%)
Not documented 5 (6%) 2 (3%)
Residual disease at None 41 (53%) 40 (54%)
site Microscopic 4(5%) 7(9%)
Macroscopic 21 (27%) 19 (26%)
Unknown 11(14%) 8 (11%)
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Table 1-3 Any subsequent operations
Patient l05AD7/ Timel o . 2 Site Residual
number Placebo
peration
disease
11 105AD7 34 rev i1eo - micro
13 * 105AD7 164 EUA+biopsy rectum macro
19 105AD7 194 laparotomy - macro
24 * 105AD7 161 ileo bypass colon macro
29 105AD7 579 excision umbil lesion none
29 105AD7 33 def ileost - macro
30 105AD7 277 cryotherapy liver mets macro
37 * 105AD7 790 endo+biopsy rectum macro
42 105AD7 308 exc loc rec anastomosis macro
42 105AD7 201 laparotomy - macro
44 105AD7 590 lobectomy right lung met none
46 105AD7 83 colectomy sigmoid colon macro
51 105AD7 218 exc loc rec anastomosis micro
63 * 105AD7 603 EUA+biopsy rectum macro
63 * 105AD7 181 def end col - macro
66 * 105AD7 161 def end col colon none
73 105AD7 485 resection left liver lobe unknown
79 105AD7 1325 resection right liver none
84 105AD7 916 resection liver macro
85 * 105AD7 35 ileo-sig byp colon macro
87 105AD7 936 def col colon none
87 105AD7 756 rev Hart - macro
98 * 105AD7 95 il trans byp -
130 105AD7 206 cryotherapy liver unknown
149 105AD7 362 resection right liver none
149 105AD7 256 resection
-
none
152 * 105AD7 195 def col colon macro
152 * 105AD7 41 laparotomy unknown macro
162 105AD7 644 resection anastomosis none
7 Placebo 455 excision skin nodules none
7 Placebo 358 laparotomy
-
macro
9 Placebo 868 resection liver mets none
9 Placebo 716 resection liver mets none
9 Placebo 412 resection small bowel macro
9 Placebo 351 aspiration abdom abscess macro
9 Placebo 198 aspiration abdom abscess macro
14 Placebo 304 EUA+biopsy rectum macro
* Primary tumour not removed.
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Table 1-3 Any subsequent operations (continued)
Patient 105AD7/ Timet Operation' Site 2 Residual
number disease
18 Placebo 222 Laparotomy - macro
20 Placebo 254 bypass ileocaecum macro
21* Placebo 725 ileostomy
-
macro
23 Placebo 322 excision skin nodule unknown
28 Placebo 470 excision perineal nod micro
41 Placebo 635 exc loc rec anastomosis unknown
45 Placebo 809 colostomy rectum unknown
45 Placebo 450 excision perineal rec ea macro
49 Placebo 601 exc loc rec anastomosis macro
49 Placebo 74 resection small bowel macro
53 Placebo 279 resection liver none
54 Placebo 1354 sub tot col colon none
56 Placebo 61 transv col colon macro
57 Placebo 278 rev col - macro
59 Placebo 69 Hartmann's colon none
60 Placebo 692 exc loc res anastomosis unknown
62 Placebo 402 resection pelvic mass macroscopi
69 Placebo 1100 resection liver none
69 Placebo 890 debulking op rect+uterus+ unknown
omentum+liv
78 Placebo 1202 resection right liver none
88 Placebo 638 colectomy colon unknown
93 Placebo 69 laparotomy unknown macro
94 Placebo 126 laparotomy smal bowel res macro
95 Placebo 351 tran col. - none
97 Placebo 45 bypass unknown micro
100 Placebo 347 rev col - unknown
106 Placebo 1246 excision wound rec none
106 Placebo 1127 excision rec nod groin none
107* Placebo 104 i1 trans byp colon macro
115 Placebo 49 laparotomy - macro
135 Placebo 171 colostomy colon macro
141 * Placebo 84 colostomy colon macro
160 Placebo 491 resection right liver none
t
2
Time from surgery to
exc loc rec
sub tot col
transv col
rev col
il transv byp
recca
nod
entry into the study.
excision of local recurrence
subtotal colectomy
transverse COlostomy
reversal of colostomy
ileotransverse bypass
recurrent carcinoma
nodule
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Table 1-4 Radiotherapy prior to diagnosis of advanced disease
Radiotherapy prior Treatment
to diagnosis of 105AD7 Placebo
ad vanced disease
n 10 10
Time since start of Mean (sd) 353.7 (330.3) 823.8 (495.5)
radiotherapy to entry Median 178.5 678
into the study Min 125 307
(in days) Max 1107 1946
Time since end of Mean (sd) 315.6 (330.9) 784.1 (500.2)
radiotherapy to entry Median 144.5 641.0
into the study I\fin 89 264
(in days) Max 1076 1916
n 10 10
Length of Mean (sd) 38.1 (17.6) 39.7 (10.4)
radiotherapy Median 34 37
(in days) Min 10 30
Max 72 61
n 10 10
Site of Radiotherapy Left iliac fossa 0 1 (10%)
Pelvis 10 (100%) 9 (90%)
Total Dose (cGy) 2 1 (10%) 0
40 1 (10%) 0
45 0 1 (10%)
133 1 (10%) 0
300 1 (10%) 0
4500 1 (10%) 1 (10%)
5000 1 (10%) 0
missing 4 (40%) 8 (80%)
Type of Radical 3 (30%) 4 (40%)
Radiotherapy Palliative 5 (50%) 2 (20%)
Unknown 2 (20%) 4 (40%)
Response CR 0 1 (10%)
PR 0 1 (10%)
NC 1 (10%) 0
PO 3 (30%) 2 (20%)
NE 3 (30%) 2 (20%)
NK 3 (30%) 4 (40%)
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Table 1-5 Any subsequent courses of radiotherapy prior to diagnosis of
advanced disease
Pt no. 105AD7/ Time1 Time2 Length Site Response
Placebo of RTH
45 Placebo 140 110 30 Perineum Not
evaluable
1 Time since start of radiotherapy (RTH) to entry into the study
2 Time since end of radiotherapy to entry into the study
Table 1-6 Radiotherapy where date of diagnosis of advanced disease is
not known
Pt no. 105AD7/ Time1 T' 2 Length of Site Response
Placebo
rme
RTH
18 Placebo 194 163 31 Pelvis Not
Evaluable
28 Placebo 259 238 21 Perineum Not
Evaluable
36 Placebo Not Not Not Pelvis Not
known3 known3 known3 Evaluable
158 105AD7 Not 73 Not Pelvis Not
known4 known4 Known
1 Time since start of radiotherapy to entry into the study
2 Time since end of radiotherapy to entry into the study
3 Day and month of start and end of radiotherapy not known
4 Start of radiotherapy not known
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Table 1-7 Radiotherapy where date of start of radiotherapy is not
known
Patient 105AD7/ Time1 Time2,3 Length Site Response
No. Placebo of RTH
5 Placebo Not Not Not Not Not
known known known known Known
116 105AD7 Not Not Not Pelvis Not
known known known Known
153 Placebo Not Not Not Pelvis Not
known known known Known
1 Time since start of radiotherapy to entry into the study
2 Time since end of radiotherapy to entry into the study
3 Date of end of radiotherapy not known for all patients
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Table 1-8 Radiotherapy after diagnosis of advanced disease
Radiotherapy after Treatment
diagnosis of 105AD7 Placebo
ad vanced disease
n 13 13
Time since start of Mean (sd) 226.3 (160.1) 370.1 (268.4)
radiotherapy to entry Median 188 478
into the study Min 63 48
(in days) Max 609 748
n 13 13
Time since end of Mean (sd) 215.7 (158.5) 326.7 (275.7)
radiotherapy to entry Median 163.5 168.0
into the study Min 77 27
(in days) Max 581 716
n 12 11
Length of Mean (sd) 24.2 (16.4) 52.9 (108.3)
radiotherapy Median 28 30
(in days) Min 0 0
Max 61 377
n 12 11
Site of Radiotherapy Pelvis 11 (85%) 12 (92%)
Lung 1 (8%) 1 (8%)
Right femur 1 (8%) 0
Total Dose (cGy) 8 1 (8%) 0
45 0 2 (15%)
450 0 1 (8%)
1770 0 1 (8%)
2550 1 (8%) 0
3000 1 (8%) 1 (8%)
3250 0 1 (8%)
3500 0 1 (8%)
4000 1 (8%) 0
4500 2 (15%) 1 (8%)
5350 1 (8%) 0
missing 6 (46%) 5 (38%)
Type of Radical 3 (23%) 2 (15%)
Radiotherapy Palliative 10 (77%) 9 (69%)
Adjuvant 0 1 (8%)
Unknown 0 1 (8%)
Response NA 1 (8%) 0
PR 1 (8%) 1 (8%)
PO 2 (15%) 2 (15%)
NE 6 (46%) 2 (15%)
Not Known 3 (23%) 8 (61%)
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Table 1-9 Any subsequent courses of radiotherapy after diagnosis of
ad vanced disease
Pt no. 105AD7/ Timel T' 2 Length of Site Response
Placebo
Ime
RTH
162 105AD7 244 244 0 Abdo wall NK
162 105AD7 184 184 0 Pelvis NK
31 Placebo 118 104 14 Pelvis NE
1 Time since start of radiotherapy to entry into the study
2 Time since end of radiotherapy to entry into the study
Table 1-10 HonnoneLimmunoLbiological treatment prior to diagnosis
of advanced disease
Hormone / immuno Treatment
biological treatment 105AD7 Placebo
prior to diagnosis of
ad vanced disease
n none
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Table 1-11 Hormone/immuno/biological treatment after diagnosis of
advanced disease
Hormone / immuno Treatment
/ biological treatment 105AD7 Placebo
after diagnosis of
advanced disease
n 2 4
Time since start of Mean (sd) 588 (268.7) 694 (418.6)
treatment to entry Median 588 742.5
into the study Min 398 198
(in days) Max 778 1093
n 2 4
Time since end of Mean (sd) 507 (250.3) 591 (350.8)
treatment to entry Median 507 651
into the study Min 330 137
(in days) Max 684 925
n 2 4
Length of treatment Mean (sd) 81 (18.4) 103 (87.6)
(in days) Median 81 114.5
Min 68 0
Max 94 183
n 2 4
Treatment Interferon 1 (50%) 2 (50%)
Interleukin 2 0 1 (25%)
Investigational 1 (50%) 1 (25%)
Dose schedule 3 courses 1 (50%) 0
3 inj. dose 0 1 (25%)
6 million units 0 1 (25%)
Not Known 1 (50%) 2 (50%)
Response PR 0 1 (25%)
PD 1 (50%) 2 (50%)
NK 1 (50%) 1 (25%)
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Table 1-12 Any subsequent hormone/immuno/biological treatment
after diagnosis of advanced disease
Pt No. Treatment Time1 Time2 Length of Treatment Response
group treatment
69 Placebo 1093 925 168 Interferon PR
1 Time since start of hormone/immuno/biological treatment to entry into
the study
2 Time since end of hormone/immuno/biological treatment to entry into
the study
Table 1-13 Hormone/immuno/biological treatment where start date is
not known
Pt no. 105AD7/ Timel Time2,3 Length of Treatment Response
Placebo treatment
59 Placebo not not not known Not NK
known known known
1. Time since start of hormone/immuno/biological treatment to entry into
the study.
2. Time since end of hormone/immuno/biological treatment to entry into
the study.
3. Date of end of hormone/immuno/biological treatment not known.
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Table 1-14 Chemotherapy prior to diagnosis of advanced disease
Chemotherapy prior Treatment
to diagnosis of 105AD7 Placebo
ad vanced disease
n 11 13
Time since start of Mean (sd) 463.6 (302.6) 518.2 (309.6)
chemotherapy to Median 376 375
entry into the study Min 125 193
(in days) Max 1076 1080
n 11 13
Time since end of Mean (sd) 334.5 (233.9) 412.2 (341.4)
chemotherapy to Median 290 283
entry into the study Min 89 117
(in days) Max 711 1045
n 11 13
Length of Mean (sd) 129.1 (100.2) 105.9 (57.9)
chemotherapy Median 105 92
(in days) Min 4 0
Max 365 197
n 11 13
Chemotherapy'' 5-FU 5 (45%) 5 (38%)5-FU+FA 4 (36%) 6 (46%)
5-FU+Leuc 1 (9%) 0
5-FU+Levam 1 (9%) 1 (8%)
Invest 0 1 (8%)
No of courses 1 1 (9%) 1 (8%)
2 0 2 (15%)
3 1 (9%) 1 (8%)
4 0 2 (15%)
5 0 1 (8%)
6 6 (55%) 5 (38%)
52 1 (9%) 0
missing 2 (18%) 1 (8%)
Response CR 0 1 (8%)
NC 2 (18%) 0
PD 5 (45%) 5 (38%)
NE 2 (18%) 5 (38%)
NK 2 (18%) 2 (15%)
1Leuc=Leucovorin, Levam=Levamisole, Invest=Investigational drug
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Table 1-15 Any subsequent courses of chemotherapy. prior to diagnosis
of advanced disease
Pt no. 105AD7/ Time1 Time2 Length of Chemo Response
Placebo chemo. agent.3
11 105AD7 85 84 1 5-FU+FA NE
130 105AD7 571 448 123 5-FU+FA PD
45 Placebo 291 171 120 Mitomycin C PD
78 Placebo 1045 912 133 5-FU+Levam CR
Table 1-16 Chemotherapy where date of diagnosis of advanced disease is
not known
Pt no. 105AD7/ Time1 Time2 Length of Chemo Response
Placebo chemo. agent. 3
36 Placebo 268 118 150 5-FU+FA Ne
127 Placebo 1036 700 336 5-FU+Levam NK
158 105AD7 NK NK NK FA PD
158 105AD7 NK NK NK 5-FU PD
158 105AD7 NK 94 NK RaItitrexed NC
Table 1-17 Chemotherapy where date of start of chemotherapy is not
known
Pt no. Treatment Time1 Time2 Length of Chemotherapy Response
chemo.
59 Placebo NK NK NK Unspecified NK
37 105AD7 NK 77 NK Mitomycin C NK
124 105AD7 NK NK NK Fluorouracil NK
124 105AD7 NK NK NK Folinic acid NK
1
2
3
Time since start of chemotherapy to entry into the study
Time since end of chemotherapy to entry into the study
Levam = Levamisole.
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Table 1-18 Chemotherapy after diagnosis of advanced disease
Chemotherapy after Treatment
diagnosis of 105AD7 Placebo
ad vanced disease
n 30 21
Time since start of Mean (sd) 368.7 (211.1) 443.8 (280.3)
chemotherapy to Median 291.5 357
entry into the study Min 108 157
(in days) Max 888 1093
n 30 21
Time since end of Mean (sd) 247.4 (188.3) 309.8 (251.2)
chemotherapy to Median 161 174
entry into the study Min 84 91
(in days) Max 698 925
n 29 21
Length of Mean (sd) 109.0 (82.4) 134.0 (128.3)
chemotherapy Median 90 105
(in days) Min 21 28
Max 402 640
n 29 21
Chemotherapy+ Doxorubicin 1 (3%) 0
5-FU 4 (13%) 5 (24%)
5-FU+FA 21 (71%) 15 (71%)
FA+Cisp+5-FU 1 (3%) 0
Investigational 1 (3%) 1 (5%)
Raltitrexed 2 (7%) 0
No of courses 1-5 12 (39%) 6 (24%)
6-10 10 (33%) 7 (34%)
12 0 1 (5%)
13 1 (3%) 0
14 0 1 (5%)
18 1 (3%) 0
22 0 1 (5%)
missing 6 (20%) 5 (24%)
Response PR 1 (3%) 1 (5%)
NC 3 (10%) 4 (19%)
ID 18 (60%) 8 (38%)
NE 1 (3%) 2 (10%)
NK 7 (23%) 6 (29%)
1 Investigational-Investigational drug; Cis-Clsplatin.
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Table 1-19 Any subsequent courses of chemotherapy, after diagnosis of
advanced disease
Pt no. 105AD7/ Time1 Time2 Length of Chemo Response
Placebo chemo. agent.3
37 105AD7 520 422 98 Zilascorb NK
37 105AD7 419 NK NK 5-FU NK
39 105AD7 552 475 77 Invest NK
111 105AD7 369 369 0 Mitomycin C PD
119 105AD7 190 146 44 Lometrexol PD
159 105AD7 176 92 84 5-FU+FA NK
31 Placebo 366 NK NK 5-FU+ Epir+ PD
BCNU+FA
41 Placebo 270 150 120 5-FU NK
62 Placebo 235 119 116 5-FU+FA PD
69 Placebo 862 452 410 5-FU+Leuc CR
160 Placebo 226 117 109 5-FU+FA PD
1
2
3
Time since start of chemotherapy to entry into the study
Time since end of chemotherapy to entry into the study
Leuc= Leucovorin, Epir-Epirubicin, NK=Not known.
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Table 1-20 Off study treatment for malignant disease
Pt no. 105AD7/ Treatment Information Time2 Indication
Placebo
14 Placebo Radiotherapy Pelvis 574 Malignant
disease
60 Placebo Radiotherapy Palliative 235 Malignant
disease
70 Placebo Surgery - 135 Small bowel
obstruction
101 Placebo Chemotherapy 5-FU Bolus1 133 Malignant
disease
102 Placebo Chemotherapy 5-FU+FA1 159 Malignant
disease
115 Placebo Radiotherapy Pelvis 118 Pain
155 Placebo Radiotherapy Para-aortic 41 Malignant
disease
51 105AD7 Surgery - 121 Intestinal
obstruction
68 105AD7 Surgery Sympathectomy NK NK
98 105AD7 Chemotherapy 5-FU+FA1 153 Malignant
disease
1
2
NK= Not known, FA= Folinic acid (leucovorin).
Time since start of study (in days)
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Table 1-21 Results of protocol investigations at time of entry to study
and week 12
Entry to study Week 12
105AD7 I Placebo 105AD7 I Placebo
Chest X-ray Normal 38 (48%) 25 (33%) 9 (29%) 16 (48%)
Abnormal 28 (35%) 32 (42%) 16 (52%) 11 (33%)
Not Done 13 (16%) 19 (25%) 6 (19%) 6 (18%)
missing 6 1 54 44
er scan Abnormal 26 (37%) 23 (34%) 2(7%) 6 (21%)
Not Done 44 (63%) 45 (66%) 27 (93%) 23 (79%)
missing 15 9 56 48
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Table 1-22 Patient status
Treatment
105AD7 Placebo
Weight (kg) WeekO Mean (sd) 66.9 (12.5) 69.0 (16.0)
Median 66.3 67.0
Min 38 40.3
Max 97.2 105.4
n 77 73
Week6 Mean (sd) 68.8 (12.2) 69.1 (15.7)
Median 67.4 67.9
Min 40 38.1
Max 97.1 106
n 48 51
Week 12 Mean (sd) 67.6 (13.0) 69.9 (16.1)
Median 66.6 68.6
Min 42 44.2
Max 94.3 104
n 39 34
Height (cm) WeekO Mean (sd) 168.1 (8.9) 167.3 (9.1)
Median 167.4 167.5
Min 147 151
Max 190 191
n 76 68
Surface Area WeekO Mean (sd) 1.74 (0.18) 1.74 (0.25)
( mg/m2) Median 1.74 1.70Min 1.35 1.22
Max 2.10 2.19
n 24 28
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Table 6 Patient status (continued)
Treatment
105AD7 Placebo
WHO Week 0 0 28 (33%) 20 (26%)
Performance 1 43 (51%) 47 (61%)
status 2 14 (16%) 10 (13%)
Week6 0 23 (42%) 13 (25%)
1 22 (40%) 30 (57%)
2 8 (15%) 9 (17%)
3 2(4%) 1 (2%)
4 0 0
missing 30 24
Week 12 0 19 (49%) 9 (23%)
1 16 (41%) 24 (62%)
2 4 (10%) 5 (13%)
3 0 0
4 0 1 (3%)
missing 46 38
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Table 1-23 Haematology
Week 0
105AD7 Placebo
WBC (x109/1) Mean (sd) 9.20 (4.27) 9.24 (4.73)
Median 7.6 8.6
n 85 74
Platelets (x109/1) Mean (sd) 332.4 (158.6) 333.3 (117.9)
Median 286 314
n 85 74
Haemoglobin Mean (sd) 11.89 (1.69) 11.81 (1.84)
(xg/dl) Median 11.8 11.8
n 84 74
Neutrophils Mean (sd) 6.77 (3.74) 7.02 (4.47)
(x109/1) Median 5.59 6.11
n 83 74
Lymphocytes Mean (sd) 1.35 (0.57) 1.36 (0.63)
(x109/l) Median 1.27 1.20
n 84 74
Week 6
105AD7 Placebo
WBC (x109/1) Mean (sd) 8.42 (3.53) 9.37 (3.74)
Median 7.45 8.6
n 62 57
Platelets (x109/1) Mean (sd) 292.7 (118.2) 339.3 (114.7)
Median 271.5 319.0
n 62 57
Haemoglobin Mean (sd) 11.92 (1.78) 11.58 (1.99)
(xg/dl) Median 12.3 11.9
n 62 57
Neutrophils Mean (sd) 6.18 (3.44) 7.11 (3.54)
(x109/1) Median 5.21 5.88
n 62 57
Lymphocytes Mean (sd) 1.45 (0.69) 1.42 (0.65)
(x109/1) Median 1.30 1.26
n 62 57
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Table 1-23 Haematology Results
Week 12
105AD7 Placebo
WBC (x109/1) Mean (sd) 8.49 (3.44) 8.88 (2.77)
Median 7.3 8.4
n 47 44
Platelets (x109 II) Mean (sd) 285.7 (106.3) 335.6 (141.4)
Median 265.0 316.5
n 47 44
Haemoglobin Mean (sd) 12.26 (1.78) 11.88 (1.86)
(xg/dl) Median 12.8 12.05
n 47 44
Neutrophils Mean (sd) 6.26 (3.38) 6.35 (2.53)
(x109/1) Median 5.00 5.88
n 47 44
Lymphocytes Mean (sd) 1.44 (0.62) 1.47 (0.64)
(x109II) Median 1.40 1.33
n 47 44
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Table 1-24 Chemical Pathology
WeekO
105AD7 Placebo
Na (mmol/l) Mean (sd) 137.9 (4.0) 138.3 (3.4)
Median 138 139
n 83 75
K (mmol/l) Mean (sd) 4.44 (0.43) 4.27 (0.47)
Median 4.4 4.2
n 82 75
Urea (mmol/l) Mean (sd) 5.57 (3.22) 6.01 (3.91)
Median 4.8 5.1
n 83 76
Creatinine Mean (sd) 85.1 (34.6) 91.4 (72.1)
(mmol/l) Median 79 79
n 83 75
Total Protein (gIl) Mean (sd) 69.1 (6.3) 70.6 (8.3)
Median 69.5 70
n 12 12
Albumin (gIl) Mean (sd) 37.9 (4.6) 38.3 (5.7)
Median 38 39
n 84 76
Bilirubin Mean (sd) 20.4 (59.7) 14.9 (31.7)
(mmol/l) Median 10 10
n 84 76
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Table 1-24 Chemical Pathology (continued).
WeekO
105AD7 Placebo
Alk Phos (IU /1) Mean (sd) 303.2 (388.0) 260.0 (273.4)
Median 149 158.5
n 83 76
ALT (IU/l) Mean (sd) 39.2 (39.8) 39.5 (30.4)
Median 29.5 32
n 84 76
AST (IU/l) Mean (sd) 26.7 (12.4) 30.0 (22.2)
Median 23.5 20.5
n 10 6
Urate (mmol/l) Mean (sd) 0.33 (0.06) 0.34 (0.12)
Median 0.32 0.32
n 6 10
GGT (IV/I) Mean (sd) 240.5 (308.5) 233.1 (307.9)
Median 104 105
n 75 71
CEA(mg/l) Mean (sd) 669.2 (1135.5) 475.4 (1174.8)
Median - 134.5 61
n 80 70
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Table 1-24 Chemical Pathology (continued)
Week 6
105AD7 Placebo
Na (mrnol/J) Mean (sd) 138.4 (3.9) 138.2 (3.2)
Median 139 139
n 60 56
K (mmol/l) Mean (sd) 4.36 (0.39) 4.34 (0.50)
Median 4.4 4.2
n 60 55
Urea (mmol/ I) Mean (sd) 5.41 (2.37) 5.62 (2.50)
Median 4.75 5.1
n 60 56
Creatinine Mean (sd) 90.8 (36.1) 85.4 (28.4)
(mmol/ l) Median 79.5 79.5
n 60 56
Total Protein (g/I) Mean (sd) 68.8 (7.1) 69.7 (7.4)
Median 67 71
n 9 10
Albumin (g/ I) Mean (sd) 38.4 (4.2) 38.4 (5.4)
Median 39 39
n 60 56
Bilirubin Mean (sd) 13.6 (13.5) 12.9 (14.9)
(mmol/l) Median 10 9.5
n 60 56
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Table 1-24 Chemical Pathology (continued)
Week6
105AD7 Placebo
Alk Phos (IU / I) Mean (sd) 270.6 (333.8) 238.6 (232.7)
Median 145.5 151
n 60 56
ALT (IU/1) Mean (sd) 32.2 (21.1) 35.2 (23.4)
Median 26.5 26.5
n 60 56
AST (IU/l) Mean (sd) 30.6 (14.3) 35.4 (30.5)
Median 27 22.5
n 11 8
Urate (mmol/l) Mean (sd) 0.34 (0.07) 0.36 (0.15)
Median 0.33 0.34
n 8 7
GGT(IU/I) Mean (sd) 218.9 (301.1) 243.5 (362.9)
Median 79 93
n 55 52
CEA(mg/l) Mean (sd) 881.1 (1325.8) 341.6 (554.4)
Median 181.5 91.5
n 56 52
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Table 1-25 Adverse events- non-serious.
Treatment
105AD7 Placebo
n 57 30
Highest ere 1 26 (47%) 11 (38%)
Grade 2 15 (27%) 13 (45%)
3 9 (16%) 5 (17%)
4 5 (9%) 0
missing 2 1
Relation to Almost certainly 1 (2%) 0
Study drug Possibly 9 (16%) 8 (27%)
Unlikely 47 (82%) 22 (73%)
Outcome Resolved 20 (35%) 11 (37%)
Improved 2 (4%) 3 (10%)
Unchanged 29 (51%) 15 (50%)
Worse 6 (11%) 1 (3%)
Time from entry Mean (sd) 28.2 (29.9) 31.2 (28.5)
into the study & Median 22 26
start of adverse Minimum 0 0
event (days) Maximum 120 90
n 46 29
Missing 11 1
Duration of Mean (sd) 2.73 (2.05) 24.1 (29.8)
adverse event. Median 2 14
Minimum 1 2
Maximum 7 84
n 11 7
Missing 46 23
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Table 1-25 Adverse events- Serious.
Patient 105AD7/ Highest Relation Outcome. Time 2 Time 3
number. Placebo ere to study
grade. drug 1
2 Placebo 3 Unlikely Improved 26 NK
7 Placebo 3 Unlikely Unchanged NK NK
22 105AD7 3 Unlikely Unchanged 9 NK
1.Excludes all adverse events classified by investigators as "unrelated" to
the study drug.
2. Time to onset (days).
3. Time at which adverse event ceased (if applicable).
239
Table 2-1. Immunohistochemistry Results CD25.
Patient No Site 1. Trial Abs2• ConAbs Trial T/N3 Con TIN
1.DT Centre 0.59 0.80 0.62 1.13
Edge 0.52 0.30 0.55 0.42
2.EN Centre 0.89 0.05 0.93 0.10
Edge I 0.74 0.07 0.77 0.13
Edge2 0.95 0.08 0.99 0.16
3.ER Centre 0.218 0.93 0.68 0.34
Edge 0.50 0.13 1.55 0.05
5.JGr Centre 0.28 0.61 0.45 2.00
Edge I 0.24 0.59 0.38 1.93
Edge2 0.11 0.34 0.18 1.12
6.ET Centre 1.33 0.64 0.86 1.07
Edge 1.62 1.20 1.05 2.00
8.MB Centre 0.40 1.53 0.62 1.09
Edgel 0.43 1.33 0.66 0.97
Edge2 0.71 0.21 1.08 0.15
9.DH Centre 1.45 0.14 1.80 0.27
Edge I 1.00 0.26 1.25 0.44
Edge2 0.51 0.11 0.63 0.21
n.jx Centre 0.44 0.79 3.01 0.42
Edge I 0.92 1.48 6.33 0.79
E~ge2 1.69 0.78 11.59 0.41
l2.JGa Centre 0.33 1.50 1.59 0.99
Edge I 0.11 0.15 0.51 0.10
Edge2 0.79 0.11 3.74 0.21
240
13. TB Centre DAD 1.24 0.70 1.06
Edge I 0.77 1.29 1.34 1.10
IS.Fel Centre 2.14 2.36 lAO 15.67
Edge I 1.91 0.94 1.24 5.79
17.FHa Centre 0.98 0.51 1.38 1.38
Edge1 1.20 0.14 1.70 0.39
IS.Feh Centre 1.46 0.79 1.56 0.41
Edge I 1.08 0.32 1.15 0.16
Edge2 1.96 1.32 2.09 0.68
A. 4 Centre. - 0.45 - -
Ae Edge. 1.46 0.56 1.08
-
B. 4 Centre. 1.87 0.08 3.22 0.16
HS Edge 1. 0.76 0.20 1.31 DAD
Edge2. 0047 0.14 0.80 0.28
c.4 Centre 0.14 0.18 0.32 -
AGe Edge 1. 0.08 0.48 0.18
-
Edge2. 0.10 0.33 0.23
-
t Site of tumour specimen was taken from.
2 Absolute infiltration of lymphocytes into tumours from trial
patients who had received 105AD7, and their matched controls.
3 Ratios of tumour edge and centre lymphocyte infiltration, to that of
infiltration into normal bowel.
4 Specimens from patients immunised by the previous CRC Fellow.
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Table 2-2 Immunohistochemistry results - CD4
Patient No Site 1. Trial Abs2• ConAbs Trial T/N3 Con TIN
I.DT Centre 1.12 0.62 0.47 1.17
Edge 2.48 1.00 1.04 1.88
2.EN Centre 1.33 0.16 1.04 0.93
Edgel 0.56 0.20 0.44 1.13
E<!g_e2 1.89 0.27 1.48 1.53
3.ER Centre 1.20 1.17 1.38 0.52
Edge 0.78 0.81 0.99 0.36
S.JGr Centre 0.57 0..75 0.45 0.19
Edgel 0.37 0.83 0.29 0.22
Edge2 0.19 1.25 0.15 0.32
6.ET Centre 0.92 0.19 0.59 0.34
Edge 2.00 0.33 1.25 0.60
8.MB Centre 1.20 1.44 2.13 1.25
Edgel 0.59 0.26 1.04 0.23
Edge2 0.59 1.30 1.05 1.12
9.DH Centre 1.87 1.35 1.95 2.05
Edgel 0.78 0.68 0.82 1.02
Edge2 0.66 0.58 0.69 0.88
11.JK Centre 0.99 2.43 0.91 1.04
Edgel 1..57 2.84 1.44 1.21
Edge2 0.75 1.83 0.69 0.78
12.JGa Centre 1.13 0.56 1.11 1.04
Edgel 1.02 0.42 1.00 0.78
Edge2 1.22 0.58 1.19 1.08
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13. TB Centre '0.94 1.41 0.88 0.88
Edge I 1.20 2.42 1.14 1.52
15.FCI Centre 2.26 2.25 1.52 5.41
Edge I 2.20 2.28 1,48 5.47
17.FHa Centre 1.54 0.15 1.17 0.23
Edge I 1.79 0.08 1.35 0.12
18.FCh Centre 2.16 1.04 2.34 0.72
Edge I 1.86 1.46 2.02 1.01
Edge2 3.30 1.42 3.58 0.98
A4 Centre. - 0.96 - 0.73
AC Edge. 1.49 1.20 1.01 0.91
B4 Centre. 2.18 0.44 2.13 0.80
HS Edge I. 0.95 0.27 0.93 0.49
Edge2. 1.98 0.09 1.93 0.18
C4 Centre. 0.77 0.79 0.69 -
AGe Edge 1. 0.58 0.20 0.52 -
Edge2. 0.10 1.63 0.23
-
1 Site of tumour specimen was taken from.
2 Absolute infiltration of lymphocytes into tumours from trial
patients who had received 10SAD7, and their matched controls.
3 Ratios of tumour edge and centre lymphocyte infiltration, to that of
infiltration into normal bowel.
4 Specimens from patients immunised by the previous CRC Fellow.
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Table 2-3 Immunohistochemistry results - CD 8
Patient No Site 1. Trial Abs2• ConAbs Trial T/N3 Con TIN
1.OT Centre 1.17 0.18 0.92 0.60
Edge 0.61 0.21 0.43 0.71
2. EN Centre 0.91 0.12 - 0.45
Edge1 2.25 0.10 - 0.38
Edge2 1.10 0.29 - 1.11
3.ER Centre 0.17 0.24 0.22 0.11
Edge 0.58 0.07 0.74 0.03
S.JGr Centre 0.24 0.47 0.38 1.79
Edgel 0.32 0.40 0.51 1.54
Edge2 0.17 0.04 0.28 0.15
6.ET Centre 0.92 0.81 1.15 0.16
Edge 1.57 0.58 1.96 0.11
8.MB Centre 0.33 2.47 3.34 3.09
Edge1 0.45 1.13 4.46 1.42
Edge2 0.68 2.04 6.82 2.57
9.0H Centre 0.69 0.69 0.88 0.50
Edgel 0.69 0.61 0.89 0.45
Edge2 0.81 0.24 1.03 0.18
11.JK Centre 0.27 1.38 0.42 0.58
Edge1 0.74 1.54 1.12 0.65
Edge2 0.99 1.25 1.51 0.53
l2.JGa Centre 0.46 1.48 0.43 1.52
Edgel 0.76 1.06 0.70 1.09
Edge2 1.12 1.01 1.04 1.04
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13. TB Centre 1.39 1.02 1.00 0.63
Edge I 0.39 1.34 0.28 0.82
15. FCI Centre 2.33 1.45 1.13 1.55
Edge I 1.86 0.98 0.91 1.04
17. FHa Centre 0.91 0.26 0.63 0.49
Edge I 0.85 0.26 0.59 0.48
18. FCh Centre 0.81 1.39 0.47 1.30
Edge I 1.41 1.96 0.81 1.83
Edge2 1.15 2.03 0.66 1.90
A4 Centre. - - - -
AC Edge. 1.46 0.94 10.81 1.47
B4 Centre. 1.85 0.03 4.14 0.04
HS Edge 1. 1.53 0.23 3.41 0.30
Edge2. 0.84 0.03 1.88 0.04
C4 Centre. 0.10 1.82 0.40
-
AGe Edge I. 0.52 0.44 2.06 -
Edge2. 0..60 1.27 2.38
1 Site of tumour specimen was taken from.
2 Absolute infiltration of lymphocytes into tumours from trial
patients who had received 10SAD7, and their matched controls.
3 Ratios of tumour edge and centre lymphocyte infiltration, to that of
infiltration into normal bowel.
4 Specimens from patients immunised by the previous CRC Fellow.
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Table 2-4 Immunohistochemistry results - CD 56
Patient No Site 1. Trial Abs2• ConAbs Trial T/N3 Con TIN
l.DT Centre 0.79 0.76 0.28 0.53
Edge 1.32 0.40 0.46 0.28
2.EN Centre 1.23 0.04 1.71 0.07
Edge I 0.45 0.06 0.63 0.10
Edge2 - 0.48 - 0.80
3.ER Centre 0.12 0.60 0.08 0.22
Edge 0.68 0.84 0.46 0.31
S.JGr Centre 0.19 0.26 0.33 0.09
Edge I 0.29 0.92 0.51 0.33
Edge2 0.10 0.81 0.17 0.29
6.ET Centre 0.22 0.09 0.09 0.07
Edge 2.93 0.41 1.16 0.32
B.MB Centre 0.92 1.73 6.45 1.01
Edge I 0.92 0.17 6.48 0.10
Edge2 0.73 0.43 5.11 0.25
9.DH Centre 0.84 0.04 1.09 0.12
Edge I 0.61 0.14 0.79 0.41
Edge2 1.17 0.13 1.51 0.40
ll.JK Centre 0.44 2.56 0.22 1.03
Edge I 0.77 1.76 0.38 0.71
Edge2 1.23 1.02 0.60 0.41
l2.JGa Centre 0.99 0.44 0.46 4.42
Edge I 0.65 0.22 0.31 2.22
Edge2 1.27 0.33 0.59 3.32
246
13.TB Centre 0.55 1.65 0.43 1.37
Edge I 2.18 1.69 1.69 1.41
15.FCI Centre 4.28 1.34 1.64 1.28
Edge I 2.43 1.99 0.94 1.89
17. FHa Centre 1.41 0.18 0.88 0.36
Edgel 2.23 0.15 1.39 0.31
18. FCh Centre 1.78 1.24 2.44 1.19
Edgel 0.96 1.43 1.32 1.36
Edge2 0.51 1.45 0.70 1.38
A4 Centre. - 2.12 - 1.57
AC Edge. - 0.62 - 0.46
B4 Centre. - 0.15 - 0.08
HS Edgel. - 0.16 - 0.09
Edge2. - 0.23 - 0.13
C4 Centre. 0.03 0.25 0.03 -
AGe Edge 1. 0.63 0.54 0.56 -
Edge2. - 0.42 - -
1 Site of tumour specimen was taken from.
2 Absolute infiltration of lymphocytes into tumours from trial
patients who had received 105AD7, and their matched controls.
3 Ratios of tumour edge and centre lymphocyte infiltration, to that of
infiltration into normal bowel.
4 Specimens from patients immunised by the previous CRC Fellow.
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Immunohistochemistry results - t chain expression.
Patient No Site 1. Trial Abs2• ConAbs Trial T/N3 Con TIN
2EN Centre 0.40 0.49 0.45 0.56
Edge1 0.44 0.89 0.50 1.02
Edge2 1.63 0.44 1.85 0.51
3.ER Centre 0.50 0.89 0.24 0.89
Edge 0.96 0.81 0.47 0.81
5.JGr Centre 2.36 1.91 7.47 0.70
Edge1 2.12 0.81 6.70 0.30
Edge2 0.34 - 1.08 -
6.ET Centre 0.76 0.42 0.70 0.48
Edge 0.59 0.09 0.54 0.10
8.MB Centre 0.36 0.55 0.63 0.49
Edge1 0.45 0.26 0.78 0.24
Edge2 0.18 0.22 0.32 0.19
9.DH Centre 0.12 - 0.14 -
Edge1 0.45 0.94 0.51 0.98
Edge2 0.30 0.59 0.34 0.61
11.JK Centre 0.22 0.61 0.11 0.38
Edge1 0.55 0.37 0.28 0.22
Edge2 - 1.30 - 0.80
13. TB Centre 0.35 1.37 0.41 1.07
Edge1 0.59 1.09 0.68 0.85
15. FCI Centre 0.58 0.23 0.57 0.16
Edge1 0.42 0.33 0.41 0.24
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17. FHa Centre 0.31 0.97 0.30 0.50
Edge I 0.56 1.01 0.55 0.52
18. FCh Centre 1.19 0.35 0.59 0.25
Edge I 0.86 0.80 0.43 0.57
Edge2 2.39 0.62 1.18 0.44
1 Site of tumour specimen was taken from.
2 Absolute infiltration of lymphocytes into tumours from trial
patients who had received 105AD7, and their matched controls.
3 Ratios of tumour edge and centre lymphocyte infiltration, to that of
infiltration into normal bowel.
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Table 2-6 Immunohistochemistry results - CD 68
Patient No Site 1. Trial Abs2• ConAbs Trial T/N3 Con TIN
2EN Centre 0.99 1.24 0.45 0.80
Edge I 1.26 1.17 0.57 0.76
Edge2 1.16 0.71 0.53 0.45
30ER Centre 1.06 1.70 0.72 -
Edge 1.44 0.91 0.98 -
50JGr Centre 2.24 0.88 1.82 0.55
Edge I 1.23 2.09 0.64 1.31
Edge2 1.32 - 1.08 -
60ET Centre 0.83 0.89 1.02 0.84
Edge 0.87 1.19 1.07 1.12
80MB Centre 0.69 1.02 0.89 2.12
Edge I 0.41 0.43 0.53 0.90
Edge2 0.57 0.48 0.74 1.00
9.0H Centre 1.10 - 0.93 -
Edge I 0.27 0.94 0.23 0.57
Edge2 0.99 0.64 0.83 0.39
11.JK Centre 1.22 2.08 0.89 0.96
Edge1 1.06 2.22 0.78 1.03
Edge2 - 1.36 - 0.63
13. TB Centre 2.45 0.61 1.18 0.40
Edgel 0.57 1.05 0.27 0.69
15. FCI Centre 1.12 1.65 0.90 2.64
Edge I 1.13 1.01 0.91 1.62
250
17. FHa Centre 0.49 1.53 0.36 0.75
Edge1 0.91 1.46 0.67 0.72
18. Feh Centre 2.45 0.68 1.45 0.62
Edge1 1.86 1.69 1.10 1.54
Edge2 1.41 0.89 0.83 0.81
t Site of tumour specimen was taken from.
2 Absolute infiltration of lymphocytes into tumours from trial
patients who had received 105AD7, and their matched controls.
3 Ratios of tumour edge and centre lymphocyte infiltration, to that of
infiltration into normal bowel.
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Table 2-7 Immunohistochemistry results - CD 69
Patient No Site 1. Trial Abs2• ConAbs Trial T/N3 Con TIN
2EN Centre 0.74 0.45 1.00 0.24
Edge I 0.92 0.53 1.25 0.29
Edge2 0.90 1.21 1.21 0.66
3.ER Centre 0.45 1.62 0.51 -
Edge 1.40 0.84 1.59 -
5.JGr Centre 0.33 0.74 0.26 0.45
Edge I 0.55 1.77 0.45 1.08
Edge2 0.47 - 0.38 -
6. ET Centre 0.52 0.98 0.84 1.81
Edge 0.31 0.52 0.50 0.96
8.MB Centre 0.15 0.29 0.32 0.58
Edge I 0.14 0.64 0.29 1.29
Edge2 0.39 0.28 0.80 0.57
9.DH Centre 0.49 - 0.38 -
Edge I 2.90 0.57 2.22 0.47
Edge2 0.59 0.98 0.45 0.82
11.JK Centre 1.02 1.51 1.40 0.90
Edge I 0.44 1.47 0.61 0.87
Edge2 - 1.68 - 1.00
13. TB Centre 1.33 1.18 0.97 1.51
Edge I 0.66 1.10 0.48 1.41
15. FCl Centre 0.41 0.45 0.66 0.73
Edge I 0.48 0.83 0.78 1.33
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17. FHa Centre 0.64 0.65 0.66 1.44
Edge1 0.43 1.92 0.45 4.26
18. FCh Centre 0.73 0.79 0.34 0.69
Edge1 0.47 0.40 0.28 0.35
Edge2 1.21 0.63 0.56 0.55
1 Site of tumour specimen was taken from.
2 Absolute infiltration of lymphocytes into tumours from trial
patients who had received 105AD7, and their matched controls.
3 Ratios of tumour edge and centre lymphocyte infiltration, to that of
infiltration into normal bowel.
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Table 2-8 Immunohistochemistry control results. Ig Cl.
Patient No Site 1. Trial Abs2• ConAbs Trial T/N3 Con TIN
2EN Centre 0.05 0.16 0.13 0.15
Edgel 0.20 0.17 0.46 0.16
Edge2 0.55 0.25 1.28 0.24
3.ER Centre 0.24 0.55 0.19 0.76
Edge 0.40 0.24 0.31 0.33
5.JGr Centre 0.13 0.24 0.62 0.29
Edgel 0.36 0.81 1.71 0.98
Edge2 0.86 - 4.11 -
6.ET Centre 0.11 0.06 0.46 0.26
Edge 0.20 1.19 0.84 1.12
8.MB Centre 0.13 0.21 0.60 0.51
Edgel 0.05 0.08 0.22 0.18
Edge2 0.07 0.02 0.32 0.05
9.0H Centre 0.52
-
2.87 -
Edgel 0.19 0.15 1.05 1.06
Edge2 0.24 0.12 1.32 0.82
11.JK Centre 0.08 0.48 0.59 1.23
Edgel 0.30 0.14 2.30 0.36
Edge2 0.16
-
0.41
13. TB Centre 0.33 0.34 0.68 0.81
Edgel 0.28 0.21 0.57 0.49
15. FCI Centre 0.17 0.03 0.62 0.74
Edgel 0.16 0.06 0.57 1.53
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17. FHa Centre 0.07 0.13 0.17 0.25
Edgel 0.15 0.30 0.40 0.59
18. FCh Centre 0.81 0.06 6.80 0.09
Edgel 0.47 0.24 4.02 0.32
Edge2 0.40 0.89 3.41 1.18
A4 Centre - - - -
AC Edge - 0.01 - 0.02
B4 Centre - 0.12 - 0.63
HS Edgel - 0.07 - 0.37
Edge2 - 0.09 - 0.47
C4 Centre - 0.11 - -
AGe Edge1 - 0.05 - -
Edge2 - 0.17 - -
1 Site of tumour specimen was taken from.
2 Absolute infiltration of lymphocytes into tumours from trial
patients who had received 105AD7, and their matched controls.
3 Ratios of tumour edge and centre lymphocyte infiltration, to that of
infiltration into normal bowel.
4 Patients immunised by previous CRC Fellow.
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Table2-9 Immunohistochemistry control results. Tris buffered saline
(TBS)
Patient No Site 1. Trial Abs2• ConAbs Trial T/N3 Con TIN
2. EN Centre 0.03 0.15 0.15 0.22
Edgel 0.09 0.12 0.38 0.71
Edge2 0.16 0.04 0.67 0.22
3.ER Centre 0.03 0.47 10.29 0.23
Edge 0.17 0.10 0.47 0.05
S.JGr Centre 0.05 0.25 0.29 1.84
Edgel 0.63 0.20 0.92 1.48
Edge2 0.92 0.25 0.63 1.87
6.ET Centre 2.07 0.04 1.85 0.77
Edge 0.58 0.48 0.52 9.31
B.MB Centre 0.15 0.14 1.29 0.44
Edgel 0.39 0.05 3.31 0.05
Edge2 0.13 3.00 1.10 3.00
9.DH Centre 0.73 0.03 1.39 0.05
Edgel 0.68 0.02 1.30 0.03
Edge2 0.50 0.06 0.96 0.10
11.JK Centre 0.03 0.03 2.29 0.26
Edgel 0.11 0.11 8.00 0.48
Edge2 0.23 0.24 17.00 0.19
13. TB Centre 0.53 0.51 1.71 0.96
Edgel 0.11 0.28 0.34 1.16
15. FCI Centre 2.22 0.88 1.63 14.7
Edge1 0.92 0.51 0.68 8.5
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17. FHa Centre 0.36 0.06 6.74 0.18
Edge I 0.64 0.15 11.89 0.44
18. FCh Centre 1.09 0.52 2.30 0.67
Edge I 0.13 0.23 0.27 0.30
Edge2 0.43 1.07 0.90 1.39
A4 Centre
AC Edge I 0.53 - 0.49 -
Edge2
84 Centre 0.18 - 0.23 -
HS Edge I 0.35 - 0.44 -
Edge2 0.17 - 0.22 -
C4 Centre 0.03 - 0.26 -
AGe Edge I 0.03 - 0.26 -
Edge2 0.04 - 0.38 -
1 Site of tumour specimen was taken from.
2 Absolute infiltration of lymphocytes into tumours from trial
patients who had received 105AD7, and their matched controls.
3 Ratios of tumour edge and centre lymphocyte infiltration, to that of
infiltration into normal bowel.
4 Patients immunised by previous CRC Fellow.
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Table 2-10 Immunohistochemistry APO 2.7 results. Control Ig G].
Patient No Site 1. Trial Abs2• ConAbs Trial T/NJ Con TIN
2. EN Centre 0.72 0.73 1.25 1.41
Edge I 0.98 0.89 1.72 1.73
3.ER Centre 0.32 0.31 - -
Edge 1.35 1.22
- -
6.ET Edge 1.99 1.39 1.14 0.95
8.MB Centre 0.37 0.37 0.74 0.82
9.DH Centre 0.01 0.01 0.01 0.01
11.JK Centre 0.02 0.24 0.53 0.38
Edge I 0.02 0.01 0.53 7.50
13. TB Edge I 0.02 0.02 - -
18. FCh Centre 0.73 0.70 0.65 0.83
1 Site of tumour specimen was taken from.
2 Absolute infiltration of lymphocytes into tumours from trial
patients who had received 105AD7, and their matched controls.
3 Ratios of tumour edge and centre lymphocyte infiltration, to that of
infiltration into normal bowel.
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Table 2-11 Immunohistochemistry results. APC 2.7
No. Site 1. Trial abs infil 2 Control abs inf Trial TIN 3 Control TIN
2. EN Centre 3.95 2.49 3.68 2.17 1.73 2.59 1.20 0.55 0.76 0.57 0.43 0.73
Edgel 3.51 4.12 5.65 1.67 1.88 1.77 1.06 0.91 1.17 0.44 0.46 0.50
3.ER Centre 1.61 1.92 2.65 2.62 1.55 1.70 - - - - - -
Edge 3.49 3.42 3.24 1.82 2.10 1.63 - - - - - -
6.ET Edge 1.75 2.41 2.86 1.52 0.96 1.56 0.27 0.38 0.43 0.42 0.35 0.46
8.MB Centre 7.66 6.93 5.66 2.14 2.62 2.22 2.16 2.24 2.00 0.59 0.97 0.72
9.0H Centre 0.64 0.87 0.60 0.53 0.62 0.81 0.50 0.26 0.29 2.24 0.53 0.80
II.JK Centre 2.06 1.91 1.82 2.99 2.21 3.00 0.57 0.51 0.58 0.82 0.56 0.66
Edgel 0.90 1.96 1.82 3.63 3.56 2.04 0.25 0.52 0.59 0.99 0.90 0.45
13. TB Edge1 6.32 5.23 4.51 1.65 1.77 1.76
- - - - - -
18.Fel Centre 2.92 2.89 2.22 0.87 0.94 1.04 0.66 0.47 0.51 0.28 0.23 0.28
1 Site of tumour specimen was taken from.
2 Absolute infiltration of lymphocytes into tumours from trial
patients who had received 105AD7, and their matched controls.
3 Ratios of tumour edge and centre lymphocyte infiltration, to that of
infiltration into normal bowel.
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Table 2-12. Assessment of intra observer variation.
JG. Trial pt number 12
Site CDAg Abs inf 1 Abs inf 2 TIN 1 TIN 2. .
Edge 1. C056 0.65 0.78 0.31 0.71
CD4 1.02 1.20 1.00 0.59
C08 0.76 1.97 0.70 0.98
C025 0.11 0.66 0.51 2.06
Edge2 C056 1.27 1.0 0.59 0.91
C04 1.22 0.91 1.19 0.45
C08 1.12 1.17 1.04 0.58
C025 0.79 0.59 3.74 1.84
Centre C056 0.99 0.68 0.44 0.62
C04 1.13 1.65 1.11 0.82
C08 0.46 1.23 0.43 0.61
C025 0.33 1.24 1.59 3.88
1 Image analysis of immunohistochemically stained sections.
2 Second image analysis performed by the same observer (CMA),
approximately 9 months following the first analysis.
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Table 2-12. Assessment of intra observer variation.
JG. Trial pt number 12
Site CDAg Abs inf 1 Absinf 2 TIN 1 TIN 2. .
Edge1. CD56 0.65 0.78 0.31 0.71
CD4 1.02 1.20 1.00 0.59
CD8 0.76 1.97 0.70 0.98
CD25 0.11 0.66 0.51 2.06
Edge2 CD56 1.27 1.0 0.59 0.91
CD4 1.22 0.91 1.19 0.45
CD8 1.12 1.17 1.04 0.58
CD25 0.79 0.59 3.74 1.84
Centre CD56 0.99 0.68 0.44 0.62
CD4 1.13 1.65 1.11 0.82
CD8 0.46 1.23 0.43 0.61
CD25 0.33 1.24 1.59 3.88
1 Image analysis of immunohistochemically stained sections.
2 Second image analysis performed by the same observer (CMA),
approximately 9 months following the first analysis.
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Table 2-12. Assessment of intra observer variation.
ET. Trial pt number 6
Site CDAg Abs inf 1 Absinf2 TIN 1 TIN 2. .
Edgel. C056 2.93 1.16 1.16 1.51
C04 2.00 0.55 1.25 1.38
C08 1.57 0.30 1.96 0.28
C025 1.62 0.22 1.05 0.39
Centre C056 0.22 0.06 0.09 0.08
C04 0.92 0.44 0.59 1.1
C08 0.92 0.32 1.15 0.30
C025 1.33 0.34 0.86 0.61
1 Image analysis of immunohistochemically stained sections.
2 Second image analysis performed by the same observer (CMA),
approximately 9 months following the first analysis.
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Table 2-12. Assessment of intraobserver variation.
Control patient for EN.
Site CDAg Abs inf 1 Abs in£2 TIN 1 TIN 2. .
Edge 1. C056 0.06 O.OS 0.10 0.24
C04 0.20 0.11 1.13 0.41
COS 0.10 0.06 0.3S 0.15
C025 0.07 0.03 0.13 0.10
Edge2. C056 0.48 0.53 o.so 1.56
C04 0.27 0.41 1.53 1.52
COS 0.29 - 1.11 -
C025 O.OS 0.33 0.16 1.10
Centre C056 0.04 0.22 0.07 0.65
C04 0.16 0.06 0.93 0.22
COS 0.12 0.16 0.45 0.41
C025 0.05 0.17 0.10 0.57
1 Image analysis of immunohistochemically stained sections.
2 Second image analysis performed by the same observer (CMA),
approximately 9 months following the first analysis.
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Table 97. Assessment of intraobserver variation.
Control patient for DT.
Site CDAg Abs inf 1 Absinf2 TIN 1. TIN 2.
Edge. C056 DAD 0.31 0.28 1.24
C04 1.00 0.24 1.88 0.37
COS 0.21 0.98 0.71 2.18
C025 0.30 0.37 0.42 0.37
Centre C056 0.76 0.53 0.53 2.12
C04 0.62 0.54 1.17 0.83
C08 0.18 0.58 0.60 1.29
C025 0.80 0.50 1.13 0.50
1 Image analysis of immunohistochemically stained sections.
2 Second image analysis performed by the same observer (CMA),
approximately 9 months following the first analysis.
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Table 2-13. Assessment of interobserver variation. Analysis of a control
patient by two independent observers.
MAb Tumour Observer! Observer 2 Observer! Observer2
specimen TIN ratios. TIN ratios.
CD25 Centre 0.14 0.52 0.27 0.91
Edge! 0.26 0.26 0.44 0.46
Edge2 0.11 0.41 0.21 0.72
COB Centre 0.69 0.65 0.50 0.87
Edge! 0.61 0.46 0.45 0.61
Edge2 0.24 0.80 0.18 1.07
CD4 Centre 1.35 1.56 2.05 1.22
Edge! 0.68 1.41 1.02 1.10
Edge2 0.58 1.71 0.88 1.34
CD56 Centre 0.04 0.56 0.12 0.32
Edge! 0.14 0.98 0.41 0.56
Edge2 0.13 0.85 0.40 0.49
TBS Centre 0.03 0.22 0.05 0.71
Edge! 0.02 0.11 0.03 0.35
Edge2 0.06 0.19 0.10 0.61
Observer 1 (CMA) and Observer 2 (RM) performed both analysis using
identical techniques, approximately 2 months apart.
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Table 2-14. Results of all tumour specimens disaggregated.
No. %Lym %Tcell %CD4 %CDB %CD19 CD16+56 CD4+Dr CD4-Dr
1. - - - - - - - -
2. 62 (43) 69 (17) 27 (28) 45 (10) 16 (1) 2 - -
3.
- - - - - - - -
4. 59 (34) 58 (26) 44 (12) 20 (15) 25 (2) 3 (14) 24 (22) 37
5. 91 (81) 89 (53) 58 (21) 23 (6) 7 (1) 1 (32) 35
6. 50 (40) (23) (16) (4) (1) (3) (11)
7. 55 (49) 89 (16) 29 (34) 62 (2) 4 (0) 0 (9) 16 (28) 51
8. 94 (77) 82 (49) 52 (28) 30 (11) 12 (1) 1 (32) 34 (38) 40
9. 91 (81) 89 (60) 66 (22) 24 (3) 3 (1) 1 (45) 49 (23) 25
10. 73 (60) 82 (42) 58 (16) 22 (6) 8 (1) 1 - -
11. 63 (37) 59 (25) 40 (13) 21 (t7) 27 (0) 0 (8) 13 (30) 48
12.
- - - - - - - -
13. 42 (26) 62 (18) 43 (7) 17 (6) 14 (3) 7 (11) 26 (29) 69
14. 21 (t9) 90 (14) 67 (7) 33 (3) 14 (t) 5 (10) 48 (21)
15. - - - - - - - -
16. 90 (83) 92 (49) 54 (31) 34 (2) 2 (4) 4 (38) 42 (35) 39
17. 73 (62) 85 (23) 32 (41) 56 (6) 8 (1) 1 (15) 21 (48) 66
18. 79 (41) 52 (19) 24 (28) 35 (21) 27
-
(13) 16 (44) 56
19. 36 (29) 81 (21) 58 (7) 19 (3) 8 - (9) 25 (11) 31
20. 84 (65) 77 (30) 36 (35) 42 (6) 7 (14) 17 (16) 19 (43) 51
21. 87 (76) 87 (15) 17 (60) 69 (4) 5 (6) 7 (to) 11 (65) 75
22. 73 (59) 81 (30) 41 (31) 42 (4) 5 (4) 5 (19) 26 (34) 47
23.
- - - - - -
- -
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Table 3-1 Results of all tumour specimens disaggregated.
No. %Lym % Teell %CD4 %CD8 B cell NK cell 4+Dr 4-Dr
24.
- - - - - - - -
25. 52 (41) 79 (15) 29 (31) 60 (4) 8 (1) 2 (6) 12 (29) 56
26. 52 (37) 71 (10) 19 (28) 54 (7) 13 (4) 8 (6) 12 (38) 73
27. 67 (62) 93 (22) 33 (36) 54 (1) 1 (1) 1 (16) 24 (40) 60
28. 85 (75) 88 (52) 61 (20) 24 (14) 16 (1) 1 (22) 26 (32) 38
29. 56 (47) 84 (28) 50 (20) 36 (6) 11 (2) 4 (15) 27 (30) 54
30. 31 (27) 87 (21) 68 (5) 16 (1) 3 (1) 3 (19) 61 (14) 45
31. 60 (38) 63 (26) 43 (13) 22 (12) 20 (1) 2 (5) 8 (20) 33
32. 48 - - - - - - -
33. 48 (SO) (40) (12) (9) (3) (19) (19)
34.
- - - - - - -
-
35. 62 (43) (30) (17) (4) (12) (19) (21)
36. 43 (29) (16) (15) (14) (1) (5) (28)
37. 23 (14) 61 (10) 43 (5) 22 (4) 17 (1) 4 (4) 17 (11) 48
38. 77 (48) 62 (22) 29 (25) 32 (26) 34 (3) 4 (11) 14 (49) 64
39. 76 (60) 80 (53) 70 (10) 13 (10) 13 (4) 5 (21) 28 (19) 25
40. 97 (94) 97 (18) 19 (76) 78 (3) 3 (1) 1 (15) 15 (79) 81
41. 64 (56) 89 (33) 52 (23) 36 (4) 6 (2) 3 (28) 44 (25) 39
42. 95 (89) 94 (62) 65 (26) 27 (4) 4 (2) 2 (54) 57 (33) 35
43. 67 (57) 85 (21) 31 (38) 57 (1) 1 (2) 3 (19) 28 (44) 66
44. 95 (34) 36 (30) 32 (8) 8 (60) 63 (1) 1 (12) 13 (58) 61
45. 77 (53) 69 (22) 29 (28) 36 (24) 31 (1) 2 (16) 21 (54) 70
46. 92 (59) 64 (33) 36 (26) 28 (13) 14 (6) 7 (29) 32 (34) 37
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Table 3-1 Results of all tumour specimens disaggregated.
No. %Lym % Tcell %CD4 %CD8 B cells NKcell 4+Dr 4-Dr
47. 88 (48) 54 (30) 34 (17) 19 (36) 41 (1) 1 (10) 11 (42) 48
48. 66 (47) 71 (27) 41 (26) 40 (7) 11 (7) 3 (20) 30 (40) 61
49. 65 (60) 92 (31) 48 (30) 46 (1) 2 (3) 5 (14) 22 (23) 35
50. 81 (59) 73 (29) 36 (31) 38 (6) 7 (4) 5 (22) 27 (43) 53
51. 67 (44) 66 (14) 21 (34) 51 (12) 18 (9) 13 (11) 16 (41) 61
52 89 (57) 64 (32) 36 (31) 35 (30) 34 (1) 1 (23) 26 (52) 58
53. 82 (31) 38 (18) 22 (8) 10 (51) 62 (2) 2 (7) 9 (46) 56
54. 79 (77) 97 (20) 25 (61) 77 (2) 2 (3) 4 (20) 25 (66) 83
1 Figures in parentheses are the percentage of lymphocytes, as analysed
from FACScan.
2 Lymphocyte numbers corrected for the lymphocyte percentage.
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Table 3-1. Results of all tumours disaggregated.
No. +4/25 -4/25 +3/69 -3/69 C04RO CD4RA C08RO C08RA
1. - - - - - - - -
2. - · - - - - · -
3. - - - - - - - -
4. (8) 14 (3) 5 - - · · - -
5. (23) 25 (4) 4 - - - - - -
6. - - - - - - - -
7. (6) 11 (2) 4 - - - · - -
8. (15) 16 (3) 3 - · - · · -
9. (16) 18 (3) 3 · · · · - .
10. · - · · - · · -
11. (5) 8 (4) 6
· -
- - - -
12. · · · · · · - -
13. (2) 5 (1) 2 - - - - - -
14. (2) 10 (1) 5
· - - -
- -
15. · · · · - · · .
16. (20) 22 (4) 4
· -
94% 6% 85% 15%
17. (7) 10 (2) 3 - - 100% 0% 98% 2%
18. (10) 13 (22) 28 - - 89% 11% 69% 31%
19. (3) 8 (3) 8 (27) 75 (9) 25 - - - -
20. (17) 20 (6) 7 - - - - - -
21. (9) 10 (20) 23 (72) 83 (9) 10 - - - -
22. (12) 16 (8) 11 (8) 11 (1) 1 98% 2% 79% 21%
23. - · - · . - - -
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Table 3-1 Results of all tumour specimens disaggregated.
No. +4/25 -4/25 +3/69 -3/69 CD4RO CD4RA COBRO CD8RA
24. - - - -
25. (5) 10 (10) 19 (33) 65 (3) 6 93% 7% 84% 16%
26. (4) 8 (3) 6 (30) 58 (8) 15 83% 17% 95% 5%
27. (7) 10 (2) 3 (51) 76 (1) 1 - - - -
28. (18) 21 (4) 5 (68) 80 (12) 14 92% 8% 96% 4%
29. (9) 16 (6) 11 (37) 66 (9) 16 96% 4% 85% 15%
30. (5) 16 (1) 3 (20) 65 (2) 6
- - - -
31. (2) 3 (0) 0 (20) 33 (8) 13 91% 9% 80% 20%
32. - - - - - - - -
33. (4) (0) (38) (6)
- - - -
34.
- - - - - - - -
35. (3) (1) (33) (12) - - - -
36. (5) (1)
- - - - - -
37. (6) 26 (7) 30 - - - - - -
38. (3) 4 (1) 1 (36) 47 (14) 18 96% 4% 96% 4%
39. (8) 11 0 (31) 41 (11) 14 80% 20% 83% 17%
40. (3) 3 (1) 1 (78) 80 (3) 3 95% 5% 96% 4%
41. (7) 11 (2) 3 (50) 76 (4) 6 97% 3% 93% 7%
42. (11) 12 (1) 1 (73) 77 (6) 6 98% 2% 96% 4%
43. (5) 7 (0) 0 (51) 76 (6) 9 100% 0% 96% 4%
44. (3) 3 (1) 1 (25) 26 (42) 44 89% 11% 100% 0%
45. (6) 8 (1) 1 (47) 61 (11) 14 92% 8% 97% 3%
46. (7) 8 (1) 1 (49) 53 (24) 26 98% 2% 90% 10%
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Table 3-1 Results of all tumour specimens disaggregated.
No. +4/25 -4/25 +3/69 -3/69 CD4RO C04RA CD8RO C08RA
47. (3) 3 (1) 1 (19) 22 (23) 26 70% 30% 71% 29%
48. (2) 3 (2) 3 (37) 56 (9) 14
- - - -
49. (3) 5 0 (50) 77 (8) 12 - - - -
50. (4) 5 0 (51) 63 (11) 14 97% 3% 90% 10%
SI. (6) 9 (4) 6 (42) 63 (18) 27 96% 4% 98% 2%
52. (7) 8 (1) 1 (58) 65 (16) 18 95% 5% 91% 9%
53. (3) 4 (1) 1 (21) 26 (27) 33
- - - -
54. (5) 6 - (74) 94 (3) 4 88% 12% 93% 7%
1. Figures in parentheses are the percentage of lymphocytes, as analysed
from FACScan.
2.Lymphocyte numbers corrected for the lymphocyte percentage.
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Adjuvant
Allograft
Anergy.
ADCC
Apoptosis
Cytokines
Cytotoxic T cells
Delayed-type
hypersensi tivity
Epitope
Hapten
Glossary.
Any substance that enhances the immune response to an
antigen with which it is mixed.
A graft of tissue from an allogeneic or non-self donor of the
same species; such grafts are rejected unless the recipient is
immunosu ppressed.
Is a state of non-responsiveness to antigen.
Antibody-dependent cell-mediated cytotoxicity is the killing
of antibody coated cells by cells with Fe receptors which
recognise the Fe region of the bound antibody (usually NK
cells)
Cell death in which the cell activates an internal death
programme. It is characterised by nuclear DNA degradation,
nuclear degeneration and condensation, and the
phagocytosis of cell residua.
Proteins made by cells, that affect the behaviour of other
cells.
T cells that can kill other cells. Usually MHC class I
restricted.
A form of cell-mediated immunity elicited by antigen in
the skin, and mediated by inflammatory CD4 T cells.
A site on an antigen recognised by an antibody. A T-cell
epitope is a short peptide derived from a protein antigen,
that binds to an MHC molecule, and is recognised by a
particular T cell.
Molecules that can bind antibody, but cannot themselves
elicit an adaptive immune response.
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Helper CD4 T cell CD4+T cells that help B cells make antibody in response to
(TH2) antigenic challenge. Also make cytokines such as IL-4 and
IL-S.
Idiotopes Antigenic epitopes on the variable regions of specific
antibody molecules. a collection of idiotopes on an antibody
is an idiotype.
Inflammatory CD4 Armed effector T cells that make the cytokines interferon y
T cell (TH1) and TNF upon recognition of antigen. Their major
function is in macrophage activation, though some have
cytotoxic activity.
Major Histocompatibility Complex. Antigen recognition byMHC
Oncogene
T cells is MHC restricted. This means that a given T cell will
recognise antigen, only when its peptide fragments are
bound to a particular MHC molecule
Genes involved in regulating cell growth. When they are
defective in structure or expression, they can cause cells to
grow continuously to form a tumour
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